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ABSTRACT 
Tiffany Kristal Ricks 
Signal Regulation of Protease-activated Receptor-2 and Structural Determinants of Gαq-
dependent Activation and Deactivation of Phospholipase C-β 
(Under the direction of Dr. T. Kendall Harden and Dr. JoAnn Trejo) 
 
 
Cells respond to changes in their environment by relaying information from 
extracellular cues to intracellular compartments, and receptors play an important role in 
the transmission of these signals.  We examined signal transduction of G protein-coupled 
protease-activated receptor-2 (PAR2), a cell surface receptor for serine proteases.  Unlike 
most GPCRs, PAR2 is irreversibly activated by proteolytic cleavage, and the mechanisms 
regulating desensitization and trafficking are essential for the fidelity of PAR2 signaling.  
Most activated GPCRs are rapidly desensitized and internalized following 
phosphorylation and β-arrestin binding.  However, the role of phosphorylation in 
signaling and trafficking of PAR2 is unknown.  We found that PAR2 phosphorylation is 
required for receptor desensitization and β-arrestin binding.  Phosphorylated PAR2 
internalized through a canonical dynamin-, clathrin-, and β-arrestin-dependent pathway.  
In contrast, phosphorylation-deficient PAR2 constitutively internalized through a 
dynamin-dependent but clathrin- and β-arrestin-independent pathway.  Collectively, we 
show that phosphorylation of PAR2 is critical for β-arrestin binding and desensitization 
but not endocytic trafficking. 
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Activated PAR2 and GPCRs catalyze GTP exchange on heterotrimeric G 
proteins.  GTP-bound Gα subunits activate protein effectors including phospholipases C-
β (PLC-β) isozymes.  PLC-β isozymes are stimulated by Gαq and also accelerate GTP 
hydrolysis of on their activating G protein.  The mechanisms that regulate Gαq-dependent 
activation and deactivation of PLC-β are not clearly understood.  Inspection of a three-
dimensional crystal structure of the PLC-β3⋅Gαq complex revealed three novel contacts 
within the binding interface.  A small region following the C2 domain of PLC-β3 inserts 
into the effector binding pocket of Gαq.  Gαq also makes electrostatic interactions with a 
region preceding the C2 domain of PLC-β3.  In addition, a loop between the third and 
fourth EF hands of PLC-β3 contacts the nucleotide binding pocket of Gαq.  Mutation of 
this loop abrogated PLC-β3 GAP activity, and a GAP-deficient PLC-β3 mutant displayed 
a much slower rate of deactivation.  Consequently, PLC activity was largely unchanged 
compared to rapid termination of wildtype PLC-β3.  Our studies define the important 
domains within the PLC-β3/Gαq binding interface that are required for activation and 
deactivation of PLC-β isozymes.  The studies presented herein describe the mechanisms 
regulating PAR2 and GPCRs at the cell surface and controlling PLC-β isozymes within 
intracellular compartments.   
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CHAPTER 1 
INTRODUCTION – PROTEASE-ACTIVATED RECEPTORS 
Protease-activated receptors (PARs) are members of the G protein-coupled 
receptor (GPCR) family and transmit signals of extracellular proteases in response to 
tissue injury and inflammation mainly within the vasculture (Coughlin, 2005).  There are 
four members of the PAR family encoded in the mammalian genome.  PAR1, PAR3, and 
PAR4 are expressed primarily on platelets, endothelial cells, and leukocytes and elicit 
cellular responses to thrombin, the primary effector protease of the coagulation cascade.  
PAR1 is also activated by coagulant protease factor Xa (FXa), plasmin, and activated 
protein C (APC).  PAR2 is expressed in intestinal and airway epithelial cells, fibroblasts, 
as well as cell types of the vasculature and is activated by trypsin, mast cell tryptase, 
coagulant proteases FVIIa and FXa but not by thrombin (Nystedt et al., 1994; Bohm et 
al., 1996b; Molino et al., 1997a; D'Andrea et al., 1998; Camerer et al., 2000).  Unlike 
other GPCRs, PARs are uniquely activated through a proteolytic cleavage event 
(Coughlin, 2000).  Serine proteases cleave the extracellular N-terminus of PARs, 
exposing a new N-terminus that intramolecularly binds and activates the receptors.  PARs 
are also fully activated in the absence of proteolytic cleavage by small synthetic peptides 
that mimic the new N-terminus of the receptors. 
1.1 PAR1 
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Coughlin and colleagues first discovered PAR1 as the receptor that mediates 
thrombin signaling in the vasculature (Vu et al., 1991a).  Vu et al. injected Xenopus 
oocytes with mRNA from megakaryocyte cell lines that were responsive to thrombin and 
demonstrated conferrance of a thrombin-dependent increase in intracellular calcium and 
inward Cl- currents (Vu et al., 1991a).  They then enriched for thrombin receptor mRNA 
by size fractionation on sucrose gradients, generated a cDNA library from the enriched 
mRNA pool, and identified a single cDNA that retained thrombin sensitivity in Xenopus 
oocytes.  Characterization of the predicted protein sequence revealed that the thrombin 
receptor contains a seven transmembrane spanning region similar to known GPCRs and a 
relatively long N-terminal extension (Vu et al., 1991a).  The PAR1 N-terminus contains 
the sequence LDPR41/S42FL and Arg41 at the P1 site that are essential for protease 
recognition and cleavage by thrombin and other serine proteases (Fig. 1.1A).  A second 
location of thrombin binding is an acidic region (WEDEEKNES) C-terminal to the 
thrombin cleavage site of PAR1 (Fig. 1.1A).  Thrombin interacts with this acidic region 
to confer high affinity binding to PAR1.  A similar acidic region (DFEEIPEEY) is also 
found in the leech anticoagulant hirudin, which also binds thrombin.  Removing the 
hirudin-like domain causes a 100-fold decrease in the potency of thrombin at PAR1, and 
replacing the region with the leech hirudin domain recovers receptor function (Vu et al., 
1991b). 
Thrombin recognizes both the PAR1 hirudin-like domain and LDPR41/S42FL 
cleavage site in the receptor N-terminus and cleaves the peptide bond between 
Arg41/Ser42 (Fig. 1.1A), exposing a tethered ligand domain that intramolecularly binds 
and activates the receptor (Vu et al., 1991a; Vu et al., 1991b).  Substituting the essential 
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Arg41 residue with alanine prevents activation by thrombin (Vu et al., 1991b).  In 
addition, replacing the entire LDPR41 protease cleavage sequence with the enterokinase 
or trypsin cleavage sequences also inhibits activation by thrombin and allows activation 
by enterokinase or trypsin, respectively (Vu et al., 1991b; Hammes and Coughlin, 1999).  
These results show that cleavage and formation of the tethered ligand domain is sufficient 
for receptor activation.  PAR1 is activated by picomolar concentrations of thrombin and 
is also fully activated independent of proteolytic cleavage by a small synthetic peptide 
agonist S42FLLRN (Vu et al., 1991a).  S42FLLRN mimics the newly formed N-terminus 
of PAR1 but is less potent (~5 µM) than thrombin. 
PAR1 also acts as a cell surface sensor for other serine proteases including those 
that function upstream of thrombin in the coagulation cascade (Fig. 1.1B and 1.2).  The 
coagulant protease FXa cleaves and activates PAR1 as a soluble protease or in complex 
with tissue factor (TF)-FVIIa (Camerer et al., 2000; Riewald and Ruf, 2001).  Tissue 
factor, the initiator of the coagulation cascade, is constitutively expressed on cells 
extrinsic to the vasculature or induced on monocytes and endothelial cells in the presence 
of inflammatory mediators. When the vasculture is disrupted, TF can associate with 
circulating zymogen FVII in plasma to convert it to active FVIIa.  The TF-FVIIa 
complex then generates FXa, which can elicit responses on its own through PARs or can 
generate thrombin from prothrombin with the aid of an additional cofactor, FVa 
(Camerer et al., 2000; Riewald and Ruf, 2001).  Thus, PAR1 transmits cellular responses 
of thrombin and upstream coagulant proteases under conditions of vascular injury and 
inflammation. 
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Thrombin and coagulant proteases activate PAR1 to elicit pro-inflammatory 
responses and promote endothelial barrier permeability within the vasculature (Coughlin, 
2005).  Alternatively, activated protein C (APC) stimulates PAR1 to induce opposing 
effects including anti-inflammatory responses and endothelial barrier protection (Riewald 
et al., 2002; Feistritzer and Riewald, 2005).  Protein C is localized to the cell surface by 
its cofactor endothelial protein C receptor (EPCR) and is converted to anti-coagulant 
protease APC by the thrombin-thrombomodulin complex (Stearns-Kurosawa et al., 
1996).  While bound to EPCR, APC cleaves and inactivates FVa and FVIIa to prevent 
thrombin generation and thus, inhibits the coagulation cascade and thrombin signaling. 
EPCR also localizes APC for activation of PAR1 on endothelial cells.  Recent studies 
show that compartmentalization of APC, EPCR, and PAR1 is required for PAR1 to 
induce its anti-inflammatory effects and promote endothelial barrier protection (Bae et 
al., 2007a; Bae et al., 2007b; Russo et al., 2009a).  APC, EPCR, and PAR1 are localized 
to lipid rafts in endothelial cells and are present in membrane fractions containing 
caveolin-1, a structural scaffolding protein that is needed for invagination of caveolae 
lipid microdomains (Bae et al., 2007b).  Unlike the soluble ligand thrombin, APC 
activation of PAR1 requires caveolin-1 in membrane microdomains and 
compartmentalization for protease-selective cytoprotective signaling in endothelial cells 
(Russo et al., 2009a).    
Initial characterization of the PAR1 exodomain suggested that receptor activation 
is strictly mediated by extracellular serine proteases.  Serine proteases recognize and 
cleave a specific recognition sequence, LDPR41/S42FL in the PAR1 N-terminal 
exodomain (Vu et al., 1991a), which requires a basic residue at the P1 site (Fig. 1.1A).  
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Interestingly, Kuliopulos and colleagues showed that matrix metalloproteinase-1 (MMP-
1) also activates PAR1 on breast cancer cells and platelets but not PAR2, PAR3, or PAR4 
(Boire et al., 2005; Trivedi et al., 2009).  The MMP-1 cleavage site is distinct from the 
site required for thrombin and other serine proteases.  MMPs usually prefer a 
hydrophobic residue at the P1′ site, a basic residue at the P2′ site, and a small residue at 
P3′ (Fig. 1.1A).  As such, MMP-1 cleaves PAR1 at LD39/P40RSFL within the exodomain, 
two residues N-terminal to the thrombin cleavage site (Trivedi et al., 2009).  Mutation of 
Pro40 to an Asn prevented activation of PAR1 by MMP-1 but not by thrombin and 
inhibited signaling to RhoA, p38 mitogen-activated protein kinase (MAPK), and cell 
migration in MCF-7 breast cancer cells (Trivedi et al., 2009).  Furthermore, in the 
absence of PAR1 proteolytic cleavage, a synthetic peptide PR-SFLLRN that mimics the 
MMP-1-generated tethered ligand also stimulated platelet activation and signaling 
(Trivedi et al., 2009). 
Activated PAR1 couples to multiple heterotrimeric G protein subtypes to transmit 
intracellular signaling (Fig. 1.1B).  Activated PAR1 couples to Gαi and inhibits adenylyl 
cyclase activity and accumulation of cAMP (Hung et al., 1992b).  PAR1 also interacts 
with Gαq and stimulates PLC-β isozymes, which hydrolyze PtdIns(4,5)P2 to second 
messengers, diacylglycerol and Ins(1,4,5)P3 (Hung et al., 1992b; Baffy et al., 1994).  
These second messengers mobilize intracellular calcium and activate protein kinase C to 
elicit various cellular responses.  The initial, rapid phase of PAR1-stimulated 
phosphoinositide hydrolysis is mediated by PLC-β isozymes whereas sustained 
phospholipid signaling occurs through activation of Gα12/13 and PLC-ε (Kelley et al., 
2006).  Additional studies have found that PAR1 coupling to Gα12/13 subtypes also 
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promotes RhoGEF activity and actin remodeling (Offermanns et al., 1994; Gohla et al., 
1999).  Thus, PAR1 activates several heterotrimeric G proteins to transmit signals from 
extracellular proteases, and coupling to a specific pathway appears to depend on 
expression of different effectors in a particular cell type, protease selectivity, and 
compartmentalization of PAR1 and its signaling partners into membrane microdomains. 
1.2 PAR2 
PAR2 was discovered through a mouse genomic library screen of GPCRs using 
transmembrane probes of the substance K receptor and was identified as a second 
protease-activated receptor (Nystedt et al., 1994; Nystedt et al., 1995; Bohm et al., 
1996b).  The PAR2 protein sequence has an overall 30% identity to the PAR1 sequence 
and 44% sequence identity within the transmembrane domains.  PAR2 lacks the acidic 
hirudin-like domain of PAR1 and is not activated by thrombin.  PAR2 is cleaved and 
activated at picomolar concentrations by trypsin and other serine proteases (Nystedt et al., 
1994; Nystedt et al., 1995; Bohm et al., 1996b).  Similar to PAR1 activation, serine 
proteases cleave the Arg34/Ser35 peptide bond, and the newly formed N-terminus activates 
the receptor (Fig. 1.1A).  The PAR2-specific agonist peptide S35LIGKV also activates 
PAR2 at low micromolar concentrations in the absence of proteolytic cleavage (Nystedt 
et al., 1995; Bohm et al., 1996b). 
Upstream coagulant proteases FVIIa and FXa directly cleave and activate PAR2 
expressed in the vasculature (Fig. 1.2).  The TF-FVIIa complex cleaves and activates 
PAR2 at nanomolar concentrations in both fibroblasts and endothelial cells induced to 
express TF in the presence of cytokines (Camerer et al., 2000; Riewald and Ruf, 2001).  
A recent study showed that a fraction of PAR2 and TF localize to lipid raft microdomains 
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and co-localize with caveolin-1 by immunofluorescence microscopy (Awasthi et al., 
2007).  Additionally, disruption of caveolae by cholesterol depletion and siRNA-
silencing of caveolin-1 impaired TF-FVIIa signaling whereas signaling induced by free 
PAR2 agonist peptide was not affected.  These results suggest that TF-FVIIa signaling 
may require compartmentalization of TF and PAR2 in lipid raft microdomains for 
protease-selective signaling. 
The TF-FVIIa complex generates FXa (Fig. 1.2), which cleaves and activates 
PAR2 as a free monomer or in a tertiary complex with TF-FVIIa (Camerer et al., 2000; 
Riewald and Ruf, 2001).  Endothelial cells derived from PAR2 knockout mice were 
markedly impaired in FXa signaling compared to wild-type endothelial cells (Camerer et 
al., 2002).  PAR1-/- endothelial cells also displayed defects in FXa signaling but not to the 
same extent as endothelial cells lacking PAR2.  These findings indicate that FXa 
signaling is mostly attributed to activation of PAR2.  Thus, similar to PAR1, PAR2 is a 
cell surface receptor for upstream coagulant proteases and may require formation of 
membrane signaling platforms for activation within the vasculature. 
PAR2 is also implicated as a cell surface receptor for other serine proteases.  For 
example, PAR2 is directly cleaved and activated by mast cell tryptase.  Mast cell tryptase 
is a protease expressed in the airways and infiltrating immune cells where it induces 
inflammatory responses and tissue remodeling (Molino et al., 1997a).  Tryptase was 
found to activate PAR2 in heterologous systems as well as cell types that endogenously 
express PAR2, and tryptase signaling was selectively inhibited by PAR2-specific 
blocking antibodies (Molino et al., 1997a; Akers et al., 2000; Berger et al., 2003; 
Ramachandran and Hollenberg, 2008).  PAR2 is also expressed on immune cells and 
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elicits cellular responses of proteinase-3, a protease secreted from neutrophils that 
promotes inflammation (Uehara et al., 2002).  In a recent study, PAR2 was found to 
induce the cellular functions of kallikreins, a large family of serine proteases that are 
widely expressed and exhibit trypsin and chymotrypsin activity (Oikonomopoulou et al., 
2006).  Although a few proteases have been shown to activate PAR2 mainly in the 
vasculature and at sites of inflammation, these proteases probably represent only a 
handful of the potential physiological activators.  To fully understand PAR2 function in 
physiological and pathological processes, identification of other activating proteases of 
PAR2 will be an important future pursuit. 
There is no direct evidence demonstrating PAR2 coupling to specific 
heterotrimeric G proteins.  However, numerous studies show that PAR2-selective 
agonists stimulate phosphoinositide hydrolysis and calcium mobilization, suggesting that 
PAR2 couples to Gαq, Gαi, and possibly Gα12/13 subtypes (Arora et al., 2007).  Some 
PAR2 responses are also sensitive to pertussis toxin treatment, indicating a role for Gαi 
proteins in some cellular contexts (Schultheiss et al., 1997; Yu et al., 1997).  In addition, 
activated PAR2 appears to signal independent of heterotrimeric G proteins through a 
stable complex with β-arrestins in endocytic compartments (DeFea et al., 2000; Stalheim 
et al., 2005).  β-arrestins function as signaling scaffolds and promote sustained MAPK 
activation, actin remodeling, cell migration, and cell permeability (DeFea et al., 2000; Ge 
et al., 2003; Jacob et al., 2005b; Zoudilova et al., 2007).   
1.3 PAR3  
Characterization of PAR1-/- knockout mice revealed the existence of an additional 
member of the PAR family (Connolly et al., 1996).  In humans, PAR1 is required for 
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thrombin-mediated activation of platelets.  Surprisingly, PAR1-deficient mouse platelets 
respond normally to thrombin and exhibit platelet activation similar to those derived from 
wildtype mice (Connolly et al., 1996).  These results implicated an additional PAR in 
mediating thrombin signaling in mouse platelets and suggested species-specific 
expression and function of different PARs.  Consequently, Coughlin and colleagues 
identified PAR3 using PCR and degenerate primers derived from conserved regions of 
PAR1, PAR2, and glycoprotein hormone GPCRs (Connolly et al., 1996; Ishihara et al., 
1997).  Human PAR3 has 27% amino-acid sequence similarity to PAR1 and 28% 
similarity to PAR2.   
PAR3 has a similar mechanism of activation as other PAR family members 
(Ishihara et al., 1997).  The N-terminus of PAR3 is proteolytically cleaved at residues 
Lys38/Thr39 to unmask a tethered ligand domain that binds and activates the receptor (Fig. 
1.1A).  PAR3 also contains a hirudin-like domain in its N-terminus that confers protease 
specificity for thrombin.  Thrombin activates PAR3 at picomolar concentrations in COS-
7 cells overexpressing the receptor.  Unlike PAR1 and PAR2, addition of synthetic 
agonist peptides that mimic the new N-terminus of PAR1, PAR2, or PAR3 do not 
activate the receptor or induce transmembrane signaling even at high concentrations of 
peptide (Ishihara et al., 1997).   
Studies of PAR3 signaling show that the receptor is less efficacious in 
transmitting signals through heterotrimeric G proteins (Coughlin, 2000; Coughlin, 2005).  
PAR3 is essential for mouse platelet activation at low thrombin concentrations, but does 
not promote inositol phosphate accumulation or calcium mobilization despite cleavage of 
its exodomain by thrombin (Kahn et al., 1998; Nakanishi-Matsui et al., 2000).  Instead, 
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PAR3 acts as a cell surface cofactor for PAR4, the second thrombin receptor in platelets.  
Thrombin binds to the PAR3 cleavage site and hirudin-like domain for localization and 
activation of PAR4, a PAR with lower affinity for thrombin (Nakanishi-Matsui et al., 
2000).  In the presence of PAR3, thrombin cleaves PAR4 more efficiently and shows an 
increase in potency at PAR4.  In a recent study, PAR3 was found to elicit cellular 
responses without the aid of an additional PAR family member.  Seminario-Vidal et al. 
showed that human PAR3 was the only PAR expressed in A549 lung epithelial cells and 
was sufficient to induce thrombin-promoted ATP release through a RhoA- and calcium-
dependent pathway (Seminario-Vidal et al., 2009).  Future work is needed to better 
characterize the signaling pathways downstream of PAR3 depending on its expression in 
different cell types and the presence of other PAR family members. 
1.4 PAR4 
 PAR1 is required for human platelet activation, but PAR1-deficient mouse 
platelets remain responsive to thrombin (Kahn et al., 1998).  Consequently, PAR3 was 
identified as the thrombin receptor expressed in mouse platelets.  At low thrombin 
concentrations, PAR3-deficient mouse platelets exhibit little to no activation compared to 
wildtype platelets but at higher concentrations exhibit a delayed response, suggesting the 
existence of another thrombin receptor (Kahn et al., 1998).  PAR4 was discovered by 
searching for expressed tag sequences (ESTs) related to PAR1, PAR2, and PAR3 (Kahn 
et al., 1998; Xu et al., 1998).  The PAR4-specific agonist peptide stimulated wildtype and 
PAR3-deficient mouse platelets as well as PAR1-desensitized human platelets (Kahn et 
al., 1998; Xu et al., 1998; Kahn et al., 1999).  These results suggested that PAR4 is the 
second thrombin receptor in both mouse and human platelets and required for platelet 
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responses at high concentrations of thrombin (Kahn et al., 1998; Xu et al., 1998; Kahn et 
al., 1999). 
Serine proteases cleave the PAR4 N-terminus (Kahn et al., 1998; Xu et al., 1998), 
and the exposed tethered ligand domain binds and activates the receptor (Fig. 1.1).  The 
PAR4-specific agonist peptide GYPGKF fully activates PAR4 although at a lower 
potency than the PAR1 agonist peptide at PAR1.  Thrombin is less potent at PAR4 than 
PAR1 but induces a similar maximal response, explaining the increased thrombin-
sensitivity in PAR3-deficient mouse platelets with higher concentrations of thrombin.  
PAR4 is also activated by other serine proteases including trypsin, TF-FVIIa-FXa, 
plasmin, and cathepsin G (Kahn et al., 1998; Xu et al., 1998).  In fibroblasts, activated 
PAR4 stimulates phosphoinositide hydrolysis but not inhibition of adenylyl cyclase, 
suggesting that PAR4 couples to Gαq and possibly Gα12/13 but not Gαi (Faruqi et al., 
2000).   
1.5 Physiology of PARs 
PARs primarily function in the vasculature and transmit signals from extracellular 
proteases in response to tissue injury and inflammation (Coughlin, 2000; Coughlin, 
2005).  PAR1, PAR3, and PAR4 have overlapping and distinct tissue distribution and are 
expressed on cell types of the vasculature including platelets, endothelial cells, 
leukocytes, smooth muscle cells, fibroblasts, and neurons (Coughlin, 2000; Coughlin, 
2005).  PAR2, unlike the other PAR family members, is not found on platelets or 
activated by thrombin but is present on endothelial cells, fibroblasts, smooth muscle cells, 
neurons, and immune cells within the vasculature (Nystedt et al., 1994; Nystedt et al., 
1995; D'Andrea et al., 1998).  PAR2 is also expressed on epithelial cells in the lung, 
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kidney, skin, and, eye and found at high levels in the gastrointestinal tract where it is 
cleaved by one of its physiological activators, trypsin (Nystedt et al., 1994; Nystedt et al., 
1995). 
1.5.1 PARs in Vascular Biology 
 Thrombin is the primary effector protease of the coagulation cascade and the most 
potent activator of platelets.  Thrombin elicits its cellular responses through cleavage and 
activation of cell surface receptors PAR1, PAR3, and PAR4 (Coughlin, 2000; Coughlin, 
2005).  Thrombin is generated through a series of zymogen conversions initiated by the 
transmembrane protein, tissue factor.  Tissue factor is basally expressed on the surface of 
epithelial cells, macrophages, and other cell types that normally are not in contact with 
blood.  Under conditions of vascular injury, tissue factor associates with circulating 
coagulant proteases and initiates thrombin formation (Fig. 1.2).  Consequently, thrombin 
elicits cellular responses through activation of PARs on cell types of the vasculature.  
Thrombin also generates fibrin from circulating fibrinogen, which polymerizes into a 
meshwork over sites of vascular injury to form blood clots.    
 Studies of PAR knockout mice and PAR-specific agonist peptides and inhibitors 
have uncovered particular roles for PAR subtypes in vascular biology.  In humans, PAR1 
and PAR4 are expressed on platelets (Vu et al., 1991a; Ishihara et al., 1997; Kahn et al., 
1998; Kahn et al., 1999; Nakanishi-Matsui et al., 2000).  Addition of PAR1-specific 
agonist peptide, SFLLRN, activates human platelets, resulting in platelet shape change 
and aggregation, ATP release, and activation of αIIb/β3 integrin, a cell adhesion receptor 
that binds fibrinogen and von Willebrand Factor to promote platelet aggregation (Vu et 
al., 1991a; Vassallo et al., 1992; Coughlin, 2005).  Thrombin also promotes synthesis and 
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secretion of thromboxane A2 and expression of pro-inflammatory mediators, P-selectin 
and CD40 ligand on the surface of platelets (Jennings, 2009).  In human platelets, 
thrombin responses were inhibited with PAR1 blocking antibodies but only at low 
thrombin concentrations (Brass et al., 1992; Hung et al., 1992a).  Incubation with both 
PAR1 and PAR4 blocking antibodies completely ablated platelet activation at high and 
low concentrations of thrombin, indicating that both receptors are required for cellular 
responses to thrombin in human platelets (Kahn et al., 1999).  Thus, PAR1 is the main 
cell surface receptor for thrombin in human platelets and stimulates platelet aggregation 
and secretion in the presence of low levels of thrombin whereas PAR4 can elicit these 
same responses in the absence of PAR1 activity at high levels of thrombin. 
 In contrast to human platelets, mouse platelets use PAR3 and PAR4 as cell 
surface receptors for thrombin signaling.  PAR1 agonist peptides were shown to fully 
activate human platelets as well as PAR1 expressed in various cell types.  In mouse 
platelets, however, PAR1 agonist peptides had no effect (Connolly et al., 1994; Derian et 
al., 1995; Connolly et al., 1996; Kahn et al., 1998).  In addition, platelets from PAR1-/- 
knockout mice are still responsive to thrombin stimulation, indicating that PAR1 is 
dispensable in mouse platelet activation and that another thrombin receptor mediates this 
response (Connolly et al., 1996). 
Coughlin and colleagues cloned PAR3 and showed that PAR3-deficient mouse 
platelets are unresponsive to low concentrations of thrombin (Ishihara et al., 1997).  
PAR4 was identified as the second thrombin receptor in mouse platelets and responsible 
for cellular functions of thrombin at high concentrations (Kahn et al., 1998; Xu et al., 
1998).  Studies examining activation and signaling of recombinant PAR3 in COS-7 cells 
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revealed that PAR3 does not promote signaling on its own but requires expression of 
PAR4 to mediate cellular responses to thrombin (Nakanishi-Matsui et al., 2000).  
Expression of PAR3 increases thrombin cleavage of PAR4 and promotes signaling at low 
thrombin concentrations (Nakanishi-Matsui et al., 2000).  In addition, expression of just 
the N-terminal domain of PAR3 on the cell surface also increased thrombin cleavage and 
activation of PAR4 in the presence of low levels of thrombin (Nakanishi-Matsui et al., 
2000).  Collectively, these results suggested that PAR3 is a cofactor for PAR4 and 
localizes thrombin to the cell surface for PAR4 activation.  In PAR4-deficient mice, loss 
of PAR4 completely ablates platelet activation at high and low concentrations of 
thrombin, indicating that PAR4 is essential for thrombin signaling in mouse platelets and 
the presence of PAR3 alone cannot rescue this effect (Sambrano et al., 2001). 
PARs are also found on other cell types of the vasculature either surrounding or in 
blood vessels.  In the event of vascular injury, generation and release of thrombin, 
upstream coagulant proteases FVIIa and Xa, or other extracellular proteases may result in 
activation of PARs expressed on endothelial cells, smooth muscle, immune cells, 
neurons, or other cell types (Coughlin, 2000; Coughlin, 2005).  Activation of PAR1 on 
endothelial cells induces release of von Willebrand factor and expression of P-selectin on 
the cell surface for rolling and adhesion of leukocytes and platelets.  Thrombin activation 
also induces expression of platelet-activating factor, chemokines, prostaglandins, and 
COX2 (Weksler et al., 1978; Houliston et al., 2002).  In the vasculature, PAR2 is 
expressed on endothelial and smooth muscle cells and is upregulated by inflammatory 
mediators and tissue damage (Nystedt et al., 1996; Damiano et al., 1999).  Activation of 
both PAR1 and PAR2 regulates vascular tone, primarily by inducing relaxation of blood 
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vessels through release of nitric oxide and prostaglandins (al-Ani et al., 1995; Hamilton 
et al., 1998; Saifeddine et al., 1998; Hamilton et al., 2001).  In addition, thrombin 
activation of PAR1 promotes endothelial cell permeability whereas proteolytic cleavage 
by APC induces endothelial barrier protection, suggesting that PARs may mediate 
different responses depending on the activating protease and downstream signaling 
pathways (Feistritzer and Riewald, 2005; Finigan et al., 2005).  PAR1 and PAR2 
expressed on vascular smooth muscle and the endothelium promote cell proliferation and 
production of growth factors and matrix proteases for tissue remodeling (Mirza et al., 
1996).  On sensory neurons, activation of PAR1 and PAR2 induces neurogenic 
inflammation, edema, and hyperalgesia (de Garavilla et al., 2001; Vergnolle et al., 2001).  
Thus, PARs elicit responses to extracellular proteases within the vasculature and function 
in various events related to vascular injury and inflammation. 
1.5.2 PARs in Hemostasis and Thrombosis 
 Hemostasis is essential to prevent uncontrolled bleeding at sites of vascular injury 
(Jennings, 2009).  Under pathological conditions, however, this process can lead to 
thrombi formation in blood vessels, which obstruct blood flow and can lead to various 
vascular diseases including stroke, angina, and myocardial infarction (Jennings, 2009).  
Hemostasis and thrombosis requires the presence of platelets and thrombin as well as 
many other agonists that activate potentially redundant signaling pathways of these 
events.  Since PAR4-deficient mouse platelets are completely unresponsive to thrombin 
activation, studies of PAR4-deficient mice have provided an in vivo model to specifically 
examine the function of thrombin-dependent platelet activation and PARs on hemostasis 
and thrombosis (Coughlin, 2005). 
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PAR4-deficient mice exhibited prolonged bleeding times and displayed 
significant resistance to thrombolytic challenge in experimental hemostasis and 
thrombosis models (Sambrano et al., 2001; Hamilton et al., 2004; Vandendries et al., 
2007).  This phenotype was reversed when PAR4+/+ bone marrow was reconstituted into 
lethally irradiated PAR4-deficient mice (Hamilton et al., 2004).  These observations 
suggest that the protective effect is completely due to loss of PAR4 signaling in platelets 
and not other cell types within the vasculature that could contribute to hemostasis and 
thrombosis.  Since PAR4-deficient mice do not exhibit spontaneous bleeding or excessive 
bleeding after giving birth, PARs may serve as potential therapeutic targets for the 
treatment of vascular diseases associated with thrombosis without affecting the normal 
physiological process of hemostasis (Sambrano et al., 2001).  In accordance with these 
genetic experiments, studies of non-human primates have provided promising results for 
the use of PAR antagonists as antiplatelet drugs.  Similar to humans, PAR1 signaling is 
considered to be more important than PAR4 signaling in monkeys.  Inhibiting PAR1 with 
either a blocking antibody or the small molecule antagonist, RWJ-58259, protected 
monkeys from experimental arterial thrombosis without affecting PAR4 signaling (Cook 
et al., 1995; Derian et al., 2003).  These results suggest that inhibiting PAR1 alone is 
sufficient to block thrombosis in humans. 
1.5.3 PARs in Cancer 
 The tumor microenvironment contains a multitude of extracellular proteases, 
including PAR activators, thrombin, coagulant proteases FVIIa and FXa, trypsin, and 
matrix metalloproteases.  PAR1 is overexpressed in breast, colon, and prostate cancer as 
well as melanoma (Even-Ram et al., 1998; Chay et al., 2002; Tellez and Bar-Eli, 2003; 
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Darmoul et al., 2004).  PAR1 and PAR2 expression is also upregulated in stromal 
fibroblasts surrounding malignant tumors whereas neither receptor is present in normal or 
benign tumor samples (D'Andrea et al., 2001).  Ectopic expression of PAR1 transforms 
NIH-3T3 cells, suggesting an oncogenic role for PAR1 in cancer progression (Whitehead 
et al., 1995).  In addition, thrombin activation of PAR1 promotes tumor cell invasion of 
highly invasive breast cancer cells in vitro (Even-Ram et al., 1998; Booden et al., 2004).  
Boire et al. found that overexpression of PAR1 in non-invasive breast carcinoma cells 
increased tumor cell migration and invasion, and injection of these PAR1-expressing 
cells into the mammary fat pads of nude mice markedly increased tumor cell growth 
compared to wildtype cells (Boire et al., 2005).  In accordance with these studies, shRNA 
depletion of PAR1 from highly invasive breast carcinoma cells markedly impaired tumor 
cell growth in a mouse xenograft tumor model compared to control cells (Arora et al., 
2008).   
 PAR2 is also expressed in breast carcinoma and highly invasive cancer cell lines, 
and its physiological activator trypsin is upregulated in colon, ovarian, lung, and gastric 
cancers (Ducroc et al., 2002; Arora et al., 2007).  The PAR2 activators, TF-FVIIa and Xa 
were shown to induce breast cancer cell migration and invasion through a PAR2-
dependent pathway (Ge et al., 2004; Morris et al., 2006).  In addition, siRNA depletion of 
PAR2 prevented invasion and migration of breast carcinoma cells toward NIH-3T3 
conditioned medium (Morris et al., 2006).  In a recent study, Versteeg et al. validated 
these in vitro results using the mouse mammary tumor virus-polyoma middle T (MMTV-
PyMT) mouse model (Versteeg et al., 2008).  This breast cancer model closely resembles 
breast tumor progression in humans, and mice exhibit widespread transformation of 
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mammary epithelium and metastasis to the lymph nodes and lungs (Fantozzi and 
Christofori, 2006).  Genetic crossing of PAR2-/- and MMTV-PyMT mice resulted in a 
significant delay in breast cancer progression whereas mice lacking PAR1 were identical 
to wildtype MMTV-PyMT mice (Versteeg et al., 2008).  These results imply a role for 
PAR2 and not PAR1 in breast cancer progression, suggesting that PAR2 may be a 
therapeutic target for the treatment of breast cancer. 
1.6 Canonical paradigm of GPCR signal regulation 
 G protein-coupled receptors (GPCRs) are the largest and most diverse family of 
cell surface receptors encoded in the mammalian genome.  In humans, there are ~1000 
GPCRs that transduce signals of a variety of extracellular stimuli such as hormones, 
peptides, neurotransmitters, proteases, ions, photons, and many others.  Signaling 
downstream of these receptors regulates an array of physiological responds including 
cardiac function, vision, olfaction, and neurotransmission.  Consequently, approximately 
half of the drugs currently available target GPCRs either directly or indirectly to 
modulate intracellular signaling and cellular physiology, indicating the huge success of 
targeting GPCR signaling for therapeutic treatments of many diseases. 
 GPCRs elicit their cellular response through association with heterotrimeric G 
proteins.  Upon binding of agonist, GPCRs undergo conformational changes and expose 
intracellular domains for heterotrimeric G protein binding.  GPCRs act as guanine 
nucleotide exchange (GEF) factors and catalyze exchange of GDP for GTP on Gα 
subunits.  GTP-bound Gα subunits dissociate from Gβγ dimers, and both signaling 
molecules directly bind and activate various effector proteins including adenylyl 
cyclases, ion channels, phospholipases, and GEF proteins for small monomeric GTPases.  
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In addition, GPCRs also signal independent of heterotrimeric G proteins through stable 
association with the adaptor proteins, arrestins.  Arrestins can function as scaffolds and 
form stable complexes with some GPCRs and a variety of signaling proteins. 
 GPCR signaling is tightly regulated by mechanisms of receptor desensitization 
and trafficking.  The mechanisms controlling receptor desensitization are best 
characterized for the photoreceptor rhodopsin and β2-adrenergic receptor (β2AR).  In the 
classic model, agonist-occupied GPCRs undergo rapid phosphorylation by G protein-
coupled receptor kinases (GRKs) or second messenger kinases (Krupnick and Benovic, 
1998; Pitcher et al., 1998).  GRKs recognize activated receptors and phosphorylate serine 
and threonine residues within the third intracellular loop and/or cytoplasmic tail (C-tail) 
of GPCRs.  The cytosolic adaptor proteins, β-arrestin 1 and β-arrestin 2 (also known as 
arrestin 2 and 3) translocate to the plasma membrane and bind to the activated and 
phosphorylated receptor.  β-arrestins competitively bind and sterically hinder 
heterotrimeric G protein binding to receptors.  Thus, β-arrestins uncouple activated 
GPCRs from G proteins and attenuate transmembrane signaling. 
 GPCR signal regulation is also tightly controlled by receptor trafficking and is 
best characterized for the β2AR (Fig. 1.3).  β2AR and other GPCRs internalize through a 
β-arrestin-dependent pathway (Krupnick and Benovic, 1998; Pitcher et al., 1998).  β-
arrestins directly associate with clathrin and adaptor protein complex-2 (AP-2), 
components of the endocytic machinery, and facilitate receptor internalization through 
clathrin-coated pits (Goodman et al., 1996; Laporte et al., 1999).  β2AR internalization 
requires dephosphorylation of β-arrestin 1 and 2 to enhance clathrin binding and targeting 
of the β2AR/β-arrestin complex to clathrin-coated pits (Lin et al., 1997; Lin et al., 2002).  
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In addition, β2AR internalization also requires ubiquitination of β-arrestin 2 by the E3 
ubiquitin ligase mouse double minute-2 (MDM2) (Shenoy et al., 2001).  Once 
internalized, β2AR is sorted to recycling endosomes where it is dephosphorylated and 
targeted to the plasma membrane for additional signaling (Fig. 1.3).  After prolonged 
agonist exposure, the receptor is targeted to lysosomes for degradation through a 
ubiquitin-dependent pathway. 
1.7 Signal regulation of PARs 
In contrast to β2AR, PARs are irreversibly activated by proteolytic cleavage and 
contain a tethered ligand domain that does not diffuse away.  Studies of PAR signal 
regulation indicate that the regulatory mechanisms are relatively unique from reversibly 
activated GPCRs.  Once activated, PARs are rapidly desensitized, endocytosed, and 
quickly sorted to lysosome for degradation without recycling to the cell surface for 
subsequent signaling (Arora et al., 2007).  Thus, the mechanisms controlling 
desensitization and trafficking of PARs are essential for regulating the temporal and 
spatial aspects of receptor signaling.  In fact, a chimeric receptor consisting primarily of 
PAR1 and the C-tail domain of substance P receptor was fully activated by thrombin 
cleavage but recycled to the cell surface and displayed prolonged receptor signaling due 
to the intact tethered ligand domain (Trejo et al., 1998).  In highly invasive breast 
carcinoma cells, proteolytically cleaved PAR1 was not sufficiently sorted to lysosomes 
and degraded (Booden et al., 2004).  Consequently, PAR1 exhibited prolonged 
phosphoinositide and MAPK signaling after thrombin was removed.  These results 
demonstrate the importance of receptor internalization and lysosomal degradation in 
terminating signaling downstream of PARs. 
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Signal regulation of PARs is best characterized for PAR1.  Upon proteolytic 
cleavage, PAR1 is rapidly desensitized despite irreversible activation by extracellular 
proteases.  GRKs phosphorylate PAR1 on intracellular serine and threonine residues, and 
β-arrestin binding uncouples the receptor from heterotrimeric G proteins (Ishii et al., 
1994; Tiruppathi et al., 2000; Paing et al., 2002).  While PAR1 phosphorylation is 
required for receptor endocytosis (Fig. 1.3), PAR1 internalizes independent of β-arrestin 
1 and β-arrestin 2 through a clathrin and dynamin-dependent pathway (Trejo et al., 2000; 
Paing et al., 2002).  Once internalized, PAR1 is quickly sorted through the endocytic 
pathway and targeted to lysosomes for degradation at a half-life of 1 hour (Fig. 1.3) 
(Trejo et al., 1998).  Unlike β2AR and other GPCRs, degradation of PAR1 is not 
regulated by ubiquitination.  A PAR1 mutant lacking all intracellular lysine residues was 
shown to degrade normally in HeLa cells (Wolfe et al., 2007).  Other studies found that 
PAR1 degradation is regulated by sorting nexin 1 (SNX1), a protein involved in vesicular 
trafficking (Wang et al., 2002; Gullapalli et al., 2006).  A dominant negative mutant of 
SNX1 significantly impaired PAR1 degradation, and these results were confirmed by 
siRNA depletion (Gullapalli et al., 2006). 
PARs are considered single use receptors because they are quickly internalized 
and sorted from endocytic compartments to lysosomes for degradation.  Thus, activated 
PARs are not recycled to the cell surface for additional signaling, and PAR1 
resensitization occurs through a distinct mechanism from other GPCRs.  Under basal 
conditions, an internal pool of unactivated PAR1 constitutively cycles between the cell 
surface and an intracellular compartment and is protected from cleavage by thrombin and 
other extracellular proteases (Fig.1.3).  After protease exposure, PAR1 is cleared from the 
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cell surface by internalization, and the protected pool of PAR1 cycles to the plasma 
membrane for subsequent stimulation (Hein et al., 1994).  Constitutive internalization of 
unactivated PAR1 is regulated by a tyrosine-based motif (Y420XXΦ; where X is any 
amino acid and Φ is a bulky hydrophobic residue) in the PAR1 cytoplasmic tail (Paing et 
al., 2006).  The tyrosine-based motif is recognized by the µ-subunit of AP-2, which binds 
protein cargo for sorting to clathrin-coated pits.  Mutation of the tyrosine-based motif in 
the PAR1 cytoplasmic tail or depletion of AP-2 abrogated constitutive PAR1 
internalization but not agonist-promoted endocytosis (Paing et al., 2006).  Surface 
plasmon resonance studies confirmed that the µ-subunit of AP-2 binds directly to 
synthetic peptides of the PAR1 cytoplasmic tail but not peptides mutated at the tyrosine-
based motif (Paing et al., 2006). 
Studies of PAR1 intracellular trafficking revealed a novel role for receptor 
ubiquitination (Fig. 1.3).  PAR1 is basally ubiquitinated and deubiquitinated upon agonist 
exposure (Wolfe et al., 2007).  A PAR1 mutant lacking all intracellular lysine residues 
exhibited enhanced constitutive internalization, and this effect was blocked by fusing a 
ubiquitin moiety to the cytoplasmic tail (Wolfe et al., 2007).  These results suggested that 
basal PAR1 ubiquitination negatively regulates constitutive internalization.  Similar to 
wildtype PAR1, the ubiquitin-deficient mutant also required clathrin, dynamin, and the 
endocytic adaptor protein, AP-2 to facilitate constitutive internalization (Trejo et al., 
2000; Paing et al., 2006; Wolfe et al., 2007).  Unlike wildtype PAR1, however, siRNA 
depletion of AP-2 also blocked agonist-promoted internalization of ubiquitin-deficient 
PAR1 (Wolfe et al., 2007).  The authors speculated that PAR1 ubiquitination might 
regulate the interaction between AP-2 and PAR1.  Interestingly, within the AP-2 binding 
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sequence (Y420KKL) of PAR1 are two lysine residues.  Mutation of Lys421 and Lys422 
revealed that these are the primary sites of PAR1 ubiquitination and that these sites 
negatively regulate PAR1 constitutive internalization (Wolfe et al., 2007).  While this 
evidence is intriguing, studies examining direct binding of AP-2 and ubiquitinated PAR1 
are needed to support these observations.  Collectively, these studies show that unlike the 
role of ubiquitination in controlling degradation of β2AR and other GPCRs, 
ubiquitination of PAR1 instead functions to negatively regulate receptor internalization. 
Receptor desensitization and trafficking are also essential for PAR2 signal 
regulation, but the regulatory mechanisms are less well defined (Bohm et al., 1996a).  
Previous studies found that pharmacological inhibitors of protein kinase C increased 
PAR2-stimulated calcium mobilization in two epithelial cell lines, KNRK and hBRIE 
380 cells, suggesting a role for phosphorylation in mediating receptor desensitization 
(Bohm et al., 1996a).  PAR2 contains multiple serine and threonine residues on its C-tail 
and intracellular loops that could function as potential sites of receptor phosphorylation.  
However, it remains to be determined if PAR2 is directly phosphorylated and what is the 
function of this modification on PAR2 regulatory mechanisms.  In addition, the role of 
specific GRKs and/or second messenger kinases in controlling PAR2 signaling requires 
further investigation. 
Previous studies also have demonstrated a role for β-arrestins in regulating PAR2 
signaling and trafficking (Fig. 1.3).  PAR2 displayed enhanced phosphoinositide 
signaling in mouse embryonic fibroblast (MEFs) lacking β-arrestin 1 and β-arrestin 2 
compared to wildtype MEFs, suggesting that β-arrestins are required for uncoupling 
PAR2 from heterotrimeric G proteins (Stalheim et al., 2005).  In addition, agonist-
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induced internalization of PAR2 was severely impaired in β-arrestin1,2-/- MEFs, 
confirming previous results using dominant negative β-arrestin mutants (DeFea et al., 
2000; Stalheim et al., 2005).  β-arrestins were also found to co-localize with internalized 
PAR2 in endosomal compartments and form a stable complex consisting of PAR2, β-
arrestins, raf-1, and activated ERK1/2 (DeFea et al., 2000).  Formation of this stable 
complex was required for sustained ERK1/2 signaling and was proposed to occur 
independent of heterotrimeric G protein activation (DeFea et al., 2000; Stalheim et al., 
2005; DeFea, 2007).   
Binding of β-arrestins to activated GPCRs involves multiple interactions with 
intracellular loops and/or cytoplasmic tails of receptors.  Sequential deletion of the PAR2 
C-tail had no effect on rapid translocation of β-arrestins to the cell surface or β-arrestin-
dependent desensitization, suggesting that the C-tail is not required for β-arrestin 
recruitment or uncoupling from heterotrimeric G proteins (Stalheim et al., 2005).  In 
contrast, internalized PAR2 truncation mutants failed to form stable complexes with β-
arrestins in endocytic compartments or stimulate sustained ERK1/2 activation (Stalheim 
et al., 2005).  Collectively, these results show that β-arrestins are critical for signal 
regulation of PAR2, but the molecular determinants controlling the diverse functions of 
β-arrestins in PAR2 signaling and trafficking are not clearly understood. 
Internalized PAR2 is quickly sorted through the endocytic pathway to lysosomes 
where the receptor is degraded at a half-life of 3h (Fig. 1.3).  Similar to β2AR and 
CXCR4, lysosomal sorting of PAR2 requires ubiquitination (Marchese and Benovic, 
2001; Shenoy et al., 2001; Jacob et al., 2005a).  A PAR2 mutant lacking all intracellular 
lysine residues is not ubiquitinated or degraded after prolonged agonist exposure (Jacob 
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et al., 2005a).  Co-localization studies found that ubiquitin-deficient PAR2 internalizes 
and sorts to an early endosomal compartment like wildtype PAR2 but fails to sort to 
lysosomes.  Further analysis suggested that the E3 ubiquitin ligase Cbl catalyzes 
ubiquitination of PAR2 (Jacob et al., 2005a).  The molecular determinants for Cbl 
binding and ubiquitination of PAR2 remain to be determined and are likely unique from 
other proteins since Cbl normally recognizes tyrosine phosphorylated substrates for 
binding. 
PAR2 lysosomal sorting and degradation are also tightly regulated by two 
deubiquitinating enzymes, AMSH (associated molecule with the Src homology 3 domain 
of STAM (signal-transducing adaptor molecule)) and UBPY (ubiquitin-associated 
protease Y) (Hasdemir et al., 2009).  AMSH and UBPY are present on endosomal 
membranes and associate with endosomal adaptor proteins to regulate lysosomal sorting 
of ubiquitinated protein cargo (Clague and Urbe, 2006).  Catalytically inactive mutants 
and siRNA knockdown of AMSH and UBPY prevented deubiquitination of PAR2 and 
blocked sorting of the receptor from endosomal compartments to lysosomes for 
degradation (Hasdemir et al., 2009).  These results suggest that deubiquitination is 
required for proper post-endocytic trafficking of PAR2 and receptor downregulation. 
Research Goals 
 Protease-activated receptor 2 (PAR2) is a G protein-coupled receptor (GPCR) that 
acts as a cell surface sensor for extracellular proteases such as trypsin, mast cell tryptase, 
and coagulant proteases, factor VIIa and Xa (Nystedt et al., 1994; Nystedt et al., 1995; 
Bohm et al., 1996b; Molino et al., 1997b; Camerer et al., 2000).  PAR2, like other 
members of the PAR family, has a unique mechanism of activation.  Extracellular 
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proteases cleave the N-terminus of the receptor to unmask a tethered ligand domain that 
intramolecularly binds to the body of PAR2 and activates the receptor.  Upon activation, 
PAR2 couples to Gαq, Gαi, and possibly Gα12/13 to induce transmembrane signaling, 
primarily leading to migratory and inflammatory responses to vascular injury.  The 
mechanisms controlling PAR2 signaling, however, are not clearly defined. 
Signal regulation of GPCRs involves receptor desensitization and internalization.  
Most GPCRs are rapidly phosphorylated on their intracellular loops and/or cytoplasmic 
tails upon ligand binding and recruit the multifunctional adaptor proteins, β-arrestins, to 
the cell surface (Krupnick and Benovic, 1998; Pitcher et al., 1998).  β-arrestins 
recognized both the activated and phosphorylated form of GPCRs and sterically hinder 
binding of heterotrimeric G proteins.  In addition, β-arrestins also interact with 
components of the endocytic machinery and facilitate GPCR internalization, removing 
activated receptors from the cell surface to prevent further stimulation. 
Unlike classic GPCRs, PARs are irreversibly activated by extracellular proteases, 
and the molecular mechanisms of signal regulation are likely unique from reversible 
activated GPCRs.  We hypothesize that the mechanisms controlling receptor 
desensitization and trafficking are critical for regulating the magnitude and duration of 
PAR2 signaling.  The goal of this research is to define the role of receptor 
phosphorylation in regulating PAR2 signaling and trafficking.  We will measure PAR2 
phosphorylation directly and define the region of phosphorylation using mutational 
analysis.  In addition, we will use phosphorylation-deficient mutants to assess the 
function of phosphorylation in PAR2 signaling, internalization, and endocytic sorting. 
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Figure 1.1. Protease-activated receptor family. (A) Amino-terminal sequences of 
human PARs preceding the first transmembrane domain (TM1).  The tethered ligand 
domain is shown in red, and the hirudin-like domain in PAR1 and PAR3 is underlined 
and required for high affinity thrombin binding.  The protease recognition sites are 
defined as P3-P2-P1/P1′-P2′-P3′ where (P) and (P′) represent unprimed and primed 
sites respectively, and / depicts the site of proteolytic cleavage.  The critical basic 
residues recognized by serine proteases are shown in blue.  The number of amino 
acids not listed is shown in brackets.  (B) Table of PAR family members and their 
respective tethered ligand domains, activating proteases, and signaling partners.  
Synthetic peptides that mimic the tethered ligand domain fully activate PARs in the 
absence of proteolytic cleavage except for PAR3.  Figure was modified from Russo et 
al., 2009. 
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Figure 1.2. Activation of PARs by coagulant proteases.  Tissue (TF) acts as a 
transmembrane cofactor for FVIIa, which converts coagulant protease FX to activated 
FXa.  FXa with the aid of an additional cofactor, FVa, generates α-thrombin (α-Th) 
from prothrombin.  α-Th elicits cellular responses through proteolytic cleavage and 
activation of PAR1, PAR3, and PAR4 but not PAR2.  The TF-FVIIa complex directly 
cleaves and activates PAR2 whereas the tertiary TF-FVIIa-FXa complex activates 
both PAR1 and PAR2 to induce transmembrane signaling. 
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Figure 1.3. Endocytic trafficking of β2AR vs. PARs. Reversibly activated β2-
adrenergic receptor (β2AR) requires phosphorylation, arrestin binding, and arrestin 
ubiquitination by the E3 ubiquitin ligase MDM2 for endocytosis. Internalized β2AR is 
sorted to recycling endosomes where it is dephosphorylated and recycled to the cell 
surface for additional signaling.  Prolonged agonist exposure leads to degradation of 
β2AR through a ubiquitin-dependent pathway.  In contrast, PARs are considered single 
use receptors due to irreversible activation by extracellular proteases and are rapidly 
internalized and sorted to lysosomes for degradation.  PAR1 exhibits two types of 
internalization. The endocytic adaptor protein, AP2, facilitates constitutive 
internalization of a pool of PAR1 that tonically cycles between the cell surface and 
recycling endosomes.  Ubiquitination of PAR1 negatively regulates this constitutive 
internalization. Agonist-induced PAR1 internalization requires receptor 
phosphorylation but occurs independent of arrestin binding.  Internalized PAR1 is 
rapidly sorted from endosomes to lysosomes through a SNX1-dependent pathway and 
degraded.  Unlike PAR1, PAR2 internalizes through an arrestin-dependent pathway 
and appears to signal independent of G proteins through its interaction with arrestins 
within intracellular compartments.  Internalized PAR2 is sorted to lysosomes and 
degraded through a ubiquitin-dependent pathway. Figure was adapted from Arora et 
al., 2007. 
 
 
  
 
CHAPTER 2 
PHOSPHORYLATION OF PROTEASE-ACTIVATED RECEPTOR-2 
DIFFERENTIALLY REGULATES DESENSITIZATION AND 
INTERNALIZATION 
 
2.1 Abstract 
Protease-activated receptor 2 (PAR2) is a G protein-coupled receptor (GPCR) 
irreversibly activated by extracellular proteases.  Activated PAR2 couples to multiple 
heterotrimeric G protein subtypes including Gαq, Gαi, and Gα12/13. Most activated 
GPCRs are rapidly desensitized and internalized following phosphorylation and β-
arrestin binding. However, the role of phosphorylation in regulation of PAR2 signaling 
and trafficking is not known.  To investigate the function of phosphorylation, we 
generated a PAR2 mutant in which all serines and threonines in the C-tail were converted 
to alanines and designated it PAR2 0P.  In mammalian cells, the addition of agonist 
induced a rapid and robust increase in phosphorylation of wildtype PAR2 but not the 0P 
mutant, suggesting that the major sites of phosphorylation occur within the C-tail domain.  
Moreover, desensitization of PAR2 0P signaling was markedly impaired compared to 
wildtype receptor. Wildtype phosphorylated PAR2 internalized through a canonical 
dynamin, clathrin- and β-arrestin-dependent pathway.  Strikingly, PAR2 0P mutant 
internalization proceeded through a dynamin-dependent but clathrin- and β-arrestin-
independent pathway in both a constitutive and agonist-dependent manner.  Collectively, 
our studies show that PAR2 phosphorylation is essential for β-arrestin binding and 
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uncoupling from heterotrimeric G protein signaling and that the presence of serine and 
threonine residues in the PAR2 C-tail hinder constitutive internalization through a non-
canonical pathway.  Thus, our studies reveal a novel function for phosphorylation that 
differentially regulates PAR2 desensitization and endocytic trafficking.  
2.2 Introduction 
Protease-activated receptor 2 (PAR2) is a member of the protease-activated G 
protein-coupled receptor (GPCR) family that includes PAR1, PAR3 and PAR4 (Arora et 
al., 2007). PAR2 is expressed in intestinal and airway epithelial cells, fibroblasts and in a 
variety of cell types of the vasculature and functions in inflammatory processes 
associated with tissue injury. PAR2 is also expressed in certain types of metastatic 
cancers and stimulates tumor cell migration and invasion (Ge et al., 2004; Morris et al., 
2006). Multiple extracellular proteases cleave and activate PAR2 including trypsin, mast 
cell tryptase, and the coagulation protease factor VIIa in complex with tissue factor and 
Xa and others, but not thrombin (Bohm et al., 1996b; Dery et al., 1999; Camerer et al., 
2000). Similar to other PARs, proteolytic cleavage of PAR2 results in the formation of a 
new N-terminus that acts like a tethered ligand by binding intramolecularly to the 
receptor to trigger transmembrane signaling (Nystedt et al., 1994; Bohm et al., 1996b). 
Synthetic peptides that mimic the tethered ligand sequence of the newly exposed N-
terminus can activate PAR2 independent of proteolytic cleavage.  Upon activation, PAR2 
couples to multiple heterotrimeric G protein subtypes including Gαq, Gαi, and Gα12/13 
which signal to a variety of effectors and promotes diverse cellular responses (Arora et 
al., 2007). Unlike other PARs, however, activated PAR2 also signals independently of G 
proteins through its interaction with β-arrestins, which promotes sustained mitogen-
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activated protein (MAP) kinase signaling, actin remodeling, and cell migration (Ge et al., 
2003; Jacob et al., 2005b; Zoudilova et al., 2007). The molecular determinants that 
specify PAR2 coupling to distinct heterotrimeric G protein subtypes and binding to β-
arrestins remain to be determined.  
The known regulatory processes that control GPCR signaling are based largely on 
studies of the β2-adrenergic receptor (β2-AR) (Pitcher et al., 1998).  In the classic 
paradigm, ligand-activated GPCRs are rapidly phosphorylated on serine and threonine 
residues localized within the third intracellular loop or cytoplasmic tail (C-tail) by G 
protein-coupled receptor kinases (GRKs). β-arrestins are then rapidly recruited and 
associate with activated and phosphorylated GPCRs at the plasma membrane. The 
binding of β-arrestins to activated and phosphorylated GPCRs mediates receptor 
uncoupling from G proteins and facilitates receptor internalization (Ferguson et al., 1996; 
Goodman et al., 1996; Laporte et al., 1999). Once internalized, some GPCRs signal from 
intracellular compartments through stable interaction with β-arrestins, which functions as 
a scaffold and transducer of MAP kinase signaling independent of G proteins (Luttrell, 
2003).  Internalized GPCRs are then targeted to recycling endosomes, dephosphorylated 
and returned to the cell surface, or sorted to lysosomes and degraded. 
Unlike most classic GPCRs, PAR2 is irreversibly activated by extracellular 
proteases. Thus, we hypothesize that PAR2 signal regulatory mechanisms are likely 
unique since most other GPCRs are reversibly activated. We previously reported that β-
arrestins are essential for activated PAR2 desensitization and internalization. Indeed, in 
mouse embryonic fibroblasts (MEFs) deficient in β-arrestin 1 and 2 expression, PAR2 
desensitization was significantly impaired compared to wildtype β-arrestin expressing 
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cells (Stalheim et al., 2005).  Internalization of activated PAR2 was also virtually 
abolished in cells lacking β-arrestin 1 and 2 expression (Stalheim et al., 2005). The 
binding of β-arrestins to activated GPCRs is known to involve multiple interactions with 
the receptor intracellular loops and C-tail (Gurevich and Gurevich, 2006). Interestingly, 
activated PAR2 C-tail truncation mutants displayed normal agonist-induced 
internalization, caused rapid redistribution of β-arrestins to the plasma membrane, and 
desensitized in a β-arrestin-dependent manner similar to wildtype PAR2 (Stalheim et al., 
2005), suggesting that the C-tail of PAR2 is not critical for rapid β-arrestin recruitment. 
However, activated PAR2 C-tail mutants lost the capacity to form stable complexes with 
β-arrestins, and failed to promote sustained MAP kinase signaling. These findings 
suggest that the PAR2 C-tail regulates the stability of β-arrestin interaction and sustained 
MAP kinase signaling, but is not essential for rapid β-arrestin recruitment nor β-arrestin-
dependent receptor desensitization or internalization. These findings further suggest that 
the diverse functions of β-arrestins in the regulation of PAR2 signaling and trafficking 
are likely to be controlled by distinct determinants. However, the PAR2 specific 
determinants that are critical for the diverse functions of β-arrestins in regulation of 
receptor signaling and trafficking remain poorly understood.  
In the present study, we examine for the first time the role of phosphorylation in 
regulation of PAR2 signaling and trafficking.  We report that phosphorylation of PAR2 
distinctly regulates desensitization and endocytic trafficking.  Our findings further 
demonstrate that PAR2 phosphorylation is critical for receptor desensitization and β-
arrestin binding and that serine and threonine residues in the PAR2 C-tail domain impede 
constitutive internalization and lysosomal degradation.  These studies reveal a novel 
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function for phosphorylation in differentially regulating PAR2 desensitization and 
endocytic trafficking.  
2.3 Materials and Methods 
Reagents and Antibodies 
Agonist peptides TFLLRNPNDK (PAR1-specific) and SLIGKV (PAR2-specific) 
were synthesized as the carboxyl amide and purified by reverse-phase high-pressure 
chromatography (UNC Peptide Facility, Chapel Hill, NC).  α-Trypsin treated with 
tosylamide-2-phenylethyl chloromethyl ketone, leupeptin, and cycloheximide were from 
Sigma-Aldrich (St. Louis MO).  [32P]orthophosphate was purchased from Perkin-Elmer 
(Boston, MA).  Monoclonal M1 and M2 anti-FLAG, polyclonal anti-FLAG, and anti-β-
actin antibodies were from Sigma-Aldrich (St. Louis, MO).  Anti-early endosome 
antigen-1 (EEA1) monoclonal antibody was purchased from BD Biosciences.  Anti-
clathrin monoclonal antibody X22 was from GeneTex, Inc (San Antonio, TX).  Anti-
lysosomal-associated membrane protein 1 (LAMP1) H4A3 monoclonal antibody was 
from the Developmental Studies Hybridoma Bank (University of Iowa, Iowa City, IA).  
Anti-β-arrestin polyclonal antibody A1CT was a gift from R. J. Lefkowitz (Duke 
University).  Horseradish peroxidase (HRP) conjugated goat anti-mouse and goat anti-
rabbit secondary antibodies were purchased from Bio-Rad (Hercules, CA).  Alexa Fluor-
488 and Alexa Fluor-594 conjugated goat anti-mouse and goat anti-rabbit antibodies 
were from Invitrogen (Eugene, OR). 
cDNAs, siRNAs, and Cell Lines 
A cDNA encoding the wildtype PAR2 containing an N-terminal FLAG epitope 
was previously described (Stalheim et al., 2005). PAR2 mutants were generated by site-
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directed mutagenesis using QuikChange (Stratagene, La Jolla, CA), and mutations were 
confirmed by dideoxy sequencing.  The PAR1 chimera containing the substance P 
receptor C-tail (P/S) was previously described (Trejo and Coughlin, 1999).  The green 
fluorescent protein (GFP) tagged β-arrestin 1 and 2 constructs were a gift from M. Caron 
(Duke University). The GFP-tagged dynamin K44A mutant was a gift from M. McNiven 
(Mayo Clinic and Foundation). 
HeLa cells and Rat1 fibroblasts were cultured as previously described (Trejo and 
Coughlin, 1999; Trejo et al., 2000; Stalheim et al., 2005).  HeLa cells and Rat1 
fibroblasts stably transfected with FLAG-tagged PAR2 wildtype and mutants were 
generated as previously published (Trejo and Coughlin, 1999; Trejo et al., 2000). 
HeLa cells were transiently transfected for 72 h with 100 nM nonspecific siRNA 
or smart pool siRNAs targeting the clathrin heavy chain (CHC) or β-arrestin 1 and 2 
using LipofectAMINE 2000 or DharmaFECT 2 according to manufacturer’s protocol.  
All siRNAs were purchased from Dharmacon, Inc. (Lafayette, CO) 
Phosphoinositide Hydrolysis 
Cells stably expressing FLAG-tagged PAR2 wildtype or mutants were plated at 
0.8 x 105 cells per well in 24-well plates and grown overnight.  Cells were labeled with 1 
µCi/ml myo-[3H]inositol (American Radiolabeled Chemicals, St. Louis, MO) in serum- 
and inositol-free DMEM containing 1 mg/ml BSA overnight.  [3H]Inositol phosphates 
(IPs) were measured as previously described (Paing et al., 2002). 
Receptor Immunoprecipitation, Phosphorylation and Immunoblot Analysis 
Rat1 fibroblasts stably expressing FLAG-tagged PAR2 wildtype or mutants were 
plated at 3.5 x 105 cells per well in 6-well plates and grown for 48 h.  Cells were labeled 
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with 200 µCi [32P]orthophosphate in phosphate-free DMEM containing 1 mg/ml BSA for 
3 h, washed and incubated in the absence or presence of 100 µM SLIGKV diluted in 
DMEM containing 1 mg/ml BSA and 10 mM HEPES for various times at 37oC.  Cells 
were lysed with Triton lysis buffer (50 mM Tris-HCl, pH 7.4, 100 mM NaCl, 5 mM 
EDTA, 50 mM NaF, 10 mM sodium pyrophosphate, 200 mM sodium orthovanadate, and 
1% Triton-X-100) containing protease inhibitors.  Cell lysates were immunoprecipitated 
with M2 anti-FLAG antibody, resolved by SDS-PAGE and transferred to membranes.  
Phosphorylated receptor was detected by autoradiography. The amount of PAR2 in 
immunoprecipitates was determined by immunoblotting with polyclonal anti-FLAG 
antibody and HRP-conjugated goat anti-rabbit antibody.   
HeLa cells stably transfected with FLAG-tagged PAR2 wildtype or mutants were 
plated at 1.5 x 106 cells per well in a 6-well plate and grown for 48 h at 37oC.  Cells were 
incubated for various times with or without 100 µM SLIGKV diluted in DMEM 
containing 10 µM cycloheximide, 1 mg/ml BSA, and 10 mM HEPES.  Cells were lysed, 
immunoprecipitated and immunoblotted as described above.  Immunoblots were 
quantified using Image J software. 
Cell Surface ELISA 
Cells expressing FLAG-tagged PAR2 wildtype or mutants were plated on 
fibronectin-coated 24-well plates and grown for 48 h.  After incubations, cells were 
washed and fixed with 4% paraformaldehyde (PFA).  The amount of cell surface receptor 
was quantitated by incubation with M1 anti-FLAG antibody at 25oC for 1 h and HRP-
conjugated goat anti-mouse antibody at 25oC for 1 h.  The amount of bound secondary 
antibody was determined by incubating cells with 1-STEP ABTS (2,2’-azino-bis-3-
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ethylbenzthiazoline-6-sulfonic acid) (Pierce, Rockford, IL) for 10-20 min at 25oC.  An 
aliquot was taken to measure the optical density at 405 nm using a Molecular Devices 
microplate spectrophotometer. 
Internalization Assay 
Cells stably expressing FLAG-tagged PAR2 wildtype or mutants were plated on 
fibronectin-coated 24-well plates and grown for 48 h.  Cells were prelabeled with M1 
anti-FLAG antibody for 1 h at 4oC and then incubated with or without agonist for various 
times at 37oC.  The loss of cell surface receptor was measured by ELISA. 
Immunofluorescence Confocal Microscopy 
HeLa cells stably expressing FLAG-tagged PAR2 wildtype or mutant were plated 
at 0.8 x 105 cells per well on fibronectin-coated glass cover slips in 12-well plates for 48 
h at 37oC.  Cells were washed with ice-cold DMEM and prelabeled with polyclonal anti-
FLAG antibody on ice for 1 h.  Cells were incubated in the absence or presence of 100 
µM SLIGKV for 30 min at 37oC, washed and fixed with 4% PFA.  Cells were 
permeabilized with ice-cold 100% methanol and washed with PBS containing 1% nonfat 
dry milk and 150 mM sodium acetate, pH 7.0.  Cells were blocked with 1% nonfat dry 
milk in PBS and incubated with Alexa Fluor-488 conjugated goat anti-rabbit antibody.  
For lysosomal-associated membrane protein-1 (LAMP1) co-localization studies, cells 
were incubated in DMEM containing 2 mM leupeptin, a lysosomal protease inhibitor, for 
37oC for 1 h.  Cells were then processed as described above and immunostained for 
endogenous LAMP1, using a monoclonal anti-LAMP1 antibody for 1 h and Alexa Fluor-
594 conjugated goat anti-mouse antibody.  Cells were imaged by confocal microscopy as 
previously described (Gullapalli et al., 2006; Wolfe et al., 2007).  For clathrin heavy 
 38 
chain knockdown experiments, endogenous clathrin was detected using anti-clathrin 
monoclonal antibody and Alexa Fluor-594 conjugated goat anti-mouse antibody. 
Receptor Recycling 
HeLa cells stably expressing FLAG-tagged PAR2 wildtype or mutants were 
plated on fibronectin-coated 24-well plates and grown for 48 h at 37oC.  Cells were 
washed and incubated with calcium-dependent M1 anti-FLAG antibody diluted in 
DMEM containing 1 mg/ml BSA, 1 mM CaCl2, and 10 mM HEPES for 1 h.  Cells were 
incubated in the absence or presence of 100 µM SLIGKV for 60 min at 37oC.  Antibody 
bound receptor remaining on the cell surface was stripped by washing with ice cold PBS 
containing 0.4% EDTA to chelate calcium.  Cells were incubated for various times to 
allow recovery of antibody bound receptor to the cell surface.  Receptor recovery was 
measured by cell surface ELISA. 
Data Analysis 
Prism 3.0 Software (GraphPad) was used to analyze the data and statistical 
significance was determined using InStat 3.0 (GraphPad). Statistical analysis was 
determined using one-way ANOVA and Dunnett’s Multiple Comparison Test. 
2.4 Results 
Phosphorylation of activated PAR2 occurs within the cytoplasmic tail 
To determine the importance of phosphorylation in the regulation of PAR2 
signaling and trafficking, we constructed a PAR2 mutant in which all serines (S) and 
threonines (T) in the C-tail region were mutated to alanines (A) (Fig. 2.1A).  The PAR2 
mutant was designated “PAR2 0P”. We first directly examined the time course of 
activated PAR2 phosphorylation.  Rat1 fibroblasts stably expressing FLAG-tagged PAR2 
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wildtype or 0P mutant labeled with [32P]orthophosphate were incubated in the absence or 
presence of saturating concentrations of the PAR2 specific agonist peptide SLIGKV for 
various times at 37oC.  PAR2 was immunoprecipitated from cell lysates, and 
phosphorylation was analyzed by autoradiography.  In the absence of agonist, a minimal 
amount of wildtype PAR2 phosphorylation was detected (Fig. 2.1B, lanes 1-2). This 
phosphorylation was not observed in untransfected cells and likely represents basal PAR2 
phosphorylation. The addition of agonist induced a rapid and significant peak in activated 
PAR2 phosphorylation at 2.5 min, and phosphorylation of PAR2 remained elevated for 
30 min in the continued presence of agonist (Fig. 2.1B, lanes 3-5).  In contrast, the PAR2 
mutant lacking all serines and threonines in the C-tail, designated PAR2 0P, showed little 
to no phosphorylation over the 30 min time course of agonist stimulation (Fig. 2.1B, 
lanes 6-9). Thus, agonist induced rapid and sustained PAR2 phosphorylation 
predominantly within the C-tail domain. 
Phosphorylation mediates PAR2 desensitization 
Agonist-induced phosphorylation and binding of β-arrestins mediate 
desensitization and internalization of many reversibly activated GPCRs (Krupnick and 
Benovic, 1998). We previously showed that β-arrestins are essential for PAR2 
desensitization (Stalheim et al., 2005); however, the contribution of phosphorylation to 
the termination of PAR2 signaling is not known.  To test the importance of 
phosphorylation in PAR2 signal regulation we examined agonist-induced desensitization 
by quantitating the rate of inositol phosphate (IP) accumulation.  Activated PAR2 elicits 
phosphoinositide (PI) hydrolysis in multiple cell types (Bohm et al., 1996a; Stalheim et 
al., 2005), an effect attributed to Gαq coupling to phospholipase C-β. We initially 
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compared the rates of agonist-induced PI hydrolysis in Rat1 fibroblasts and HeLa cells 
stably expressing comparable amounts of PAR2 wildtype and phosphorylation-deficient 
0P mutant on the cell surface. Cells were incubated with or without a saturating 
concentration of trypsin for various times at 37°C, and total [3H]IPs were measured.  
After 60 min of agonist exposure, a marked ~10-fold increase in PI hydrolysis was 
detected in wildtype PAR2 expressing Rat1 fibroblasts, whereas a substantially greater 
~40-fold increase in signaling was measured in cells expressing the phosphorylation-
deficient PAR2 0P mutant (Fig. 2.2A).  Similarly, in HeLa cells, activation of 
phosphorylation-defective PAR2 0P mutant resulted in a ~10-fold increase in PI 
hydrolysis, a response considerably more robust than that observed in cells expressing 
comparable amounts of wildtype PAR2 (Fig. 2.2B). In both PAR2 wildtype and 0P 
mutant expressing HeLa cells, stimulation of endogenous muscarinic acetylcholine 
receptors with carbachol resulted in comparable changes in PI hydrolysis, indicating that 
there are no cell clone specific defects in G protein signaling (data not shown). These 
data suggest that agonist-induced PAR2 phosphorylation is critical for termination of G 
protein signaling. 
 Next, we examined whether the initial coupling of activated PAR2 wildtype and 
0P mutant to Gαq-promoted PI hydrolysis was affected.  The concentration effect curves 
for trypsin at PAR2 wildtype and phosphorylation-defective 0P mutant were determined 
by incubating cells labeled with myo-[3H]inositol and varying concentrations of trypsin 
for 10 min at 37°C, and accumulation of [3H]IPs was measured. The effective 
concentration of trypsin needed to stimulate a half-maximal response after 10 min was 
similar for both PAR2 wildtype and 0P mutant expressed in HeLa cells and significantly 
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different in Rat1 fibroblasts (P<0.05) (Fig. 2.2C and D). Moreover, activation of 
phosphorylation-defective PAR2 0P mutant caused an enhanced maximal signaling 
response compared with wildtype receptor (Fig. 2.2C) in Rat1 fibroblasts and HeLa cells 
(data not shown). These findings suggest that each activated PAR2 0P mutant coupled 
longer to PI hydrolysis before signaling was shut off, indicating a slower rate of 
desensitization.  
 To determine if specific phosphorylation sites are important for regulation of 
PAR2 signaling a series of receptor mutants were constructed in which clusters of serines 
and threonines within the C-tail were replaced with alanines (Fig. 2.3A). PAR2 S/T 
cluster mutants were stably expressed in Rat1 fibroblasts, and agonist promoted 
phosphorylation was determined. Wildtype PAR2 showed robust phosphorylation after 
2.5 min of agonist activation, whereas phosphorylation of the PAR2 0P mutant lacking 
all C-tail serines and threonines was virtually abolished (Fig. 2.3B, lanes 1-4). 
Remarkably, activation of PAR2 S/T cluster mutants with SLIGKV for 2.5 min induced 
phosphorylation similar to that observed with wildtype PAR2 (Fig. 2.3B), suggesting that 
PAR2 phosphorylation occurs at multiple and/or redundant sites within the C-tail domain.  
To determine whether critical C-tail serine and threonine residues are important for 
desensitization, we examined agonist stimulated PI hydrolysis in cells expressing PAR2 
S/T cluster mutants (Fig. 2.3C).  Rat1 fibroblasts expressing similar amounts of cell 
surface PAR2 wildtype, 0P, or S/T cluster mutants were incubated in the absence or 
presence of a saturating concentration of trypsin for 30 min at 37oC, and total [3H]IPs 
were measured.  All PAR2 S/T cluster mutants exhibited an increase in agonist-induced 
PI hydrolysis comparable to wildtype PAR2, whereas the phosphorylation-defective 
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PAR2 0P mutant showed significantly enhanced signaling following agonist incubation.  
Taken together, these data suggest that multiple and/or redundant C-tail serine and 
threonine residues serve as critical sites for agonist-induced PAR2 phosphorylation and 
desensitization.  
PAR2 0P mutant internalizes constitutively 
To determine the role of phosphorylation in PAR2 intracellular trafficking, we 
first examined constitutive and agonist-induced receptor internalization.  Rat1 fibroblasts 
stably expressing FLAG-tagged PAR2 wildtype or phosphorylation-deficient 0P mutant 
were incubated with M1 anti-FLAG antibody at 4oC.  Under these conditions only 
receptors residing on the cell surface binds antibody.  Cells were then incubated in the 
absence or presence of a saturating concentration of SLIGKV for various times at 37oC, 
and the amount of receptor remaining on the cell surface was quantified by ELISA. In 
wildtype PAR2 expressing cells, agonist induced rapid receptor internalization within 15 
min, leading to a ~70%  loss of cell surface receptor after 60 min (Fig. 2.4A). The rate of 
agonist-induced internalization of phosphorylation-deficient PAR2 0P mutant was 
comparable to wildtype receptor (Fig. 2.4A). We next examined constitutive 
internalization of wildtype PAR2 and observed a slow rate of internalization resulting in 
an ~5-10% loss of cell surface receptor after 60 min (Fig. 2.4B). In striking contrast, 
phosphorylation-deficient PAR2 0P mutant displayed an increased rate of constitutive 
internalization in which ~65% of receptor was lost from the cell surface after 60 min 
(Fig. 2.4B). Similar findings were also observed in HeLa cells (data not shown). 
Immunofluorescence microscopy studies of HeLa cells are consistent with enhanced 
constitutive internalization of phosphorylation-deficient PAR2 0P mutant (Fig. 2.4C). 
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HeLa cells stably expressing FLAG-tagged PAR2 wildtype or 0P mutant were incubated 
in the absence or presence of agonist for 30 min at 37oC, fixed, immunostained and 
analyzed by confocal microscopy. A substantial amount of internalized phosphorylation-
deficient PAR2 0P mutant co-localized with early-endosomal antigen-1 (EEA1), a 
marker of early endosomes in the presence and absence of agonist stimulation or 
antibody prebinding (Fig. 2.4C). In contrast, wildtype PAR2 localized predominantly to 
the cell surface in the absence of agonist (Fig. 2.4C), whereas activated PAR2 wildtype 
showed robust internalization and co-localization with EEA1 (Fig. 2.4C). To determine 
whether PAR2 internalization requires specific serine and threonine residues, we 
examined the rates of constitutive and agonist-induced internalization of PAR2 S/T 
cluster mutants (Fig. 2.4D and E).  Agonist-promoted PAR2 S/T cluster mutant 
internalization rates were comparable to wildtype PAR2 (Fig. 2.4D). Moreover, 
constitutive internalization rates of PAR2 wildtype and all S/T cluster mutants were 
similar, whereas phosphorylation-defective PAR2 0P mutant displayed an enhanced rate 
of constitutive internalization (Fig. 2.4E). Collectively, these findings indicate that 
serines and threonines in the PAR2 C-tail prevent constitutive internalization and suggest 
that basal phosphorylation and/or a distinct conformation of the PAR2 C-tail regulates 
cell surface retention. 
 We next examined whether phosphorylation-deficient PAR2 0P mutant 
internalized through a dynamin-dependent pathway like wildtype PAR2 (Roosterman et 
al., 2003). HeLa cells expressing PAR2 wildtype or 0P mutant were transiently 
transfected with GFP-tagged dynamin K44A mutant, and receptor internalization was 
examined by immunofluorescence microscopy. Constitutive internalization of 
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phosphorylation-deficient PAR2 0P mutant was substantially inhibited in dynamin K44A 
mutant expressing cells, which showed more receptor retained on the cell surface 
compared to adjacent cells not expressing dynamin K44A (Fig. 2.5A). Indeed, in cells 
lacking dynamin K44A expression, PAR2 0P mutant localized predominantly to 
endosomes and not at the cell surface (Fig. 2.5A, arrowhead).  Internalization of 
activated PAR2 wildtype and 0P mutant were also markedly inhibited in dynamin K44A 
mutant expressing cells, which displayed more cell surface localized PAR2 than adjacent 
untransfected cells (Fig. 2.5A, arrowheads).  These findings suggest that internalization 
of phosphorylation-deficient PAR2 0P mutant is mediated by dynamin similar to the 
wildtype receptor.  
 To determine the role of clathrin in phosphorylation-deficient PAR2 0P mutant 
internalization, we used siRNA targeting endogenous clathrin heavy chain as previously 
described (Wolfe et al., 2007). The expression of clathrin heavy chain was substantially 
reduced in cells transiently transfected with siRNA specifically targeting clathrin 
compared to non-specific siRNA control as detected by immunofluorescence microscopy 
(Fig. 2.5B, bottom panels).  In cells lacking clathrin expression, activated PAR2 wildtype 
internalization was considerably impaired with more receptor retained at the cell surface 
compared to adjacent untransfected cells or cells transfected with non-specific control 
siRNA (Fig. 2.5B). In striking contrast, constitutive and agonist-induced internalization 
of phosphorylation-deficient PAR2 0P mutant occurred regardless of clathrin heavy chain 
expression (Fig. 2.5B). Thus, unlike wildtype receptor, phosphorylation- defective PAR2 
0P mutant internalization occurs through a clathrin-independent pathway. 
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 We previously reported that β-arrestins are rapidly recruited to activated PAR2 
and are essential for agonist-promoted receptor internalization (Stalheim et al., 2005). To 
assess the importance of β-arrestins in phosphorylation-deficient PAR2 0P mutant 
internalization, we initially examined β-arrestin-1-GFP and β-arrestin-2-GFP 
redistribution following the addition of agonist.  In untreated PAR2 wildtype expressing 
cells, β-arrestin-1-GFP and β-arrestin-2-GFP remained distributed throughout the 
cytoplasm, whereas stimulation with agonist peptide SLIGKV for 5 min resulted in β-
arrestin-GFP rapid redistribution and co-localization with PAR2 wildtype (Fig. 2.6A and 
B).  In contrast, β-arrestin-1-GFP and β-arrestin-2-GFP were not recruited to the cell 
surface in phosphorylation-deficient PAR2 0P mutant expressing cells but remained 
cytosolic under control, constitutive, and agonist-induced conditions (Fig. 2.6C and D). 
 Previous studies have demonstrated that β-arrestins were essential for wildtype 
PAR2 internalization (DeFea et al., 2000; Stalheim et al., 2005).  To examine the 
function of β-arrestins in phosphorylation-deficient PAR2 0P mutant internalization, we 
transfected HeLa cells with siRNAs targeting endogenous β-arrestin 1 and 2.  
Immunoblot analysis showed a significant reduction in β-arrestin 1 and 2 protein 
expression in cells transfected with siRNAs targeting β-arrestins compared to non-
specific siRNA control cells (Fig. 2.7A).  Similar to previous results in β-arrestin 1 and 2 
null MEFs, PAR2 wildtype failed to internalize in cells depleted of β-arrestins (Fig. 2.7B) 
(Stalheim et al., 2005).  In contrast, loss of β-arrestin 1 and 2 had no effect on 
constitutive or agonist-induced internalization of phosphorylation defective PAR2 0P 
mutant (Fig. 2.7B). These findings suggest that β-arrestins are not essential for 
phosphorylation-deficient PAR2 0P mutant internalization. 
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Phosphorylation-deficient PAR2 0P mutant constitutively sorts to lysosomes and 
degrades and does not recycle to the cell surface 
The increased accumulation of intracellular phosphorylation-deficient PAR2 0P 
mutant observed in the absence of agonist may result from an increased rate of 
constitutive internalization and/or an inability of the mutant receptor to recycle or sort to 
lysosomes for degradation. We therefore examined internalization and recycling of 
phosphorylation- deficient PAR2 0P mutant. HeLa cells expressing FLAG-PAR2 
wildtype or 0P mutant were incubated with calcium-dependent M1 anti-FLAG antibody 
at 4oC to label cell surface receptors and then stimulated with or without agonist for 60 
min at 37oC. In the absence of agonist, PAR2 wildtype showed a modest loss of cell 
surface receptor after 60 min of incubation at 37°C (t1), whereas agonist addition resulted 
in an ~70% decrease in the level of PAR2-bound antibody on the cell surface (Fig. 2.8A).  
In contrast, phosphorylation-deficient PAR2 0P mutant expressing cells not exposed to 
agonist during the 60 min incubation showed ~70% internalization (t1) (Fig. 2.8B), 
consistent with enhanced constitutive internalization. Exposure to agonist peptide 
SLIGKV during the 60 min incubation caused a similar ~70-80% decrease in cell surface 
PAR2 0P mutant (Fig. 2.8B).  
 After initial incubation with or without agonist, antibody was stripped from the 
cell surface and recovery of previously internalized receptor-bound antibody was 
measured at various times. In PAR2 wildtype expressing cells, little recovery of antibody 
was observed in cells irrespective of agonist incubation (Fig. 2.8A). Similarly, in 
phosphorylation-deficient PAR2 0P mutant expressing cells incubated in the absence or 
presence of agonist, there was minimal recovery of internalized antibody despite the large 
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cohort of receptor-bound antibody that had been previously internalized (Fig. 2.8B). In 
contrast to PAR2, a chimeric PAR1 bearing the cytoplasmic tail of the substance P 
receptor (P/S C-tail) pretreated with the PAR1 specific agonist peptide TFLLRNPNDK 
showed substantial recovery of antibody on the cell surface with time (Fig. 2.8C), 
consistent with its internalization and recycling as previously reported (Trejo and 
Coughlin, 1999). These data are consistent with an enhanced rate of phosphorylation-
deficient PAR2 0P mutant internalization and suggest a novel function for 
phosphorylation in negative regulation of PAR2 internalization.  
 To directly test whether phosphorylation-deficient PAR2 0P mutant constitutively 
sorts to lysosomes, we used confocal microscopy to assess whether receptors sort to a 
lysosomal-associated membrane protein-1 (LAMP1) positive compartment. LAMP1 is a 
specific marker of late endosomes and lysosomes. HeLa cells expressing PAR2 wildtype 
or 0P mutant were pretreated with or without leupeptin, a lysosomal protease inhibitor, 
and incubated in the absence or presence of peptide agonist SLIGKV for 2.5 h at 37°C. In 
the absence of agonist, PAR2 wildtype localized predominantly to the surface of cells 
treated with or without leupeptin (Fig. 2.9A). After prolonged agonist exposure, PAR2 
was no longer detectable in control cells (Fig. 2.9A), whereas cells pretreated with 
leupeptin showed significant accumulation of receptor in vesicles that co-stained for 
LAMP1 (Fig. 2.9A). These findings are consistent with agonist-induced internalization 
and lysosomal degradation of wildtype PAR2. In the absence of leupeptin, little co-
localization of phosphorylation-deficient PAR2 0P mutant and LAMP1 was observed in 
agonist treated or untreated cells (Fig. 2.9B), suggesting that internalized PAR2 0P 
mutant is sorted to lysosomes and rapidly degraded. In contrast to wildtype PAR2, 
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however, unactivated PAR2 0P mutant was found largely in LAMP1-positive vesicles in 
cells pretreated with leupeptin (Fig. 2.9B). Similarly, activated PAR2 0P mutant also 
localized predominantly to vesicles that co-localized with LAMP1 after prolonged 
agonist exposure in leupeptin treated cells (Fig. 2.9B). These results suggest that 
phosphorylation-deficient PAR2 0P mutant undergoes constitutive internalization and 
sorts from endosomes to lysosomes independent of phosphorylation.  
 We next directly compared the rates of PAR2 wildtype and phosphorylation-
deficient 0P mutant degradation. HeLa cells expressing PAR2 wildtype or 0P mutant 
were incubated with or without agonist for various times at 37°C, and the amount of 
receptor protein remaining was determined by immunoblot analysis. PAR2 wildtype 
expressing cells not exposed to agonist showed a modest basal turnover when de novo 
receptor synthesis was inhibited with cycloheximide (Fig. 2.10A). The majority of PAR2 
species migrated between ~36 and ~64 kDa, whereas higher molecular weight species are 
probably due to N-linked glycosylation and/or ubiquitination as previously reported 
(Compton et al., 2002; Jacob et al., 2005a).  In cells exposed to agonist peptide SLIGKV 
for 2 hr, a significant decrease in the amount of PAR2 wildtype protein was observed and 
receptor protein was virtually abolished after 4 hr of agonist exposure (Fig. 2.10B, lanes 
2-5). Interestingly, unlike wildtype receptor, unactivated phosphorylation-deficient PAR2 
0P mutant protein was markedly decreased in the presence of cycloheximide and was 
comparable to that observed in agonist-treated cells (Fig. 2.10A and B). These findings 
are consistent with constitutive internalization and lysosomal degradation of 
phosphorylation-deficient PAR2 0P mutant.   
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2.5 Discussion 
 In the present study, we demonstrate that PAR2 signaling and endocytic 
trafficking are differentially regulated by phosphorylation.  The PAR2 C-tail contains 
multiple serine and threonine residues that could serve as potential phosphorylation sites 
for GRKs or second messenger protein kinases.  Previous studies showed that 
pharmacological inhibitors of protein kinase C (PKC) enhance PAR2-mediated calcium 
responses in KNRK and hBRIE 380 cells, suggesting a role for PKC in PAR2 
desensitization (Bohm et al., 1996a).  However, whether PAR2 is directly modified by 
phosphorylation and the function of such phosphorylation in regulation of PAR2 
signaling and trafficking remains to be determined.  We report here that activated PAR2 
phosphorylation is critical for receptor desensitization and β-arrestin recruitment (Fig. 
2.11). We found that PAR2 internalization can proceed independent of G protein 
activation and phosphorylation. These studies suggest that phosphorylation and/or a 
distinct conformation of PAR2 is essential for retaining the receptor at the cell surface. 
We further show that phosphorylation-deficient PAR2 0P mutant internalizes 
constitutively and sorts to lysosomes through a dynamin-dependent but clathrin- and β-
arrestin-independent pathway (Fig. 2.11). Together these studies suggest that PAR2 
internalization can be uncoupled from G protein activation and phosphorylation, 
indicating that distinct determinants control the capacity of PAR2 to signal versus 
recruitment of β-arrestin and endocytosis.  
The mechanisms controlling GPCR desensitization are best characterized for the 
photoreceptor rhodopsin and β2-AR (Pitcher et al., 1998).  In this classic model, ligand-
activated receptors are rapidly phosphorylated at multiple intracellular serine and 
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threonine residues by GRKs.  Phosphorylation enhances binding of β-arrestins, which 
sterically hinders receptor interactions with G proteins.  Thus, phosphorylation and β-
arrestin binding function together to uncouple the receptor from G protein activation and 
thus, promote signal termination.  We observed a similar mechanism of desensitization 
for PAR2 in which the phosphorylation-deficient PAR2 0P mutant exhibited a slowed 
rate of desensitization, suggesting a defect in uncoupling from G protein signaling.  
Moreover, we previously showed that PAR2 desensitization is severely impaired in β-
arrestin 1 and 2 null mouse embryonic fibroblasts (MEFs), indicating that 
phosphorylation and β-arrestin binding are critical for definitively shutting-off PAR2 
signaling (Stalheim et al., 2005).  
Most activated and phosphorylated GPCRs bind to β-arrestins, which facilitates 
receptor recruitment to clathrin-coated pits and endocytosis. We previously showed that 
internalization of wildtype PAR2 is critically dependent on β-arrestins (Stalheim et al., 
2005), like most classic GPCRs. In the present study, we found that phosphorylation-
deficient PAR2 0P mutant was capable of internalization independent of β-arrestins. 
Interestingly, in the absence of agonist, PAR2 0P mutant displayed enhanced 
endocytosis, whereas unactivated PAR2 wildtype and S/T cluster mutants remained at the 
cell surface. In addition, constitutive and agonist-induced phosphorylation-defective 
PAR2 0P mutant internalization occurred normally in β-arrestin 1 and 2 siRNA depleted 
cells. In contrast, siRNA- targeted depletion of β-arrestins virtually ablated agonist-
induced wildtype PAR2 internalization, consistent with our previous findings in which 
wildtype PAR2 internalization was completely abolished in β-arrestin 1 and 2 null MEFs 
(Stalheim et al., 2005).  Collectively, these findings suggest that phosphorylation of 
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PAR2 is critical for specifying β-arrestin recruitment but is dispensable for receptor 
internalization. Thus, phosphorylation-deficient PAR2 0P has the capacity to engage the 
endocytic machinery and internalizes independent of β-arrestins even in the absence of 
agonist.  
Similar to PAR2, previous studies have shown that phosphorylation is not 
required for agonist-induced internalization of CXCR4 or the δ-opioid receptor (Haribabu 
et al., 1997; Murray et al., 1998). β-arrestins are also dispensable for internalization of 
muscarinic acetylcholine receptors (mAChRs), PAR1, and the formyl peptide receptor 
(Lee et al., 1998; Paing et al., 2002; Vines et al., 2003). Studies of the m2 mAChR 
identified a S/T cluster mutant that displayed impaired desensitization of adenylyl cyclase 
signaling and binding to β-arrestins (Pals-Rylaarsdam et al., 1997; Pals-Rylaarsdam and 
Hosey, 1997), similar to phosphorylation-deficient PAR2 0P mutant.  In addition, this m2 
mAChR S/T cluster mutant internalized like wildtype receptor in HEK 293 cells, and 
overexpression of β-arrestin 1 or β-arrestin 2 had no effect on its internalization.  The 
authors concluded that m2 mAChR predominantly uses an β-arrestin-independent 
pathway for receptor internalization and that phosphorylation may regulate both β-
arrestin-dependent and β-arrestin-independent activities (Pals-Rylaarsdam et al., 1997).  
In the case of PAR1, unactivated receptor internalizes constitutively through clathrin-
coated pits independent of phosphorylation and β-arrestin binding. Rather than β-
arrestins, PAR1 constitutive endocytosis is mediated by adaptor protein complex-2 (AP-
2), in which the µ2-subunit binds directly to a distal tyrosine-based motif within the 
receptor C-tail (Paing et al., 2006).  The adaptor protein that mediates constitutive 
internalization of phosphorylation-deficient PAR2 0P mutant is not known.  Finally, we 
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cannot exclude the possibility that mutating the PAR2 C-tail disrupts a conformation of 
the receptor important for cell surface retention and/or receptor endocytosis.  Thus, our 
results suggest that phosphorylation and/or a distinct conformation of the C-tail domain 
of PAR2 are critical for negatively regulating receptor internalization and specifying 
endocytosis through an β-arrestin-dependent pathway.   
PAR2 appears to internalize through a dynamin-dependent but clathrin- and β-
arrestin-independent pathway in the absence of phosphorylation. Most classic GPCRs 
bind β-arrestins, which engages AP-2 and the clathrin heavy chain to promote receptor 
internalization through a dynamin- and clathrin-dependent pathway; however, some 
GPCRs utilize a dynamin-dependent but clathrin-independent mode of endocytosis 
(Marchese et al., 2008). Clathrin-independent endocytosis can occur through lipid rafts, 
membrane microdomains that are highly enriched in cholesterol and glycosphingolipids 
(Mayor and Pagano, 2007). A distinct subset of lipid rafts known as caveolae, form flask-
shaped pits at the plasma membrane and are enriched in the structural scaffolding protein 
caveolin. Caveolin is thought to sequester membrane proteins, including GPCRs, into 
caveolae through protein-protein interactions with caveolin binding motifs. We have 
identified a putative caveolin-binding motif within the carboxyl-terminal portion of the 
seventh transmembrane domain of PAR2 (YYFVSHDF, φXφXXXXφ), which may 
confer an interaction with caveolin to facilitate movement into caveolar membranes and 
endocytosis.  Indeed, in MDA-MB-231 cells, a fraction of PAR2 is present in caveolin-1 
positive and detergent resistant lipid fractions and co-localizes with caveolin-1 as 
assessed by immunofluorescence microscopy (Awasthi et al., 2007).  However, whether 
PAR2 and caveolin-1 directly interact has not been determined. The phosphorylation-
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deficient PAR2 0P mutant may also utilize other clathrin-independent modes of 
endocytosis via non-caveolar pathways. In lymphocytes deficient in caveolin-1, the 
interleukin-2 receptor partitioned into detergent-resistant fractions and internalized 
through a clathrin-independent but dynamin- and RhoA- dependent pathway (Lamaze et 
al., 2001).  It is unclear, however, whether RhoA activity mediates PAR2 redistribution 
into lipid rafts and/or facilitates receptor endocytosis.  
Our studies further suggest that internalized PAR2 can sort from endosomes to 
lysosomes in the absence of receptor activation and phosphorylation. The β2-AR and 
CXCR4 traffic from endosomes to lysosomes through an ubiquitin-dependent pathway 
(Marchese and Benovic, 2001; Shenoy et al., 2001).  Ubiquitinated cargo interacts with 
the ubiquitin binding motif of hepatocyte growth factor-regulated tyrosine kinase 
substrate (Hrs) (Marchese et al., 2003).  Hrs associates with early endosomal membranes 
and sorts ubiquitinated proteins from early endosomes to late endosomes.  Hrs also 
directly binds to tumor suppressor gene product 101 (Tsg101) of the ESCRT complex, 
which is required for multivesicular body formation, lysosomal fusion, and subsequent 
degradation of proteins and lipids.  A recent study showed that activated PAR2 is 
ubiquitinated by the E3 ligase Cbl, and a receptor mutant that is not ubiquitinated fails to 
degrade in the presence of agonist (Jacob et al., 2005a).  In addition, post-endocytic 
sorting of PAR2 requires Hrs, but the role of Tsg101 and other members of the ESCRT 
machinery is currently unknown (Hasdemir et al., 2007). In contrast to wildtype PAR2, 
the δ-opioid receptor and PAR1 sort to lysosomes independent of ubiquitination 
(Tanowitz and Von Zastrow, 2002; Wolfe and Trejo, 2007).  Interestingly, δ-opioid 
receptor still requires Hrs for lysosomal sorting, suggesting alternative sorting 
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mechanisms of Hrs for non-ubiquitinated cargo (Whistler et al., 2002).  PAR1 sorts to 
lysosomes independent of Hrs and Tsg101 but requires SNX1, a protein that functions in 
vesicular trafficking (Gullapalli et al., 2006). Whether phosphorylation-deficient PAR2 
0P mutant is ubiquitinated and sorts to lysosomes through an ESCRT-dependent or 
independent pathway remains to be determined.  
Together our studies reveal a novel function for phosphorylation that 
differentially regulates PAR2 signaling and trafficking. However, whether GRKs or 
second messenger kinases phosphorylate PAR2 at distinct sites to differentially regulate 
PAR2 signaling and trafficking is not known and an important future pursuit. Moreover, 
the role of PAR2 phosphorylation in possibly regulating distinct functions of β-arrestins 
warrants further investigation. The binding of β-arrestins to activated and phosphorylated 
GPCRs appears to be independent of a consensus sequence or phosphorylation specific 
sites; however, recent studies suggest that phosphorylation by specific GRKs can have 
differential effects on β-arrestin function (Tobin, 2008). The depletion of GRK2/3 by 
siRNA knockdown reduced V2 vasopressin and AT1A angiotensin receptor 
phosphorylation and inhibited receptor internalization and desensitization whereas loss of 
GRK 5/6 only prevented prolonged MAPK activation (Kim et al., 2005; Ren et al., 2005).  
Thus, it is possible that β-arrestins form a different active conformation when bound to 
GRK2/3- versus GRK5/6-phosphorylation sites and in turn, confer different β-arrestin-
mediated functions (Tobin, 2008).  Thus far, we have been unable to identify specific 
phosphorylation sites in PAR2 that might differentially regulate β-arrestin function, 
suggesting that other determinants may also contribute to the diverse regulatory 
mechanisms that control PAR2 signaling and trafficking. 
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Figure 2.1.  Agonist-induced phosphorylation of PAR2 occurs within the C-tail 
region.  (A) The PAR2 C-tail serines (S) and threonines (T) are shown in bold and 
were mutated to alanine (A) to generate the PAR2 0P mutant.  (B) Rat1 fibroblasts 
stably expressing comparable amounts of FLAG-tagged PAR2 wildtype or 0P mutant 
labeled with [32P]orthophosphate were stimulated with 100 µM SLIGKV for various 
times at 37oC. Equivalent amounts of cell lysates were immunoprecipitated with 
monoclonal M2 anti-FLAG antibody. Receptor immunoprecipitates were resolved by 
SDS-PAGE and analyzed by autoradiography. No phosphorylated proteins were 
detected in immunoprecipitates from untransfected (UT) Rat1 fibroblasts.  Membranes 
were then probed with a polyclonal anti-FLAG antibody to detect total PAR2.  The 
FLAG-positive band at 50 kDa in the UT lane is non-specific and also detected in all 
PAR2 wildtype and PAR2 0P lanes.  The initial amounts (mean ± S.D.; n=3) of cell 
surface receptor expression measured by ELISA were 0.164 ± 0.033 and 0.112 ± 
0.015 OD units for PAR2 wildtype and 0P mutant, respectively. 
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Figure 2.2.  Activated PAR2 phosphorylation is critical for desensitization.  (A) 
Rat1 fibroblasts and (B) HeLa cells stably expressing PAR2 wildtype and 0P mutant 
labeled with myo-[3H]inositol were incubated in the absence or presence of 10 nM 
trypsin for various times at 37°C, and total [3H]IPs were measured.  The data (mean ± 
SEM; n=3) shown are expressed as -fold increase over basal [3H]IPs and averaged 
over three independent experiments.  (C) The concentration effect curves of trypsin at 
PAR2 wildtype and 0P mutant were determined in Rat1 fibroblasts.  Cells labeled with 
myo-[3H]inositol were incubated with varying concentrations of trypsin for 10 min at 
37oC, and [3H]IPs were measured.  The data (mean ± SEM; n=3) shown are averaged 
from three independent experiments. (D), The table presents the effective 
concentrations of trypsin at PAR2 wildtype and 0P mutant determined in Rat1 
fibroblasts in Fig. 2.2C and in HeLa cells using the same experimental conditions.  
The data (mean EC50 ± SEM.; n=3) presented are averaged from three separate 
experiments. The initial cell surface receptor expression (mean ± SD; n=3) measured 
by ELISA in HeLa cells was 0.253 ± 0.022 and 0.196 ± 0.023 OD units for PAR2 
wildtype and PAR2 0P mutant, respectively. 
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Figure 2.3. Activated PAR2 exhibits multiple and/or redundant sites of 
phosphorylation. (A) Several PAR2 C-tail serine (S) and threonine (T) cluster 
mutants were generated by replacing specific S/T with alanines (A) as depicted.  
Cluster mutants were designated as PAR2 S363/6A as previously described (DeFea et 
al., 2000; Stalheim et al., 2005) and C1-C5 for remaining cluster mutants. (B) Rat1 
fibroblasts stably expressing FLAG-tagged PAR2 WT, 0P or S/T cluster mutants 
labeled with [32P]orthophosphate were incubated in the absence or presence of 100 
µM SLIGKV for 2.5 min at 37°C.  Cell lysates were immunoprecipitated with M2 
monoclonal anti-FLAG antibody, resolved by SDS-PAGE and analyzed by 
autoradiography. The membranes were stripped and reprobed with polyclonal anti-
FLAG antibody to detect total PAR2. (C) Rat1 fibroblasts expressing FLAG-tagged 
PAR2 wildtype, 0P or S/T cluster mutants labeled with myo-[3H]inositol were 
incubated in the absence or presence of 10 nM trypsin for 60 min at 37oC, and total 
[3H]IPs were measured.  The data (mean ± SEM; n=3) shown are expressed as -fold 
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increase over basal [3H]IPs and averaged from three independent experiments.  A 
significant difference between PAR2 WT and PAR2 0P stimulated PI hydrolysis was 
detected (*, P < 0.05). The following are initial cell surface receptor amounts 
measured by ELISA (mean ± S.D.; n=3): WT 0.194 ± 0.027 OD units, 0P mutant 
0.138 ± 0.004 OD units, C1 0.097 ± 0.013 OD units, C2 0.136 ± 0.010 OD units, C3 
0.136 ± 0.010 OD units, C4 0.08 ± 0.015 OD units, C5 0.182 ± 0.004 OD units.  
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Figure 2.4. Phosphorylation-deficient PAR2 0P mutant constitutively internalizes. 
Rat1 fibroblasts stably expressing similar amounts of cell surface PAR2 wildtype or 
0P mutant were incubated with M1 anti-FLAG antibody at 4oC to label cell surface 
receptors.  Cells were then incubated in media with (A) or without (B) 100 µM 
SLIGKV for various times at 37°C.  Cells were fixed, and the amount of antibody 
bound receptor remaining on the cell surface was quantitated by ELISA.  The data are 
shown as the fraction of initial M1 anti-FLAG antibody bound receptor at time 0 min.  
The data (mean ± SEM.; n=4) is averaged from four independent experiments.  These  
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cell lines were also used in analyzing PAR2 signaling, and initial cell surface receptor 
expression was reported in Fig. 1.  (C) HeLa cells expressing PAR2 wildtype or 0P 
mutant were incubated in the absence or presence of 100 µM SLIGKV for 30 min at 
37°C, fixed, permeabilized and immunostained for PAR2 (green) using polyclonal 
anti-FLAG antibody and for the early endosomal marker EEA1 (red) using 
monoclonal anti-EEA1 antibody. The cells were imaged by confocal microscopy. Co-
localization of PAR2 with EEA1 is shown as yellow in the merged image. The initial 
cell surface receptor expression in HeLa cells was the same as in Fig. 2.2. Scale bar, 
10 µm.  (D and E) Rat1 fibroblasts expressing PAR2 wildtype, PAR2 0P mutant, or 
PAR2 S/T cluster mutants were examined for receptor internalization as described 
above with (D) or without (E) 100 µM SLIGKV for various times.  The data (mean ± 
SEM; n=4) shown are averaged from four separate experiments.  Initial cell surface 
expression was determined by ELISA and reported in Fig. 2.3 legend. 
 61 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Figure 2.5.  Constitutive internalization of PAR2 0P mutant requires dynamin but 
not clathrin.  HeLa cells were transiently transfected with FLAG-tagged PAR2 
wildtype or 0P mutant and GFP-tagged dynamin K44A.  (A).  Cells were labeled with 
M1 monoclonal anti-FLAG antibody for 1 h at 4oC and stimulated with or without 100 
µM SLIGKV for 30 min at 37oC.  Cells were fixed and processed for confocal 
microscopy. In GFP-tagged dynamin K44A expressing cells, PAR2 wildtype and 0P 
endocytosis was inhibited, whereas in cells lacking dynamin K44A, receptor 
internalization was partially impaired  (arrowheads).  (B) HeLa cells stably expressing 
FLAG-tagged PAR2 wildtype or 0P were transiently transfected with clathrin heavy 
chain (CHC) or non-specific (ns) siRNA for 72 h.  Cells were labeled with M1 
monoclonal anti-FLAG antibody for 1 h at 4oC and then stimulated with or without 
100 µM SLIGKV for 30 min at 37oC.  Cells were fixed and processed for confocal 
microscopy.  Cells depleted of endogenous clathrin were immunostained using anti-
clathrin monoclonal antibody X22. The images shown are representative of at least 
three separate experiments.   Scale bar, 10 µm. 
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Figure 2.6.  PAR2 0P mutant fails to induce β-arrestin-1 or -2-GFP translocation.  
(A) HeLa cells stably expressing FLAG-tagged PAR2 wildtype or 0P were transiently 
transfected with β-arrestin 1 and 2 or non-specific siRNAs for 72 h. The depletion of 
β-arrestin 1 and 2 expression was determined by immunoblot analysis using 
polyclonal anti-β-arrestin antibody A1CT. Membranes were stripped and reprobed 
with an anti-actin antibody as a control for loading. (B) Cells were labeled with 
polyclonal anti-FLAG antibody for 1 h at 4oC.  Cells were then treated with or without 
100 µM SLIGKV for 30 min at 37oC and processed for confocal microscopy.  
Confocal microscopy images are representative of results from three independent 
experiments.  Scale bar, 10 µm. 
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Figure 2.7. Constitutive internalization of PAR2 0P mutant occurs independent of 
β-arrestins.  HeLa cells stably expressing FLAG-tagged PAR2 wildtype or 0P were 
transiently transfected with β-arrestin 1 and 2 or non-specific siRNAs for 72 h.  Cells 
were labeled with polyclonal anti-FLAG antibody for 1 h at 4oC.  Cells were then 
treated with or without 100 µM SLIGKV for 30 min at 37oC and processed for 
confocal microscopy.  Images are representative of results from three independent 
experiments.  The depletion of β-arrestin 1 and 2 expression was determined by 
immunoblot analysis using polyclonal anti-β-arrestin antibody A1CT. Membranes 
were stripped and reprobed with an anti-actin antibody as a control for loading. Scale 
bar, 10 µm. 
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Figure 2.8. Phosphorylation-deficient PAR2 0P mutant constitutively internalizes 
and does not recycle. HeLa cells stably expressing FLAG-tagged PAR2 wildtype 
(A), 0P mutant (B), or the P/S chimera (C) were labeled with M1 anti-FLAG antibody 
for 1 h at 4 °C.  At to, cells were washed to remove unbound antibody and stimulated 
with or without 100 µM SLIGKV (PAR2-specific) or 100 µM TFLLRNPNDK 
(PAR1-specific) for 60 min at 37°C.  Cells were washed with PBS/EDTA to strip 
away any antibody bound receptor remaining on the cell surface and warmed for 
various times at 37°C to allow recovery of internalized receptor to the cell surface.  
Cells were then fixed and recovery of antibody bound receptor was quantitated by 
ELISA.  The data (mean ± S.D.; n=3) is represented as a fraction of total M1 antibody 
bound at time to, and representative of three independent experiments. 
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Figure 2.9.  Co-localization of PAR2 wildtype and 0P mutant with LAMP1.  HeLa 
cells stably expressing FLAG-tagged PAR2 wildtype or 0P mutant were pre-treated 
with or without 2 mM leupeptin for 1 h at 37°C.  Cells were incubated with polyclonal 
anti-FLAG antibody for 1 h at 4°C to label cell surface receptors and then incubated in 
the absence (A) or presence (B) of 100 µM SLIGKV 2.5 h at 37°C.  Cells were fixed, 
processed and immunostained for PAR2 (green) and for LAMP1 (red) and imaged by 
confocal microscopy. Co-localization of PAR2 with LAMP1 is shown as yellow in the 
merged imaged and the cells shown are representative of many cells visualized in 
three independent experiments. Scale bar, 10 µm. 
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Figure. 2.10.  Phosphorylation-deficient PAR2 0P mutant is constitutively sorted 
to lysosomes and degraded. HeLa cells expressing FLAG-tagged PAR2 wildtype (A) 
or 0P mutant (B) were incubated with or without 100 µM SLIGKV for various times 
at 37°C in presence of 10 µM cycloheximide (CHX) to prevent new receptor 
synthesis.  Equivalent amounts of cell lysates were immunoprecipitated with M2 anti-
FLAG antibody, and the amount of PAR2 remaining was detected by immunoblot 
analysis. Untransfected (UT) HeLa cells are shown in the adjacent lanes. The band 
below 98 kDa is non-specific and is also observed in untransfected control cells.  
Immunoblot data (mean ± SEM; n=2) was quantified using Image J software and 
plotted as a fraction of untreated control cells. 
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Figure 2.11. Model of PAR2 signaling and trafficking. Upon agonist exposure, 
PAR2 is rapidly phosphorylated on its cytoplasmic tail, and arrestins are recruited to 
the cell surface to uncouple the receptor from heterotrimeric G proteins and facilitate 
receptor internalization through a dynamin and clathrin-dependent pathway.  PAR2 
also signals independent of heterotrimeric G proteins through its interaction with 
arrestins.  Internalized PAR2 is sorted to lysosomes and degraded through a ubiquitin-
dependent pathway.  In contrast, the PAR2 0P mutant is deficient in phosphorylation 
and exhibits a defect in desensitization.  PAR2 0P fails to recruit arrestins to the cell 
surface and constitutively internalizes in a dynamin-dependent but clathrin- and 
arrestin-independent pathway.  PAR2 0P is also constitutively sorted to lysosomes and 
degraded.  Collectively, these results show the PAR2 phosphorylation differentially 
regulates receptor desensitization and endocytic trafficking. 
  
 
 
CHAPTER 3 
INTRODUCTION – PHOSPHOLIPASE C-β  ISOZYMES 
3.1 Phospholipase C Isozymes 
Phospholipase C (PLC) isozymes hydrolyze PtdIns(4,5)P2 to second messengers, 
diacylglycerol and Ins(1,4,5)P3 in response to numerous extracellular stimuli, including 
hormones, peptides, proteases, and growth factors (Rhee, 2001; Harden and Sondek, 
2006).  Membrane-bound diacylglycerol activates various protein kinase C isozymes, and 
Ins(1,4,5)P3 binds to receptors on the endoplasmic reticulum to mobilize intracellular 
calcium.  Generation of these two second messengers and activation of downstream 
signaling pathways leads to a host of cellular responses such as cell growth, proliferation, 
differentiation, contraction, and secretion. 
The PLC family is divided into of six major classes, PLC-β, -γ, -δ, -ε, -ζ, and -η, 
based on sequence homology, and each class has both common and unique structural 
motifs and distinct tissue distribution (Rhee, 2001; Harden and Sondek, 2006).  PLC 
isozymes have a low overall sequence homology, but all share the same core domain 
architecture typified in PLC-δ (Fig. 3.1).  PLC-δ contains a pleckstrin homology (PH) 
domain, four tandem elongation factor (EF) hands, a catalytic triose phosphate isomerase 
(TIM) barrel, and a C2 domain.  While this core structure is shared by PLC isozymes, 
other PLCs contain additional regulatory domains that allow diversity in intracellular 
signaling.  For example, PLC-β isozymes contain a long C-terminal region following the 
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C2 domain that is reported to be required for membrane binding, dimerization, and 
activation by the Gαq family of heterotrimeric G proteins (Blank et al., 1993; Park et al., 
1993b; Wu et al., 1993; Singer et al., 2002).  In addition, PLC-β isozymes are also 
activated by Gβγ dimers and members of the Rac family of small GTPases (Boyer et al., 
1992; Camps et al., 1992; Katz et al., 1992; Illenberger et al., 1998).  PLC-γ isoforms 
contain an additional split PH domain, two SH2 domains, and an SH3 domain (Fig. 3.1).  
PLC-γ1 isozymes bind receptor and nonreceptor tyrosine kinases through their N-
terminal SH2 domain, resulting in tyrosine phosphorylation and intramolecular 
interaction with the C-terminal SH2 domain to activate the phospholipase (Poulin et al., 
2005).  Recent studies have expanded regulation of PLC-γ2 to include Rac GTPases, 
which interact with the split PH domain and promote activation of PLC-γ2 (Piechulek et 
al., 2005; Walliser et al., 2008).  PLC-ε contains regulatory domains for activation by 
both Rho and Ras GTPase family members (Shibatohge et al., 1998; Kelley et al., 2001; 
Song et al., 2001; Wing et al., 2003; Seifert et al., 2004).  Thus, PLC isozymes coordinate 
signaling from distinct cellular inputs to convert PtdIns(4,5)P2 into second messengers 
and to elicit diverse physiological responses. 
3.2 Structure of PLC isozymes 
3.2.1 PH domain 
Three-dimensional crystal structures of two separate PLC-δ1 fragments provide 
structural insight into the core domains of all PLC isozymes.  The first structure consists 
of the N-terminal rat PLC-δ1 PH domain bound to Ins(1,4,5)P3, and the second structure 
contains the remaining PLC domains (Ferguson et al., 1995; Essen et al., 1996).  The 
structure of PLC-δ1 PH domain is similar to the architecture of other known PH domains 
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and consists of ~120 amino acids.  The PH domain forms a β sandwich of seven β strands 
with a C-terminal α-helix at one end (Ferguson et al., 1995).  PH domains are small 
protein modules found in molecules that function in cell signaling, cytoskeletal 
rearrangement, protein trafficking, and other cellular processes (Lemmon and Ferguson, 
2000). 
PH domains were initially reported to bind specifically to certain 
phosphoinositides with high affinity to direct membrane targeting similar to the PH 
domain of PLC-δ1, which binds tightly and selectively to PtdIns(4,5)P2.  Recent 
advances, however, suggest that this is not always the case.  A genome-wide screen of 33 
S. cerevisiae PH domains showed that 67% of PH domains exhibited no specificity for 
different phosphoinositides tested and bound phospholipids with low affinity (Yu et al., 
2004).  Six PH domains completely lacked phosphoinositide binding, and only one 
specifically associated with PtdIns(4,5)P2 (Yu et al., 2004).  In the human genome, ~10% 
of the ~230 known PH domains bind specifically and with high affinity to 
phosphoinositides, and the function of the majority of PH domains are not clearly known. 
(Lemmon, 2008).  For some PH domains, binding to protein substrates is a mechanism 
for regulating cellular processes.  For example, the PH domain of GRK2 and PLC-β 
isozymes interact with Gβγ, and the PH domains of PLC-β and PLC-γ bind Rho GTPases 
for membrane targeting and activation (Pitcher et al., 1992; Wang et al., 1999b; Wang et 
al., 2000; Illenberger et al., 2003a; Illenberger et al., 2003b; Walliser et al., 2008). 
In the case of PLC-δ1, its N-terminal PH domain has a polarized electrostatic 
surface opposite the C-terminal helix for specifically binding PtdIns(4,5)P2 and 
Ins(1,4,5)P3 (Ferguson et al., 1995).  In the crystal structure, negatively charged 
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Ins(1,4,5)P3 binds predominantly to positively charged β/β loops of the PH domain 
(Ferguson et al., 1995).  In cells, the PH domain binds PtdIns(4,5)P2 to aid in membrane 
association of PLC-δ1 and to promote its contact with phospholipid substrates (Cifuentes 
et al., 1993; Garcia et al., 1995; Lemmon et al., 1995).  Thus, the PH domain enables 
PLC-δ isozymes to interact with PtdIns(4,5)P2-containing membranes and catalyze 
hydrolysis of many phospholipid substrates before dissociating from the membrane, a 
process known as membrane scooting (Cifuentes et al., 1993; Lomasney et al., 1996).  
The Ins(1,4,5)P3 product competes with PtdIns(4,5)P2 substrate for binding to the PH 
domain, inhibits the association of PLC-δ1 with cell membranes, and acts as a negative 
feedback loop for enzymatic activity. 
 Other PLC isozymes also contain PH domains at their N-terminus.  However, 
comparisons of the PH domain of PLC-δ1 with other PLC isozymes reveal that the 
polarized electrostatic surface and the positively charged residues needed for 
PtdIns(4,5)P2 binding are not well conserved (Singh and Murray, 2003; Jezyk et al., 
2006).  Instead, the PH domains of PLC-β isozymes form protein-protein interactions 
with their regulators, Gβγ and Rac GTPases (Wang et al., 1999b; Wang et al., 2000; 
Illenberger et al., 2003a; Illenberger et al., 2003b).  Rac GTPases bind exclusively to the 
PH domain of PLC-β2 and PLC-β3, recruiting the enzymes to the cell surface and 
orienting them for contact with phosphoinositide substrates (Illenberger et al., 2003a; 
Illenberger et al., 2003b; Snyder et al., 2003).  Thus, unlike PLC-δ1, PLC-β isozymes use 
Rac GTPases and possibly other regulators to associate with membranes to control 
enzymatic activity instead of phosphoinositides.  A second PLC isozyme, PLC-γ, also 
lacks residues in its PH domain needed for binding PtdIns(4,5)P2 and Ins(1,4,5)P3 and 
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instead preferentially binds PtdIns(3,4,5)P3-containing membranes in response to PI3 
kinase activity (Falasca et al., 1998).  Thus, while PLC isozymes share the same core 
architecture, the mechanisms that regulate membrane binding and enzyme activity differ 
between the PLC family members, providing complexity and diversity in PLC signaling. 
3.2.2 EF hands 
 The second three-dimensional structure of PLC-δ1 consists of the remaining core 
architectural motifs including a series of EF hands, a catalytic TIM barrel, and a C-
terminal C2 domain (Essen et al., 1996).  PLC-δ1 and other PLC isozymes contain four 
tandem EF hands following the N-terminal PH domain.  EF hand motifs are composed of 
a helix-loop-helix domain found in calcium binding proteins such as calmodulin and 
troponin C (Strynadka and James, 1989).  Positively charged calcium binds within the 
loop region of the EF hand motif to acidic residues, Asp and Glu, as well as to the peptide 
backbone. 
The EF hands of PLC isozymes form four consecutive helix-loop-helix 
arrangements.   This domain does not interact with the C-terminal catalytic TIM barrel 
but does make extensive contacts with the C2 domain (Essen et al., 1996; Jezyk et al., 
2006).  While other characterized EF hands are known to bind calcium, the analogous 
regions of PLC isozymes are not well conserved.  In the crystal structure, PLC-δ1 lacked 
calcium binding within its EF hands (Essen et al., 1996).  However, subsequent studies 
showed that PLC-δ1 EF hands are capable of binding calcium and that this contributes to 
the affinity of the PH domain for PtdIns(4,5)P2-containing membranes (Yamamoto et al., 
1999). 
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3.2.3 TIM barrel 
 TIM barrel proteins predominantly function as enzymes for cellular metabolism 
and are ubiquitously expressed in nature (Wierenga, 2001).  The TIM barrel structure was 
first observed for triose-phosphate isomerase, which forms a barrel structure composed of 
eight βα repeats.  The eight β-strands fold into parallel β-sheets surrounded by eight α-
helices, and the catalytic domain is located near the C-terminal end of the barrel.  This 
three-dimensional fold is highly conserved in nature and found in proteins with diverse 
enzymatic functions. 
The crystal structure of PLC-δ1 revealed that the catalytic domain of this enzyme 
forms a distorted TIM barrel, consisting of two highly conserved regions, an X and Y box 
separated by a long flexible linker (Essen et al., 1996).  The X and Y box form two 
halves of the catalytic TIM barrel.  The X box encompasses the N-terminal half, forming 
a classic βα repeat arrangement of other known TIM barrels.  The Y box comprises the 
C-terminal portion and adopts a typical βα repeat topology except for a disordered loop 
between Tβ5 and Tβ6.  The active site is located at the C-terminal end of the barrel and 
forms a cleft that accommodates calcium and phosphoinositides.  Structural and 
mutational analysis of rat PLC-δ1 illustrates the importance of Lys438, Lys440, Ser522, 
and Arg549 in binding and stabilizing the 4- and 5-phosphate groups of the 
phosphoinositide ring (Fig. 3.2) (Ellis et al., 1998).  These residues are highly conserved 
amongst all PLC isozymes from bacteria to mammals.  In addition, the active site is also 
surrounded by several hydrophobic loops between Tβ1/Tα1, Tβ2/Tα2, and Tβ7/Tα6 that 
form a hydrophobic ridge, possibly important for insertion into membranes and 
localization of the active site with phosphoinositide substrates (Essen et al., 1996).  
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All PLC isozymes use the same mechanism to hydrolysis PtdIns(4,5)P2 to 
diacylglycerol and Ins(1,4,5)P3.  The residues required for substrate and calcium binding 
and acid-base catalysis are conserved in other PLC isoforms.  The catalysis reaction 
requires calcium, which is located at the bottom of the active site (Fig. 3.2A).  In rat 
PLC-δ1, Asn312, Asp343, Glu341, and Glu390 coordinate the calcium ion and also make 
contacts with hydroxyl groups and the 1-phosphate on the inositol ring (Essen et al., 
1996).  The basic imidazole rings of His311 and His356 facilitate acid-base catalysis of 
phosphoinositide substrates (Fig. 3.2B).  The 2-hydroxyl group is deprotonated and 
subsequently undergoes nucleophilic attack of the 1-phosphoryl group on the inositol 
ring, forming a 1,2-cyclic-inositolphosphate intermediate and diacylglycerol.  A water 
molecule hydrolyzes the cyclic inositol phosphate intermediate to give the linear 
Ins(1,4,5)P3 product, which is then released from the active site into the cytosol. 
3.2.4 X/Y linker   
The highly conserved X and Y boxes of the catalytic core are split by a flexible 
region known as the X/Y linker.  This region varies in length and amino acid sequence 
across PLC isozymes and lacks conserved protein domains with the exception of PLC-γ.  
The X/Y linker of PLC-γ contains various modular domains, including a split PH domain, 
two SH2 domains, and a SH3 domain.  The N-terminal SH2 domain is phosphorylated by 
receptor and non-receptor tyrosine kinases and intramolecularly binds to the C-terminal 
SH2 domain for PLC-γ activation (Poulin et al., 2005).  The split PH domain of PLC-γ2 
forms one functional unit and binds to Rac GTPases to stimulate PLC activity (Piechulek 
et al., 2005; Walliser et al., 2008). 
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Studies of the X/Y linkers of various PLC isozymes suggest that this region plays 
an autoinhibitory role and prevents basal PLC activity.  Limited trypsin digestion of the 
PLC-δ1 X/Y linker showed that proteolytic fragments of the highly conserved X and Y 
box formed a stable complex and displayed enhanced catalytic activity compared to full 
length PLC-δ1 (Ellis et al., 1993).  Similar proteolysis studies of PLC-β2 and PLC-γ also 
demonstrated that the separate X and Y box form one functional unit and exhibit higher 
basal activity (Fernald et al., 1994).  These results were further validated for PLC-β2 and 
PLC-γ1 when individual polypeptides of the X and Y regions were coexpressed in cells, 
and a significant increase in PLC activity was observed.  No activity was detected when 
these regions were expressed individually (Horstman et al., 1999; Zhang and Neer, 2001).  
Using sequential deletion, removal of the SH array in the X/Y linker of PLC-γ1 was 
found to specifically increase basal activity, suggesting that the SH domains play a 
negative regulatory role in modulating basal PLC-γ1 activity (Horstman et al., 1999). 
Two high-resolution crystal structures of PLC-β2 in complex with Rac1 and the 
unbound PLC-β2 holoenzyme provided both structural and biochemical evidence to 
explain why proteolysis or deletion of X/Y linkers enhances basal PLC activity.  Both of 
these structures revealed that an ordered 20 amino acid portion of the X/Y linker blocked 
the active site and formed hydrogen bonds with several residues on the TIM barrel (Jezyk 
et al., 2006; Hicks et al., 2008).  Removal of this ordered region increased basal activity 
in intact cells by 5-20-fold compared to wildtype PLC-β2, and deletion of the remaining 
portion of the X/Y linker increased basal activity to a much greater extent (Hicks et al., 
2008).  These results were confirmed with purified proteins reconstituted into 
phospholipid vesicles containing [3H]PtdIns(4,5)P2.  Purified PLC-β2 lacking the ordered 
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region of the X/Y linker displayed a 8-fold increase in PLC activity compared to wildtype 
PLC-β2.  In addition, PLC-β2 mutants lacking the X/Y linker were still sensitive to 
further stimulation by Gαq, Gβγ, or constitutively active Rac3 in intact cells and in 
reconstitution experiments (Hicks et al., 2008).  Removing the X/Y linkers of PLC-β1 or 
divergent isozymes PLC-δ1 and PLC-ε also resulted in constitutively active enzymes 
(Hicks et al., 2008).  Collectively, these observations supported a general mechanism for 
occlusion of the active site by X/Y linkers and autoinhibition of PLC activity. 
The X/Y linkers of PLC isozymes differ greatly in length and amino acid 
sequence, but they all contain a large portion of negatively charged residues.  Hicks et al. 
proposed that negatively charged X/Y linkers are repelled from negatively charged 
phospholipid membranes, and autoinhibition of PLC isozymes is released (Hicks et al., 
2008).  Comparison of the three-dimensional structures of PLC-β2 in complex with Rac1 
to unbound PLC-β2 revealed little to no change in conformation of the catalytic domain 
(Jezyk et al., 2006; Hicks et al., 2008).  As a whole, these results indicated that regulators 
of PLC isozymes such as Rac and possibly Gαq and Gβγ recruit and orient PLC isoforms 
to lipid bilayers, and removal of the autoinhibitory X/Y linker by negatively charged 
membranes leads to PtdIns(4,5)P2 binding and hydrolysis.  In the basal state, the X/Y 
linker blocks the active site of PLC isozymes and prevents spurious substrate hydrolysis. 
3.2.5 C2 domain 
C2 domains are protein modules of ~130 amino acids that are found in many 
proteins involved in signal transduction and membrane trafficking (Cho and Stahelin, 
2006; Lemmon, 2008).  C2 domains form an anti-parallel β-sandwich topology 
consisting of eight β-strands (Sutton et al., 1995; Perisic et al., 1998; Sutton and Sprang, 
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1998).  For some C2 domains, calcium binding facilitates association with phospholipid 
membranes.  Calcium binds to conserved loops between β-strands and changes the 
overall electrostatic potential of the membrane-binding surface from negative to positive 
(Shao et al., 1997; Murray and Honig, 2002).  Calcium ions can also “bridge” C2 
domains to anionic phospholipids.  A crystal structure of the PKCα C2 domain showed 
phosphatidylserine contacting a calcium ion and amino acids within the conserved β/β 
loops (Verdaguer et al., 1999).  In some cases, C2 domain function is calcium-
independent, and a subgroup of C2 domains use a separate positively-charged region on 
the surface of the β-sandwich to attach to phospholipid membranes (Cho and Stahelin, 
2006; Lemmon, 2008).  C2 domains are also known to form protein-protein interactions, 
which can be calcium-dependent or independent (Cho and Stahelin, 2006; Lemmon, 
2008). 
Inspection of the PLC-δ1 structure showed that its C2 domain ligates calcium at 
three or four sites through its β/β loops to facilitate membrane attachment (Essen et al., 
1996).  The C2 domain functions together with the PH domain to bind lipid bilayers 
(Essen et al., 1996; Essen et al., 1997).  In the case of PLC-β isozymes, the C2 domain 
has no apparent affinity for phospholipid membranes in the presence of calcium (Wang et 
al., 1999a).  PLC-β and other PLC isozymes lack the residues needed for calcium binding 
and use other mechanisms to associate with lipid bilayers.  Instead, PLC-β2 C2 domains 
were found to interact with activated Gαq in a nucleotide-dependent manner and 
contribute to PLC-β activation by Gαq (Wang et al., 1999a). 
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3.3 PLC-β  isozymes 
 PLC-β isozymes contain a long C-terminal extension of approximately 400 amino 
acids following their C2 domain, making these enzymes unique from other PLC family 
members (Fig. 3.3).  The C-terminal region is proposed to be required for membrane 
association and for binding and activation by Gαq subunits (Blank et al., 1993; Park et al., 
1993b; Wu et al., 1993).  In addition, PLC-β isozymes are also directly activated by Rac 
GTPases and Gβγ subunits released from the Gαi/o family of heterotrimeric G proteins 
(Boyer et al., 1992; Camps et al., 1992; Katz et al., 1992; Illenberger et al., 1998).  
Activation by these diverse protein regulators allows for modulation of phosphoinositide 
signaling from various extracellular stimuli acting on both heterotrimeric and small 
monomeric G proteins (Fig. 3.3). 
3.4 Physiology of PLC-β  isozymes 
 PLC-β isozymes are arguably the major effector proteins downstream of the Gαq 
signaling pathway.  Extracellular stimuli including hormones, peptides, and proteases 
activate ~40% of GPCRs that either couple partly or exclusively to the Gαq family of 
heterotrimeric G proteins and regulate cellular processes through the Gαq/PLC-β 
signaling axis (Harmar et al., 2009).  These cellular processes include platelet activation 
and regulation of memory, motor coordination, appetite, and sleep (Offermanns and 
Simon, 1998; Wettschureck and Offermanns, 2005; Hubbard and Hepler, 2006).  Indeed, 
Gαq signaling in the cardiovascular system controls smooth muscle tone and blood 
pressure through activation of PLC-β isozymes.  Ins(1,4,5)P3-promoted release of 
intracellular calcium leads to phosphorylation of myosin light chain, which mediates 
actin contractility and vasoconstriction. 
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Studies of PLC-β knockout mice have revealed isoform-specific functions of 
PLC-β isozymes in physiological and pathological processes.  Each member of the PLC-
β family (PLC-β1, -β2, -β3, -β4) has distinct expression profiles in various tissues and 
cell types.  PLC-β1 is highly expressed in the hippocampus and cerebral cortex whereas 
PLC-β2 is mostly restricted to hematopoietic cell types (Ross et al., 1989; Park et al., 
1992; Sun et al., 2007).  PLC-β3 is present in the brain, liver, and parotid gland, and 
PLC-β4 is highly expressed in regions of the brain and retina (Jhon et al., 1993; Tanaka 
and Kondo, 1994; Adamski et al., 1999).  Mice deficient in PLC-β1 exhibit epilepsy 
possibly due to a loss of mAChR signaling in the hippocampus (Kim et al., 1997).  PLC-
β4-/- mice display ataxia, which may be due to a defect in metabotropic glutamate 
receptor (mGluR) signaling in Purkinje cells in the cerebellum (Kim et al., 1997).  
Consistent with this conclusion, mGluR1 is predominantly expressed in Purkinje cells, 
and mGluR1-/- mice also display an ataxia phenotype (Aiba et al., 1994). 
Neutrophils isolated from PLC-β2-/- and PLC-β2-/-;PLC-β3-/- mice are impaired in 
chemokine signaling, specifically showing a decrease in inositol phosphate accumulation, 
intracellular calcium levels, superoxide production, and MAC-1 expression on the cell 
surface (Jiang et al., 1997; Li et al., 2000).  Despite this loss in chemokine signaling, 
neutrophils isolated from PLC-β2-/- and PLC-β2-/-;PLC-β3-/- mice show no defects in 
chemotaxis and in some leukocyte populations display an enhanced chemotactic response 
(Jiang et al., 1997; Li et al., 2000).  In contrast, PLC-β2-/-;PLC-β3-/- lymphocytes are 
impaired in chemotaxis, suggesting that the function of PLC-β isozymes in cell migration 
is dependent on enzyme expression in particular cell types and can have a positive, 
negative, or no effect on chemotactic activity (Bach et al., 2007). 
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PLC-β3-/- mice display an increased sensitivity to µ-opioids in behavioral assays 
measuring nociception responses, indicating that PLC-β3 negatively regulates µ-opioid 
function (Xie et al., 1999).  These results were recapitulated in dorsal root ganglia 
neurons where PLC-β3 deficiency enhanced µ-opioid-induced regulation of voltage-
gated calcium channels (Xie et al., 1999).  Another study showed a role for PLC-β3 in 
mediating signaling in sensory neurons.  Dorsal root ganglia neurons derived from PLC-
β3-/- mice showed a significant decrease in histamine-induced calcium efflux whereas 
other agonists such as ATP, UTP, and bradykinin stimulated similar calcium responses in 
both wildtype and PLC-β3-/- cells (Han et al., 2006).  Moreover, PLC-β3-/- mice displayed 
a significant decrease in scratching induced by the histamine H1 receptor, demonstrating 
that PLC-β3 is required for the histamine-mediated itch response (Han et al., 2006). 
PLC-β3 is also implicated in pathological responses.  For example, a recent study 
showed that PLC-β3 might potentiate atherosclerosis by promoting cell survival of 
macrophages in atherosclerotic plaques (Wang et al., 2008).  Loss of PLC-β3 increases 
the sensitivity of macrophages to apoptotic stimuli.  Furthermore, in an atherosclerosis 
model, PLC-β3-/-;apoE-/- mice had significantly less macrophages in atherosclerotic 
plaques and were protected from atherosclerotic lesions compared to apoE-/- mice, 
suggesting a negative role for PLC-β3 in progression of atherosclerosis (Wang et al., 
2008).  PLC-β3 may also have tumor suppressor activity (Xiao et al., 2009).  Xiao et al. 
found that PLC-β3-/- mice developed a variety of tumors including myeloproliferative 
disease, lymphoma, and skin and lung carcinomas within an age of 16 months, which was 
not observed with PLC-β2-/- mice (Xiao et al., 2009).  PLC-β3-/- mice had an increased 
number of hematopoietic stem cells that hyperproliferated, evaded apoptosis, and were 
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capable of myeloid differentiation, suggesting that PLC-β3 may act as a tumor suppressor 
in hematopoietic tissues (Xiao et al., 2009).  
PLC-β isoforms have overlapping expression profiles in some tissues, but only 
one isoform mediates a particular response.  For example, in mouse dorsal root ganglia, 
PLC-β3 is the predominant PLC-β isoform, but PLC-β4 and PLC-β1 are also expressed 
at lower levels (Han et al., 2006).  Loss of PLC-β3 had a significant effect on histamine-
induced signaling but no effect on ATP, UTP, or bradykinin-stimulated signaling, 
indicating that other PLC-β isoforms elicit responses to these ligands (Han et al., 2006).  
The selectivity of PLC-β isoforms can occur through several different mechanisms.  In 
addition to distinct tissue distribution and varying expression levels, PLC-β isozymes 
also have different sensitivities to protein regulators.  PLC-β1 and PLC-β3 are the most 
responsive to Gαq stimulation (Hepler et al., 1993; Jhon et al., 1993; Park et al., 1993a; 
Smrcka and Sternweis, 1993).  In contrast, PLC-β2 and PLC-β3 are the most responsive 
to Gβγ subunits released from Gαi whereas PLC-β1 shows little to no activation (Park et 
al., 1993a; Smrcka and Sternweis, 1993).  PLC-β2 is the most sensitive to activation by 
Rac GTPases (Illenberger et al., 2003a; Snyder et al., 2003).  Thus, differences in 
sensitivity to protein regulators provide some level of PLC-β specificity for a particular 
signaling pathway. 
In addition, PLC-β isozymes have PSD-95/Dlg/ZO-1 (PDZ) ligands on their C-
terminal regions and interact with scaffolding molecules containing PDZ domains 
(Hwang et al., 2000; Tang et al., 2000).  In Drosophila, PDZ-containing protein, INAD 
facilitates formation of a multiprotein complex composed of NorpA (PLC-β), PKC, Gαq, 
and light-sensitive ion channels TRP and TRPL.  INAD targets these proteins to 
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photoreceptor cell membranes to promote phototransduction, and disruption of the PLC 
and INAD interaction leads to abnormal termination of light responses (Chevesich et al., 
1997; Shieh et al., 1997; Tsunoda et al., 1997).  In mammalian systems, PLC-β1 and 
PLC-β2 were found to interact with the first PDZ domain of Na+/H+ exchanger regulator 
factor 1 (NHERF1) and PLC-β3 with the second PDZ domain on NHERF2 (Hwang et 
al., 2000; Tang et al., 2000).  NHERF proteins promote formation of large signaling 
complexes and modulate the function of ion channels, signaling molecules, transcription 
factors, and cytoskeletal proteins (Weinman et al., 2005).  When NHERF2 was 
exogenously expressed in COS-7 and HeLa cells, PLC activity was potentiated in the 
presence of carbachol (Hwang et al., 2000).  The molecular mechanism that controls this 
additive effect of NHERF2 is not currently known.  Nonetheless, these observations 
suggest that under certain conditions PLC-β isozymes may engage PDZ domain-
containing proteins, which facilitate formation of large signaling complexes of specific 
PLC-β isoforms and regulators and provide a mechanism for eliciting particular signaling 
responses (Hwang et al., 2000; Suh et al., 2001). 
3.5 Activation of PLC-β  isozymes by heterotrimeric G proteins 
3.5.1 Heterotrimeric G proteins 
Heterotrimeric G proteins coordinate signals from cell surface G protein-coupled 
receptors (GPCRs) to intracellular effectors through a regulated cycle of activation and 
deactivation steps.  Heterotrimeric G proteins are composed of three subunits, α, β, and γ.  
G proteins are inactive in a GDP-bound state and associate with Gβγ dimers.  
Extracellular stimuli bind to cell surface GPCRs and cause a conformational change that 
promotes coupling to heterotrimeric G proteins.  GPCRs catalyze exchange of GTP for 
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GDP on the Gα subunit.  Consequently, GTP-bound Gα subunits have a lower affinity 
for the Gβγ dimers, and both GTP-bound Gα and Gβγ dimers interact with downstream 
effectors to transmit intracellular signaling.  Signaling is terminated by the intrinsic 
GTPase activity of the Gα subunit, converting active GTP-bound Gα to an inactive GDP-
bound state.  GTP hydrolysis is accelerated by GTPase activating proteins (GAPs) 
present in some effector molecules or in regulator of G protein signaling (RGS) proteins 
to complete the activation and deactivation cycle. 
The heterotrimeric G protein family is divided into four classes, Gαs (Gαs, Gαolf), 
Gαi (Gαi1-3, Gαo, Gαt, Gαz) Gαq (Gαq, Gα11, Gα14, Gα15/16), and Gα12/13 based on 
sequence homology and function (Simon et al., 1991; Oldham and Hamm, 2006).  Gαs 
proteins bind and stimulate adenylyl cyclases, which convert ATP to cAMP.  Augmented 
cAMP levels regulate the activities of several molecules including protein kinase A and 
ion channels.  Cyclic AMP also directly binds and stimulates GEF proteins known as 
exchange proteins activated by cAMP (EPAC) to regulate the activity of Ras GTPase 
homologues Rap1 and Rap2 (Kozasa et al., 1993; de Rooij et al., 1998).  In addition, Gαs 
may also directly stimulate cardiac calcium channels and Src tyrosine kinases (Yatani et 
al., 1987; Mattera et al., 1989; Ma et al., 2000).  Gαi1-3 and Gαz proteins directly bind and 
inhibit some adenylyl cyclases to reduce cAMP levels and modulate activity of voltage-
gated ion channels through release of Gβγ subunits (Simon et al., 1991).  Gαt regulates 
phototransduction in retinal rods and cones by interacting with the inhibitory γ subunit of 
cGMP phosphodiestrase (PDE).  All Gαq proteins activate the PLC-β family of isozymes, 
which hydrolyze PtdIns(4,5)P2 to Ins(1,4,5)P3 and diacylglycerol (Exton, 1996).  
Ins(1,4,5)P3 binds receptors on the endoplasmic reticulum to mobilize intracellular 
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calcium, and diacylglycerol activates PKC.  In recent studies, Gαq was also shown to 
directly engage p63RhoGEF to stimulate GEF activity on RhoA (Lutz et al., 2005; Rojas 
et al., 2007).  Gα12/13 proteins activate the Rho pathway by binding to Rho-specific GEFs 
p115RhoGEF, PDZ-RhoGEF, and LARG (Hart et al., 1998; Fukuhara et al., 1999; 
Fukuhara et al., 2000).  Gα12/13 proteins were also shown to bind and stimulate activity of 
Bruton’s tyrosine kinase and rasGAP (Jiang et al., 1998). In addition, Gα12/13 interact 
with cadherin and radixin, proteins involved in cell-cell adhesion, cytoskeletal 
rearrangement, and gene transcription (Vaiskunaite et al., 2000; Meigs et al., 2001). 
All Gα subunits have a similar three-dimensional structure consisting of a 
GTPase domain and a helical domain.  The GTPase domain is structurally homologous to 
small, monomeric G proteins of the Ras superfamily and composed of six β-strands 
enclosed by five α-helices (Noel et al., 1993; Coleman et al., 1994; Lambright et al., 
1994).  The GTPase domain contains highly conserved regions for guanine nucleotide 
and Mg2+ binding, hydrolyzing GTP, and interactions with Gβγ, GPCRs, and RGS 
proteins.  The GTPase domain contains three highly conserved flexible loops referred to 
as Switch I, Switch II, and Switch III (Noel et al., 1993; Coleman et al., 1994; Lambright 
et al., 1994; Sondek et al., 1994; Mixon et al., 1995).  The switch regions undergo 
structural changes when bound to GDP, GTP or in the GTP-bound transition state, 
forming a more open conformation in the GDP-bound state and a collapsed conformation 
when bound to GTP.  The guanine nucleotide-binding pocket within the GTPase domain 
is capped by the six α-helices of the helical domain, burying the nucleotide in the cleft of 
the protein.  The N-terminal and C-terminal regions of Gα subunits form α-helices and 
contain sequences for lipid modifications and insertion into cell membranes (Oldham and 
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Hamm, 2006).  In addition, these domains are critical for receptor selectivity and G 
protein activation. 
 There are six β subunits encoded in the mammalian genome, and each consists of  
seven WD40 repeats that form a seven-bladed β-propeller (Sondek et al., 1996).  A 
portion of the N-terminal domain contributes to the last β-strand of the final blade, and 
the remaining portion forms an α-helix that binds to the helix-loop-helix of the Gγ 
subunit through coiled-coiled interactions.  Gγ subunits are small 7-8 kDa proteins and 
make up a family of 12 subunits (Downes and Gautam, 1999).  The Gγ subunits contain a 
C-terminal CaaX box motif for isoprenylation and membrane association of Gβγ 
subunits.  As a stable complex, Gβγ subunits directly interact with and activate 
downstream effectors including adenylyl cyclases, PLC-β isozymes, and voltage-gated 
ion channels to elicit cellular responses. 
3.5.2 Activation of PLC-β  isozymes by Gα  subunits 
In the 1950’s, Hokin and Hokin first discovered that addition of hormones to 
secretory tissues caused rapid turnover of membrane phospholipids (Hokin and Hokin, 
1953).  Twenty years later, research by Berridge, Mitchell, and others found a link 
between phospholipid turnover and calcium signaling.  Their work showed that hormone 
stimulation of secretory cells and other cell types increased generation of Ins(1,4,5)P3 and 
that this second messenger was responsible for release of intracellular calcium from the 
endoplasmic reticulum (Berridge, 1987; Berridge, 1993).  In addition, work by Nishizuka 
and colleagues found that generation of DAG activated protein kinase C to elicit a host of 
cellular responses (Nishizuka, 1992).  By the 1980’s, several studies had demonstrated a 
molecular link between hormone stimulation of cell surface receptors to phosphoinositide 
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turnover and generation of second messengers, but a key component directly coupling 
receptors to phosphoinositide turnover remained elusive. 
Studies in the 1980’s and early 1990’s were the first to provide direct evidence 
that guanine nucleotide binding proteins regulated phosphoinositide hydrolysis. 
Cockcroft and Gomperts showed that treatment of human peripheral neutrophil 
membranes with GTPγS or other non-hydrolyzable GTP analogues increased hydrolysis 
of polyphosphoinositides (Cockcroft and Gomperts, 1985).  In addition, Litosch et al. 
demonstrated that stimulating homogenates and cell membranes of blowfly salivary 
glands with 5-hydroxytryptamine and non-hydrolyzable GTP analogues increased 
inositol phosphate accumulation (Litosch et al., 1985). Collectively, these results 
implicated a guanine nucleotide binding protein in regulating hormone-stimulated 
phosphoinositide turnover and provided a molecular link between cell surface receptors 
and phospholipase activity (Cockcroft and Gomperts, 1985; Litosch et al., 1985). 
Several studies demonstrated that hormone-activated phosphoinositide hydrolysis 
occurred through both a pertussis toxin-sensitive and insensitive pathway depending on 
the tissue type or stimulating hormone.  These studies alluded to the existence of an 
unknown heterotrimeric G protein in activating the pertussis toxin-insensitive pathway.  
Taylor et al. first identified a toxin-insensitive activator of PLC in bovine liver plasma 
membranes (Taylor et al., 1990).  In this study, a GTPγS analog stimulated PLC activity 
in cholate-solubilized extracts.  The PLC activity was absorbed on heparin-Sepharose 
matrix and only restored when recombined with supernatant proteins.  The PLC activator 
was purified and identified as a unique 42-kDa Gα subunit using immunoblot analysis 
and antibodies specific and common for known Gα subunits (Taylor et al., 1990). 
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In a concurrent study, a 42-kDa G protein was purified from bovine brain using 
immobilized Gβγ subunits attached to an affinity matrix (Pang and Sternweis, 1990).  
Amino acid sequencing of tryptic protein fragments revealed that the novel Gα subunit 
was identical to Gαq and Gα11, two G proteins with high sequence homology recently 
cloned by Strathmann and Simon (Strathmann et al., 1989; Pang and Sternweis, 1990; 
Strathmann and Simon, 1990).  Further characterization of purified Gαq and Gα11 
showed activation of a partially purified PLC preparation only in the presence of Gα 
subunits and AlF-4 (Smrcka et al., 1991).  Immunoblot analysis of the PLC preparations 
identified PLC-β isozymes as the activated PLC. 
In a separate study, Harden and colleagues purified a 150-kDa PLC-β from turkey 
erythrocytes and reconstituted PLC activity in phospholipid vesicles containing 
radiolabeled PtdIns(4,5)P2 (Morris et al., 1990b; Morris et al., 1990a).  Using this assay, 
they purified the PLC-activating protein from turkey erythrocyte membranes and 
identified it as a member of the Gq family of heterotrimeric G proteins by immunoblot 
analysis (Waldo et al., 1991).  The PLC-activating G protein was later identified as Gα11 
using amino acid sequencing and immunoblotting techniques (Maurice et al., 1993). 
The Gq family of heterotrimeric G proteins includes Gαq, Gα11, Gα14, and 
Gα15/16, and each Gα subunit directly binds and activates PLC-β isozymes but not other 
PLCs (Taylor et al., 1991; Taylor and Exton, 1991; Lee et al., 1992; Wu et al., 1992).  
Studies using purified proteins established that Gαq and Gα11 activate PLC-β isozymes 
with the following relative efficacies: PLC-β1≥PLC-β3>>PLC-β2 (Hepler et al., 1993; 
Jhon et al., 1993; Smrcka and Sternweis, 1993).  PLC-β4 is also stimulated by Gαq 
subunits (Jiang et al., 1994).  Gαq family members bind directly to PLC-β isozymes, and 
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PLC-β lacking the ~50 kDa C-terminal region was not activated by Gαq but retained 
activation by Gβγ (Blank et al., 1993; Park et al., 1993b; Wu et al., 1993).  A 100-kDa 
proteolytic fragment of PLC-β1 missing the long C-terminal region was purified from 
bovine extracts and was catalytically active under basal conditions but was no longer 
stimulated by Gαq and AlF-4 (Park et al., 1993b).  Sequential deletion of the C-terminal 
region of PLC-β1 suggested that a highly basic region consisting of residues 903-1030 is 
needed for membrane association and residues 1030-1142 were needed for activation by 
Gαq (Wu et al., 1993).  Further analysis of PLC-β isozymes indicated that the C2 domain 
also contributes to activation by Gαq.  Isolated PLC-β1 and PLC-β2 C2 domains bind 
selectively to Gαq in a GTPγS specific manner whereas no binding occurs between C2 
domains and Gβγ or Gαi (Wang et al., 1999a). 
The PLC-β binding domain of Gαq was determined using small synthetic peptides 
corresponding to the entire Gαq sequence (Arkinstall et al., 1995).  Peptides 
corresponding to regions of the α3 and α4 helices of Gαq inhibited activation of PLC-β 
by GTPγS-bound Gαq.  A separate study used chimeric Gαq/Gαs proteins consisting of 
constitutively active Gαq altered with analogous regions of Gαs to identify domains 
required for PLC-β activation (Venkatakrishnan and Exton, 1996).  Using these chimeric 
proteins, the authors pinpointed a region consisting of residues Ile217-Lys276 located 
within the α3 helix and α3/β5 linker of Gαq.  Alanine scanning mutagenesis of this 
region in constitutively active Gαq revealed the importance of five residues (Asp243, 
Asn244, Glu245, Arg256 and Thr257) in activation of PLC-β isozymes.  Collectively, 
these two independent studies demonstrated an important role for the α3 helix of Gαq but 
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published conflicting results for the role of the α4 helix (Arkinstall et al., 1995; 
Venkatakrishnan and Exton, 1996). 
3.5.3 GAP activity of PLC-β  isozymes 
In vitro studies of purified Gα subunits revealed that GTP hydrolysis was 
significantly slower than physiological rates of signal termination, suggesting that 
additional regulatory proteins are required to accelerate GTP hydrolysis in vivo (Vuong 
and Chabre, 1990; Vuong and Chabre, 1991).  A similar mechanism is essential for 
deactivating monomeric G proteins of the Ras superfamily in which GTPase accelerating 
proteins (GAPs) increase the rate of GTP hydrolysis approximately 1000-fold.  PLC-β 
isozymes were the first GAPs identified for heterotrimeric G proteins (Berstein et al., 
1992).  PLC-β isozymes are not only effector molecules activated by GTP-bound Gαq 
but also accelerate GTP hydrolysis on their activating G protein.  When purified PLC-β1 
was reconstituted into phospholipid vesicles containing purified M1 mAChR and Gαq/11, 
addition of carbachol accelerated the rate of GTP hydrolysis over 1000-fold (Berstein et 
al., 1992; Biddlecome et al., 1996; Mukhopadhyay and Ross, 1999).  This effect was 
rapidly blocked in the presence of muscarinic receptor antagonist, illustrating the 
importance of receptor-catalyzed GTP exchange and PLC-β GAP activity in regulating 
the cycle of activation and deactivation of Gαq and therefore, PLC activity. 
Further analysis suggested that the region of PLC-β1 GAP activity was located in 
the C-terminal extension, a region previously reported as the binding domain of Gαq.  
Purified peptide fragments of PLC-β1 C-terminus exhibited steady-state GAP activity in 
reconstitution assays with purified Gαq/11 and M1 mAChR (Paulssen et al., 1996).  The 
peptide fragments accelerated steady-state GTP hydrolysis by 4-fold, exhibiting only 
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about 15-20% of activity observed with full length PLC-β1. The authors suggested that 
this difference in GAP activity is probably due to lower affinity of the peptides for Gαq 
and a lack of membrane binding for each of the peptide fragments.  In addition, they 
suggested that a second binding site on Gαq could contribute to the remaining GAP 
activity of PLC-β1. 
The importance of PLC-β GAP activity in phototransduction was demonstrated in 
vivo using Drosophila as a model organism (Cook et al., 2000).  In invertebrates and 
vertebrates, phototransduction is stimulated through a heterotrimeric G protein signaling 
pathway.  Light activates a GPCR, rhodopsin, that catalyzes GTP exchange on the α 
subunit of a heterotrimeric G protein.  In Drosophila, rhodopsin stimulates Gαq, which 
activates its effector NorpA (PLC-β) to induce phototransduction (Montell, 1999).  Cook 
and colleagues used mutant alleles of norpA that express reduced levels of PLC-β 
isozymes.  In flies expressing lower amounts of PLC-β, response termination was 
significantly slower when light stimulus was removed compared to wildtype flies (Cook 
et al., 2000).  In addition, the norpA mutants showed a reduction in GTPase activity with 
no effect on GTPγS binding.  GTPase activity was rescued when head membranes from 
PLC-β-deficient flies were fused with membranes from flies expressing normal PLC-β 
levels.  Using flies expressing varying amounts of PLC-β, a strong correlation was 
observed between low expression of PLC-β and reduced GAP activity.  The authors 
concluded that in norpA mutants, slow response termination is due to low PLC-β levels, 
and therefore, reduced GTPase activity on Gαq.  Consequently, active GTP-bound Gαq 
continues to elicit downstream signaling in the dark until limited PLC-β eventually 
accelerates GTP hydrolysis and signal termination. 
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3.5.4 Molecular consequences of effector GAP activity 
Biochemical and kinetic analysis has provided insight into how effector GAP 
proteins, like PLC-β isozymes, maintain signal amplitude despite the presence of 
deactivating GAP activity.  At steady-state, signal amplitude is sustained by a balance of 
activation and deactivation steps in the GTPase cycle (Ross, 2008).  This balance allows 
for a fraction of Gα subunits to remain GTP-bound and active and for rapid deactivation 
when agonist is removed.  Ross and colleagues demonstrated this effect for PLC-β1 using 
a phospholipid vesicle system and purified proteins (Biddlecome et al., 1996; 
Mukhopadhyay and Ross, 1999).  Purified PLC-β1 was reconstituted into 
proteoliposomes containing purified M1 mAChR and heterotrimeric Gq.  Despite an 
increase in GTP hydrolysis at steady-state, a significant fraction of GTP-bound Gαq 
stimulated PLC activity approximately 1000-fold (Mukhopadhyay and Ross, 1999).  
Analysis of GTP exchange activity revealed that the fraction of GTP-bound Gαq was 
maintained in the presence of GAP activity as a consequence of enhanced receptor-
catalyzed exchange activity in the presence of PLC-β1 (Mukhopadhyay and Ross, 1999; 
Turcotte et al., 2008).  A similar effect on exchange activity was demonstrated when 
purified RGS4 was added to phospholipid vesicles containing heterotrimeric Gαi and M2 
mAChR (Posner et al., 1999). 
Ross and colleagues proposed a model for kinetic scaffolding to explain these 
observations (Biddlecome et al., 1996; Mukhopadhyay and Ross, 1999; Ross, 2008).  In 
this model, a stable complex of Gαq, GPCR, and PLC-β is formed at steady-state because 
GTP hydrolysis occurs much faster than the rate of receptor and Gα dissociation 
(Biddlecome et al., 1996; Mukhopadhyay and Ross, 1999; Ross, 2008; Turcotte et al., 
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2008) (Fig. 3.4).  Consequently, agonist-bound receptor catalyzes multiple rounds of 
GDP/GTP exchange on Gαq, and Gαq proceeds through the GTPase cycle numerous 
times (Biddlecome et al., 1996; Mukhopadhyay and Ross, 1999; Ross, 2008).  Therefore, 
a sufficient fraction of GTP-bound Gαq is available for activating PLC-β1, and only 
when agonist is removed is signal transduction terminated (Biddlecome et al., 1996; 
Mukhopadhyay and Ross, 1999; Ross, 2008).   
3.5.5 Activation of PLC-β  isozymes by Gβγ  subunits 
PLC-β isozymes are also regulated by Gβγ subunits through a pertussis toxin-
sensitive pathway.  Direct evidence showed that Gβγ purified from bovine brain and 
turkey erythrocytes stimulated avian PLC-β but not bovine PLC-β1 (Boyer et al., 1992).  
In a separate study, Katz et al. found that transient transfection of COS-7 cells with Gβγ 
and PLC-β2 significantly increased phosphoinositide hydrolysis whereas no effect was 
observed with cells transfected with PLC-β1 (Katz et al., 1992).  The response was 
inhibited when cells were transfected with Gαi to scavenge free Gβγ dimers and prevent 
PLC-β2 activation.  Receptor-promoted PLC activity was also observed in cells 
transfected with M2 mAChR, which couples to pertussis toxin-sensitive Gαi proteins, 
and the response was blocked by pertussis toxin treatment (Katz et al., 1992).  In a 
concurrent study, reconstitution of purified Gβγ subunits and cell extracts expressing 
PLC-β2 into PtdIns(4,5)P2-containing phospholipid vesicles increased inositol phosphate 
accumulation, but little activity was observed with PLC-β1 expressing extracts (Camps et 
al., 1992).  PLC activity was inhibited with GDP-bound Gαt, which prevented free Gβγ 
subunits from activating PLC-β2 (Camps et al., 1992).  Using purified proteins, Gβγ 
dimers have been shown to directly bind and activate PLC-β2 and PLC-β3.  PLC-β2 is 
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the most sensitive to Gβγ stimulation whereas PLC-β1 is the least responsive (Park et al., 
1993a; Smrcka and Sternweis, 1993).   
One region of Gβγ binding was mapped to the catalytic TIM barrel of PLC-β2.  A 
116 amino acid fragment of PLC-β2 encompassing the X and Y box was co-transfected 
with Gβγ and full-length PLC-β2 in COS-7 cells and prevented Gβγ-stimulated PLC 
activity (Kuang et al., 1996).  In addition, the peptide fragment also hindered activation 
of PLC-β2 in response to the Gαi-coupled complement C5a receptor but not a Gαq-
coupled receptor, suggesting that this peptide fragment interferes with Gβγ signaling but 
not Gαq.   A subsequent study used 20 amino acid peptides to narrow down the region of 
interaction between PLC-β2 and Gβγ identified by Kuang et al.  Two overlapping 
peptides containing a 10 amino acid region (Glu574-Lys583) in the PLC-β2 Y box 
inhibited Gβγ-stimulated PLC-β2 activity in vitro and interacted with Gβγ dimers in 
crosslinking experiments (Sankaran et al., 1998).  A second Gβγ binding site occurs 
within the PH domain of PLC-β2.  Wang et al. generated a chimeric protein in which the 
PH domain of PLC-δ1 was replaced with the analogous PH domain of PLC-β2.  The 
PLC-β2/δ1 chimera was activated by Gβγ subunits whereas wild-type PLC-δ1 was not, 
suggesting that the PH domain is needed for Gβγ binding and activation of PLC-β 
isozymes (Wang et al., 1999b; Wang et al., 2000).   
3.6 Activation of PLC-β  isozymes by small monomeric G proteins 
In the late 1980’s and 1990’s, a role for heterotrimeric G proteins in regulating the 
activity of PLC-β isozymes was well established. In 1997, Gierschik and colleagues 
reported that PLC-β isozymes are also effectors for small monomeric G proteins, 
revealing that PLC isozymes coordinate signaling from several cellular inputs to create 
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diversity and complexity in phosphoinositide signaling (Illenberger et al., 1997).  
Illenberger et al. showed that soluble fractions of HL-60 granulocytes and bovine 
neutrophils contained a heterodimeric complex that stimulated recombinant PLC-β2 in 
the presence of GTP and non-hydrolyzable GTP analogues but not PLC-β1 or PLC-δ1 
(Illenberger et al., 1997).  Furthermore, a PLC-β2 mutant lacking the C-terminal region 
required for activation by Gαq was also activated in the presence of the soluble PLC-
stimulating factor, suggesting that the soluble factor was not a member of the Gαq family 
and also binds to a distinct region on PLC-β2 to activate the enzyme (Illenberger et al., 
1997).  Amino acid sequencing and immunoblot analysis determined that the components 
of the heterodimeric complex were a Rho GTPase and a guanine nucleotide dissociation 
inhibitor, LyGDI (Illenberger et al., 1998).  In a reconstitution experiment, PLC-β2 was 
directly activated by purified, recombinant Cdc42Hs but not RhoA.  In addition, Rac1, 
Rac2, and Rac3 were also reported to directly stimulate PLC-β2 in a guanine nucleotide-
dependent manner and are significantly more potent than Cdc42Hs (Illenberger et al., 
1998; Illenberger et al., 2003a; Snyder et al., 2003).  Rac GTPases also activate PLC-β1 
and PLC-β3 although to a lesser extent and at a much lower potency (Snyder et al., 
2003). 
A three-dimensional crystal structure of PLC-β2 in a GTPγS-dependent complex 
with Rac1 was solved to determine the molecular mechanism of PLC-β activation by Rac 
GTPases (Jezyk et al., 2006).  Rac1 binds exclusively to the PH domain of PLC-β2, 
confirming biochemical and cell biological data that Rac GTPases make no other contacts 
with the remaining regions of PLC-β2 (Illenberger et al., 2003a; Illenberger et al., 
2003b).  Similar to other small GTPases, Rac1 interacts with PLC-β2 entirely through its 
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switch regions and primarily makes hydrophobic contacts that are supported by hydrogen 
bonds and electrostatic interactions (Jezyk et al., 2006).  Comparison of the PLC-β2⋅Rac1 
structure to a structure of unbound PLC-β2 revealed that the isozyme undergoes little to 
no conformational change when bound to Rac1, and the residues in the PLC-β2 active 
site are in the same position regardless of Rac1 binding (Jezyk et al., 2006; Hicks et al., 
2008).  Collectively, these results suggest that active, membrane bound Rac GTPases 
enhance translocation of PLC-β isozymes to the membrane and position them in the 
correct orientation for phosphoinositide binding and hydrolysis (Jezyk et al., 2006; Hicks 
et al., 2008). 
3.7 Research Goals 
 PLC-β isozymes hydrolyze PtdIns(4,5)P2 to second messengers, diacylglycerol 
and Ins(1,4,5)P3, in response to activation by Gαq, Gβγ, and Rac GTPases.  In addition, 
PLC-β isozymes also accelerate GTP hydrolysis on their activating G proteins, and 
therefore, deactivate phospholipid signaling.  Despite numerous studies examining 
regulation of PLC-β activity, the question remains: how do heterotrimeric G proteins 
activate PLC-β isozymes.  To better understand the mechanisms of PLC-β activation, the 
Harden lab has recently generated a three-dimensional crystal structure of an AlF-4-
dependent complex of PLC-β3 and its activator Gαq.  The lab has identified three novel 
contacts within the PLC-β3·Gαq interface that we hypothesize are important for Gαq 
binding and GTPase accelerating activity of PLC-β3.  The goal of this research is to use 
structure/function analysis of the PLC-β3·Gαq complex to understand the mechanisms of 
PLC-β activation by Gαq subunits and the mechanisms of PLC-β GAP activity.  We will 
use mutational analysis to determine the importance of key residues and domains in the 
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PLC-β3·Gαq interface and examine PLC activity in intact cells and directly using in vitro 
biochemical studies.  The results from this work will further our knowledge of the 
molecular mechanisms required for the canonical Gαq signaling pathway which couples 
activation of cell surface receptors to intracellular phospholipid signaling and various 
cellular responses. 
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Figure 3.1. Mammalian phospholipase C isozymes. The mammalian genome 
encodes six major classes of PLC isozymes (PLC-β, -γ, -δ, -ε, -ζ, -η) and two catalytic 
dead PLC-like molecules (PLC-L1, -L2).  PLC isozymes share the same core domain 
architecture exemplified in PLC-δ.  PLC-δ isozymes contain a N-terminal PH domain, 
four tandem EF hands, a catalytic TIM barrel, and a C-terminal C2 domain.  Other 
PLC isozymes have regulatory domains outside of this core that provide complexity in 
phospholipid signaling.  PLC-β isozymes have a long C-terminal extension (CT) 
following the C2 domain.  The C-terminal domain is reported to be important for 
membrane association, dimerization, and binding Gαq.  PLC-γ isozymes contain an 
additional split PH domain, two Src homology 2 (SH2) domains and an SH3 domain 
flanked by regions of the TIM barrel.  Additional domains in PLC-ε include a N-
terminal cysteine (C)-rich region that may be needed for membrane binding, a Ras 
guanine nucleotide exchange factor (RasGEF) domain, and two tandem Ras 
association (RA) domains.  PLC-η isozymes contain a serine/proline (S/P)-rich region 
that has no known function.  PLC-ζ isozymes are the simplest PLC in that they only 
consist of four EF hands, a TIM barrel, and a C2 domain.  Figure is from Harden and 
Sondek, 2006. 
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Figure 3.2. Model of the catalytic domain of rat PLC-δ1.  (A) Amino acids and 
their side chains that interact with Ca2+ at the bottom of the active site and Ins(1,4,5)P3 
are depicted.  (B) Proposed mechanism of PLC-catalyzed PtdIns(4,5)P2 hydrolysis.  
See text for description of acid-base catalysis reaction.  Figure is from Essen et al., 
1996.     
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Figure 3.3. Activators of PLC-β  isozymes.  PLC-β isozymes bind to phospholipid 
membranes and hydrolyze PtdIns(4,5)P2 (PIP2) to Ins(1,4,5)P3 (IP3) and diacylglycerol 
(DAG).  All PLC-β isozymes are stimulated by the Gαq family of heterotrimeric G 
proteins.  Historical data suggests that GTP-bound Gαq binds to the basic C-terminal 
region of PLC-β isozymes and that this region is important for Gαq-dependent 
activation.  Gβγ dimers activate PLC-β2 and PLC-β3 and have been reported to bind 
to the PH domain and regions of the catalytic TIM barrel.  Some PLC-β isozymes are 
also stimulated by GTP-bound Rac GTPases, which bind exclusively to the PH 
domain to recruit PLC-β isozymes to lipid bilayers and orient them for PIP2 
hydrolysis. 
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Figure 3.4. Basic model of kinetic scaffolding. (A) The GTPase cycle of 
heterotrimeric G proteins is a regulated balance of activation and deactivation steps.  
Hormone-bound GPCRs catalyze GDP for GTP exchange on Gαq, causing 
dissociation of Gβγ. (B) GTP-bound Gαq binds and activates PLC-β isozymes, which 
hydrolysis PIP2 to IP3 and DAG.  (C) PLC-β isozymes also accelerate GTP hydrolysis 
on their activator Gαq, and therefore, deactivate phospholipid signaling. (D) A model 
for kinetic scaffolding was proposed to reconcile how PLC-β signaling is sustained 
despite deactivating GTPase accelerating activity.  In the kinetic scaffolding model, a 
stable complex of Gαq, GPCR, and PLC-β is formed at steady-state in the presence of 
hormone.  This is a consequence of GTP hydrolysis occurring much faster than the 
rate of GPCR and Gαq dissociation.  Thus, hormone-bound receptor catalyzes many 
rounds of GDP/GTP exchange on Gαq and promotes many GTPase cycles before 
dissociating from Gαq.  Consequently, a fraction of GTP-bound Gαq is available 
despite the presence of PLC-β GTPase accelerating activity. 
 
  
 
 
CHAPTER 4 
MECHANISMS OF Gαq-DEPENDENT ACTIVATION AND DEACTIVATION 
OF PHOSPHOLIPASE C-β  
 
4.1 Abstract 
 Phospholipase C-β (PLC-β) isozymes hydrolyze PtdIns(4,5)P2 to second 
messengers Ins(1,4,5)P3 and diacylgylcerol in response to extracellular stimuli.  PLC-β 
isozymes are regulated by all members of the Gq family of heterotrimeric G proteins and 
Gβγ dimers.  PLC-β isozymes also accelerate the intrinsic GTPase activity of Gαq 
subunits, and therefore, deactivate their activating G protein.  Despite numerous studies 
investigating regulation of PLC isozymes by heterotrimeric G proteins, the mechanisms 
of Gαq-promoted activation of PLC-β isozymes and termination of phospholipid 
signaling are not clearly understood.  The Harden lab has generated a three-dimensional 
crystal structure of PLC-β3 in an AlF-4-dependent complex with Gαq.  The binding 
interface of the PLC-β3/Gαq complex contains three novel interactions.  A 20 amino acid 
region following the C2 domain adopts a helix-turn-helix topology and engages the 
hydrophobic effector binding domain of Gαq.  Gαq makes additional electrostatic 
interaction with a small region preceding the C2 domain of PLC-β3.  A third region of 
contact occurs between a short loop connecting the third and fourth EF hands of PLC-β3 
and the nucleotide binding pocket of Gαq.  Deletion of the EF hand loop or single point 
mutations markedly impaired the GTPase accelerating activity of PLC-β3.  Furthermore, 
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a GAP-deficient PLC-β3 mutant displayed a much slower rate of deactivation when 
agonist was removed.  As a result, PLC activity was virtually unchanged compared to the 
rapid termination of wildtype PLC-β3 signaling.  Thus, our studies define the essential 
domains within the PLC-β3/Gαq interface that are required for Gαq-stimulated activation 
of PLC-β isozymes and deactivation of phospholipid signaling. 
4.2 Introduction 
 Phospholipase C (PLC) isozymes hydrolyze PtdIns(4,5)P2 to second messengers 
Ins(1,4,5)P3 and diacylglycerol (DAG) in response to various extracellular stimuli 
including hormones, peptides, and proteases (Rhee, 2001; Harden and Sondek, 2006).  
Soluble Ins(1,4,5)P3 binds to receptors on the endoplasmic reticulum to mobilize 
intracellular calcium, and membrane-bound DAG and calcium activate protein kinase C.  
Generation of these second messengers and activation of downstream signaling pathways 
leads to various cellular responses including cell growth, proliferation, differentiation, 
contraction, and secretion. 
The four mammalian PLC-β isozymes (PLC-β1, -β2, -β3, -β4) have the same 
core domain architecture observed in other PLC isozymes (PLC-γ, -δ, -ε, -ζ, and -η) 
encoded in the mammalian genome (Rhee, 2001; Harden and Sondek, 2006).  PLC-β 
isozymes contain an N-terminal PH domain, four EF hands, a catalytic TIM barrel, and a 
C2 domain.  PLC-β isozymes also have a long C-terminal region following the C2 
domain not present in other PLC isoforms.  PLC-β isozymes are regulated downstream of 
G protein-coupled receptors through direct interaction with GTP-bound Gαq and Gβγ 
dimers (Pang and Sternweis, 1990; Smrcka et al., 1991; Taylor et al., 1991; Taylor and 
Exton, 1991; Waldo et al., 1991; Boyer et al., 1992; Camps et al., 1992; Katz et al., 
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1992).   Historical data suggests that Gαq engages the long C-terminal extension of PLC-
β for Gαq-dependent activation (Blank et al., 1993; Park et al., 1993b; Wu et al., 1993).  
A proteolytic fragment of PLC-β1 lacking the C-terminal domain was no longer activated 
by Gαq and AlF-4 but retained activation by Gβγ (Park et al., 1993b).   Sequential deletion 
of the C-terminal region of PLC-β1 suggested that residues 903-1030 were needed for 
membrane association and residues 1030-1142 were required for binding to and 
activation by Gαq (Wu et al., 1993).  In addition, the C2 domains of PLC-β isozymes 
were also implicated in binding Gαq.  Purified C2 domains of PLC-β1 and PLC-β2 were 
found to bind selectively to Gαq in a GTPγS-dependent manner but not to Gβγ or Gαi 
(Wang et al., 1999a). 
PLC-β isozymes were the first GTPase activating proteins (GAPs) identified for 
heterotrimeric G proteins and greatly accelerate the intrinsic GTPase activity of Gαq 
(Berstein et al., 1992).  Thus, PLC-β isozymes are not only effector molecules of Gαq but 
also act as GAPs on their activating G protein, converting Gαq to its inactive GDP-bound 
state. GAP activity of PLC-β1 was first demonstrated using purified proteins in a 
reconstitution system (Berstein et al., 1992).  Purified M1 mAChR, Gαq, and Gβ1γ2 were 
reconstituted into phospholipid vesicles, and addition of carbachol and PLC-β1 greatly 
increased GTP hydrolysis up to 1000-fold (Berstein et al., 1992; Biddlecome et al., 1996; 
Mukhopadhyay and Ross, 1999).  Studies examining the kinetics of PLC-β1 activation 
and PLC-β1-promoted GAP activity have provided some insight into the molecular 
consequences of a molecule harboring an effector and GAP domain that both activates 
and terminates signaling.  Ross and colleagues found that under steady-state conditions, 
addition of PLC-β1 accelerated GTP hydrolysis on Gαq and also increased the rate of 
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receptor-promoted GTP exchange (Mukhopadhyay and Ross, 1999).  The authors 
proposed that a fraction of GTP-bound Gαq was maintained for activating PLC-β1 
isozymes as a consequence of a stable complex of receptor, Gαq, and PLC-β1.  This 
stable complex is maintained at steady-state because GTP hydrolysis occurs much faster 
than the rate of receptor and Gαq dissociation, and hormone-bound receptor can quickly 
catalyze reactivation of Gαq.  In the absence of agonist, PLC-β1 rapidly accelerates GTP 
hydrolysis and terminates phospholipid signaling.  
Towards better understanding the mechanisms of Gαq-dependent PLC-β 
activation and PLC-β GAP activity, we present a three-dimensional crystal structure of 
PLC-β3 in an AlF-4-dependent complex with its activator Gαq.  We have identified three 
novel interactions in the PLC-β3/Gαq binding interface.  PLC-β3 engages the highly 
conserved effector binding domain of Gαq using a small kinked α-helical region 
following the C2 domain.  PLC-β3 makes additional contacts with Gαq through charged 
residues in a region preceding the C2 domain.  In addition, a short loop between the third 
and fourth EF hands of PLC-β3 interacts with the nucleotide binding pocket of Gαq and 
is required for stimulating the intrinsic GTPase activity on Gαq.  When PLC activity was 
measured, GAP-deficient PLC-β3 exhibited a much slower rate of deactivation when 
agonist was removed because its activating G protein was still GTP bound.  These results 
extend our knowledge of the complex dynamics of the Gαq/PLC-β signaling axis and the 
regulatory mechanisms of PLC-β activation and deactivation.  
4.3 Materials and Methods 
Reagents and Antibodies 
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Myo-[3H]inositol was purchased from American Radiolabeled Chemicals (St. 
Louis, MO).  [Inositol-2-3H]phosphatidylinositol 4,5-bisphosphate substrate and [γ-
32P]GTP were purchased from Perkin-Elmer (Boston, MA).  Brain L-α-
phosphatidylinositol 4,5-bisphosphate and bovine liver L-α-phosphatidylethanolamine 
were from Avanti Polar Lipids (Alabaster, AL). Inositol-free Dulbecco’s Modified 
Eagle’s medium (DMEM) was from ICN Biochemicals (Costa Mesa, CA).  Polyclonal 
rabbit anti-PLC-β1, PLC-β3, and PLC-δ1 antibodies were purchased from Santa Cruz 
Biotechnology (Santa Cruz, CA), and monoclonal anti-β-actin antibody was from Sigma-
Aldrich (St. Louis, MO). 
Mutagenesis and Cloning 
To generate mutations across the helix-turn-helix and EF hand loop of PLC-β3, 
small DNA cassettes containing the desired mutations were inserted into PLC-β3 cDNA 
(Fig 4.1, A and B).  For helix-turn-helix mutants, silent mutations were first introduced 
into PLC-β3 cDNA to add unique HindIII and XbaI sites to the 5′ and 3′ ends of a ~550 
bp region of PLC-β3 (Fig. 4.1A).  This region encompasses the helix-turn-helix domain 
of PLC-β3.  To generate DNA cassettes, PCR was used to amplify the same ~550 bp 
region in PLC-β3 with a forward primer containing tandem 5′ KpnI and HindIII sites and 
a reverse primer containing a 3′ XbaI site (Fig. 4.1C).  The PCR fragments were digested 
using KpnI and XbaI restriction enzymes and ligated into a pBS SK vector.  QuikChange 
mutagenesis was used to introduce single point mutations into the helix-turn-helix region, 
and the mutated cassettes were then digested with HindIII and XbaI restriction enzymes 
and ligated into the modified PLC-β3 plasmid.  To generate mutations in the EF hand of 
PLC-β3, a similar strategy was employed except that unique ClaI and BsrGI sites were 
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added to the 5′ and 3′ ends of a ~400 bp region of the PLC-β3 EF hand (Fig. 4.1B).  To 
generate EF hand DNA cassettes, PCR was used to amplify the same ~400 bp region with 
a forward primer containing a 5′ ClaI site and a reverse primer containing tandem 3′ 
BsrGI and BamHI sites (Fig. 4.1D).  After digesting with ClaI and BamHI restriction 
enzymes and ligating into pBS SK vector, the DNA cassettes were mutated, digested with 
ClaI and BsrGI, and ligated into the modified PLC-β3 plasmid. 
All other mutations of PLC-β isozymes were generated using QuikChange 
mutagenesis according to the manufacturer’s protocol.  All mutations were confirmed by 
dideoxy sequencing. 
Quantification of Phospholipase C activity 
COS-7 cells were plated at 6.5 x 104 cells per well in a 12-well plate and grown 
overnight in DMEM containing 10% fetal bovine serum, 100 units/ml penicillin, and 100 
µg/ml streptomycin at 37oC and 10% CO2/90% air.  Cells were transfected with 
mammalian expression plasmids and empty vector equaling 700 ng total DNA using 
Fugene6 (Roche) transfection reagent according to manufacturer’s protocol.  After 
incubating for 24 h, culture medium was removed and replaced with inositol-free DMEM 
containing 1 µCi/ml myo-[3H]inositol to metabolically label membrane phospholipids.  
Cells were incubated overnight and then treated for 1 h at 37oC with 10 mM LiCl to 
inhibit inositol monophosphatases.  The reaction was stopped by removing culture 
medium, adding cold 50 mM formic acid, and neutralizing with 150 mM ammonium 
hydroxide.  Accumulation of [3H]inositol phosphates were quantified by anion exchange 
chromatography and scintillation counting. 
Immunoblotting 
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COS-7 cells were transfected as described above and lysed on ice with 200 µl 
RIPA buffer.  Cell lysates were scraped into microcentrifuge tubes and centrifuged at 
8,000 x g for 10 min at 4oC.  The supernatant was transferred to a microcentrifuge tube 
containing 2X sample buffer and boiled at 100oC.  Cell lysates were subject to SDS-
PAGE and transferred to nitrocellulose membranes.  Membranes were blocked with 3% 
bovine serum albumin in TBS-Tween before incubating with the appropriate primary and 
secondary antibodies. 
In Vitro GTPase assay 
Purified P2Y1-R, and lipidated Gαq and Gβ1γ2 were reconstituted into 
phospholipid vesicles as previously described (Cunningham et al. 2001; Waldo and 
Harden 2004).  Briefly, 15 pmol purified P2Y1-R, 50 pmol Gαq, and 150 pmol Gβ1γ2 
were reconstituted into proteoliposomes using Sephadex G-50 chromatography.  
Phospholipid vesicles consisted of L-α-phosphatidylethanolamine from liver, L-α-
phosphatidylserine from brain, and cholesteryl hemisuccinate.  Wildtype and mutant 
PLC-β3 were reconstituted into proteoliposomes, and GTPase activity was quantified by 
measuring hydrolysis of [γ-32P]GTP in the presence of 10 µM P2Y1-R agonist 
2MeSADP.  The reaction mixture contained 20 mM HEPES, pH 8.0, 50 mM NaCl, 2 
mM MgCl2, 1 mM EDTA, and 2 µM [γ-32P]GTP (~4500 cpm/pmol) in a final volume of 
50 µl.  Proteoliposomes were incubated for 30 min at 30oC, and the reaction was stopped 
with 950 µl cold 5% activated charcoal in 20 mM H3PO4.  Soluble [32P]Pi was quantified 
by scintillation counting. 
In Vitro Phosphoinositide Hydrolysis 
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Purified P2Y1-R and lipidated Gαq and Gβ1γ2 were reconstituted into 
proteoliposomes containing 50 µM [3H]PtdIns(4,5)P2 as described above for the in vitro 
GTPase assay.  The reaction mixture (60 µl final volume) contained 20 mM HEPES, pH 
7.4, 70 mM KCl, 3 mM EGTA, 2mM dithiothreitol, 0.16 mg/ml fatty acid-free bovine 
serum albumin, 10 µM free calcium, and 0.03% sodium cholate.  The reaction mixture 
was centrifuged, and accumulation of soluble [3H]inositol phosphates were quantified by 
scintillation counting. 
4.4 Results 
Structure of PLC-β3 in an AlF-4-dependent complex with Gαq 
 The six major isoforms of the PLC family share the same core domain 
architecture, consisting of an N-terminal PH domain, four tandem EF hands, a catalytic 
TIM barrel, and a C2 domain.  PLC-β isozymes are unique in that they also contain a 
long C-terminal extension following the C2 domain (Fig. 4.2A).  Previous studies have 
reported that the C-terminal extension is needed for membrane association and docking 
of Gαq subunits for PLC-β activation (Blank et al., 1993; Park et al., 1993b; Wu et al., 
1993).  In initial studies, however, the Harden lab found that a truncated mutant of PLC-
β3 (PLC-β3 ΔCT), lacking ~350 amino acids of the C-terminal region, still formed a high 
affinity complex with Gαq.  Both full-length PLC-β3 and PLC-β3 ΔCT have essentially 
the same affinity for Gαq by surface plasmon resonance analysis, suggesting that the C-
terminal region is dispensable for high affinity binding to Gαq (data not shown).  Based 
on these observations, the Harden lab solved a three-dimensional crystal structure of the 
PLC-β3 ΔCT·Gαq complex at a resolution of 2.7Å (Fig. 4.2B and Table 4.1). 
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Gαq engages PLC-β3 at three distinct interfaces (Fig. 4.2B).  The primary region 
of contact is observed between the hydrophobic effector binding domain of Gαq and a 20 
amino acid extension (residues 852-870) following the C2 domain of PLC-β3 (Fig. 
4.2B).  The C2 domain extension forms a ~70o helix-turn-helix that packs in between the 
α2 helix (Switch II) and α3 helix of Gαq.  This PLC-β3/Gαq binding interface consists 
mostly of nonpolar contacts and is reminiscent of interactions between other Gα subunits 
and their effectors, including interactions between Gαq and its effectors, GRK2 and 
p63RhoGEF (Tesmer et al., 1997b; Slep et al., 2001; Tesmer et al., 2005; Lutz et al., 
2007).  A second region of contact precedes the C2 domain and contains several charged 
residues that form salt bridges with amino acids in Gαq (Fig. 4.2B).  The third region of 
contact consists of a loop between the third and fourth EF hands of PLC-β3 and the 
nucleotide binding site of Gαq, implicating the EF hand region of PLC-β3 in facilitating 
GTPase accelerating activity on Gαq (Fig. 4.2B). 
Comparison of the Gαq interaction domain of PLC-β3 with another Gαq effector, 
p63RhoGEF, (Lutz et al., 2007) reveals a similar helix-turn-helix domain binding in the 
hydrophobic effector binding pocket of Gαq (Fig. 4.3).  The PH domain extension of 
p63RhoGEF forms an α-helix that adopts a ~70o angle and lies between the α2 and α3 
helices of Gαq similar to the C2 domain extension of PLC-β3 (Fig 4.3).  In biochemical 
studies of p63RhoGEF, mutation of five specific residues, F471, L472, L475, P478, and 
I479, prevented binding to Gαq and abolished Gαq-stimulated exchange activity in vitro 
but had no effect on basal activity (Lutz et al., 2007; Rojas et al., 2007).  These 
hydrophobic residues form nonpolar interactions with Gαq and are required for high 
affinity binding (Lutz et al., 2007).  Sequence alignment of the helix-turn-helix of 
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p63RhoGEF with that of PLC-β3 and other PLC-β isozymes highlights conservation of 
key amino acids required for effector binding in the hydrophobic pocket of Gαq (Fig 4.3, 
C and D).  Based on structural and biochemical data of the p63RhoGEF·Gαq complex, 
we hypothesized that the corresponding residues in PLC-β3 are also required for high 
affinity Gαq binding and activation of PLC-β3. 
Quantification of PLC-β  activity 
 Residue L859 of PLC-β3 is completely conserved in all PLC-β isoforms and in 
the helix-turn-helix domain of p63RhoGEF (Fig. 4.3, C and D).  In the crystal structure 
of PLC-β3 ΔCT·Gαq, L859 docks into the hydrophobic cleft formed between the α2 and 
α3 helices of Gαq, making nonpolar interactions with L254, I258, and Y261 of Gαq (Fig. 
4.6, B and C).  Mutation of the corresponding Leu residue in p63RhoGEF completely 
abrogates binding to Gαq and Gαq-stimulated exchange activity (Lutz et al., 2007; Rojas 
et al., 2007).  To examine the importance of L859 in Gαq-stimulated PLC activity, COS-
7 cells were cotransfected with Gαq and varying concentrations of wildtype or mutant 
PLC-β3 DNA, and accumulation of [3H]inositol phosphates was quantified (Fig. 4.4).  
Expression of Gαq or PLC-β3 alone resulted in a negligible increase in phosphoinositide 
hydrolysis compared to empty vector control.  As expected, expression of Gαq greatly 
stimulated wildtype PLC-β3 activity at all DNA concentrations tested (Fig. 4.4B).  In 
contrast, the PLC-β3(L859E) mutant was completely impaired in Gαq-stimulated PLC 
activity (Fig. 4.4B).  Comparable levels of protein expression were observed for both 
wildtype PLC-β3 and the PLC-β3(L859E) mutant.  The deficiency in PLC activity was 
not a consequence of misfolding or disruption of the catalytic domain because Gβ1γ2 
dimers activated both wildtype PLC-β3 and the PLC-β3(L859E) mutant to a similar 
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extent over a broad range of DNA concentrations (Fig. 4.4).  Gβγ dimers engage regions 
of PLC-β isozymes that are distinct from Gαq binding, and therefore, still interact with 
PLC-β3 to activate the enzyme despite mutation of the helix-turn-helix (Kuang et al., 
1996; Sankaran et al., 1998; Wang et al., 1999b; Wang et al., 2000).  These results 
suggest that the PLC-β3(L859E) mutant is specifically impaired in Gαq-stimulated 
activity, and the conserved leucine residue in the helix-turn-helix is required for Gαq 
binding (Fig. 4.3D and 4.4). 
 PLC-β3 and PLC-β1 have a similar binding affinity for Gαq and exhibit similar 
efficacies in vitro (Hepler et al., 1993; Jhon et al., 1993; Smrcka and Sternweis, 1993).  
To determine if the corresponding leucine residue is also required for Gαq activation of 
another PLC-β isoform, PLC activity was also quantified for PLC-β1(L810E).  Similar to 
the PLC-β3 mutant, Gαq failed to activate the PLC-β1(L810E) mutant despite similar 
amounts of protein expression for both wildtype and mutant PLC-β1 at all DNA 
concentrations tested (Fig. 4.5).  Thus, the highly conserved leucine residue within the 
helix-turn-helix of PLC-β3 is essential for Gαq-stimulated activity of PLC-β isozymes as 
well as the Gαq effector, p63RhoGEF (Lutz et al., 2007; Rojas et al., 2007). 
 To examine the importance of the remaining residues in the helix-turn-helix of 
PLC-β3 in Gαq-stimulated PLC activity, PLC-β3 was mutated at single amino acids and 
cotransfected with Gαq or Gβ1γ2 into COS-7 cells before measuring accumulation of 
[3H]inositol phosphates (Fig. 4.6).  Cells transfected with Gαq or PLC-β3 alone exhibited 
little increase in [3H]inositol phosphate accumulation over cells transfected with empty 
vector. Mutation of Y855, L859, N861, P862, and I863 in PLC-β3 resulted in a 
significant loss of Gαq-promoted PLC activity whereas Gβ1γ2 activated each of these 
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mutants similar to wildtype PLC-β3 (Fig. 4.6A).  Residues C-terminal to I863 in the 
second α-helix were also slightly impaired in Gαq-stimulated activity (Fig. 4.6A).  
Immunoblot analysis showed similar protein expression for wildtype and each mutant 
PLC-β3 tested in the presence of Gαq and Gβ1γ2 (Fig. 4.6A).  As shown in Figure 4.6B, 
Y855 makes extensive contacts with Y261, P262, and W263 in the α3-helix of Gαq.  
Residue P862 facilitates the turn between the two α-helices in PLC-β3, and this turn is 
supported by N861, which makes hydrogen bonds with the peptide backbone. Alanine 
substitution at either of these residues would disrupt the conformation of the Gαq binding 
domain in PLC-β3.  Collectively, these results indicate that the primary residues for Gαq 
binding and stabilizing the helix-turn-helix domain are in the first α-helix of PLC-β3, and 
the remaining residues in the second α-helix further facilitate PLC-β3 binding to Gαq 
(Fig. 4.6).     
 Inspection of the PLC-β3·Gαq interface reveals additional contact sites between 
Gαq and a region before the C2 domain of PLC-β3 (Fig. 4.2 and 4.7).  These PLC-β3 
residues (R707, D709, K710, and D721) form salt bridges with amino acids in Gαq (Fig. 
4.7B).  Specifically, R707 and K710 make electrostatic interactions with E191 in Switch 
I of Gαq (Fig. 4.7B).  In addition, D709 and D721 in PLC-β3 form salt bridges with R202 
and K41 in Gαq, respectively (Fig. 4.7B).  To examine whether these four charged 
residues are also required for Gαq activation of PLC-β3, single alanine mutations were 
generated in PLC-β3, and the mutants were tested for Gαq-stimulated PLC activity in 
COS-7 cells (Fig. 4.7A).  Mutation of each charged residue significantly impaired PLC 
activation by Gαq but not by Gβ1γ2.  Similar amounts of protein expression were detected 
for wildtype PLC-β3 and each PLC-β3 mutant.  Multiple sequence alignment of PLC-β 
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isozymes shows that these charged residues are completely conserved, suggesting that the 
electrostatic interactions between the C2 domain and Gαq are necessary for Gαq binding 
and activation of PLC-β isozymes (Fig. 4.7C). 
EF hand loop of PLC-β3 accelerates GTP hydrolysis of Gαq 
PLC-β isozymes were the first GTPase activating proteins identified for 
heterotrimeric G proteins and greatly accelerate the intrinsic GTP hydrolysis of Gαq 
(Berstein et al., 1992).  Thus, PLC-β isozymes are not only stimulated by Gαq but also 
act as GAPs on their activating G protein.  Analysis of the PLC-β3 ΔCT·Gαq complex 
reveals that a loop between the third and fourth EF hands of PLC-β3 interacts with the 
guanine nucleotide binding site of Gαq and may mediate PLC-β3 GAP activity (Fig. 
4.2B).  Multiple sequence alignment of PLC-β isoforms and PLC-δ1 reveals that this 
region contains an eight amino acid insert that is not present in PLC-δ1 or other PLC 
family members (Fig. 4.8, data not shown).  As shown in Figure 4.9, a conserved Asn 
residue in PLC-β3 interacts with Q209 in Switch II, a highly conserved amino acid in Gα 
subunits required for polarizing the nucleophilic water for GTP hydrolysis.  Hydrogen 
bonding occurs between the side chain nitrogen of N260 and the carbonyl oxygen of 
Q209 and stabilizes the GTP transition state of Gαq (Fig. 4.9B).  Therefore, we 
hypothesized that the EF hand loop is required for accelerating GTP hydrolysis on Gαq. 
Several PLC-β3 mutants were generated to determine the importance of the EF 
hand loop in accelerating GTP hydrolysis.  Single point mutations were introduced at 
N260 in PLC-β3.  An additional PLC-β3 mutant contained the EF hand loop of PLC-δ1 
in place of the longer PLC-β3 loop.  This mutant was designated PLC-β3 δEF.  In 
collaboration with Gary Waldo, a phospholipid vesicle assay was used in which purified 
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P2Y1 receptor (P2Y1-R), Gαq and Gβ1γ2 subunits were reconstituted into phospholipid 
vesicles.  Purified wildtype or mutant PLC-β3 was added to proteoliposomes, and 
GTPase activity was quantified by measuring hydrolysis of [γ-32P]GTP in the presence of 
the P2Y1-R agonist, 2MeSADP (Fig. 4.10).  As expected, addition of 2MeSADP and 
increasing concentrations of wildtype PLC-β3 robustly stimulated GTP hydrolysis with a 
potency of ~3 nM (Fig. 4.10A).  In contrast, PLC-β3 δEF was markedly impaired in 
stimulating agonist-induced GTPase activity (Fig. 4.10A).  Alanine, glycine, and serine 
substitutions at N260 also inhibited PLC-β3-promoted GTPase activity whereas mutating 
V262 had no effect (Fig. 4.10A).  Inspection of the EC50 values for each PLC-β3 mutant 
showed that although these mutants are defective in accelerating GTP hydrolysis, there is 
no effect on the apparent affinity, indicating that the reduction in PLC-β3-promoted GAP 
activity is not a consequence of decreased binding to Gαq (Fig. 4.10B). 
GAP-deficient PLC-β3 displays a much slower rate of deactivation in the presence 
of P2Y1-R antagonist 
Activation and deactivation of heterotrimeric G proteins occurs through a series 
of tightly regulated catalytic steps.  Ligand-bound receptors catalyze GTP exchange to 
activate G proteins, and GTP-bound Gα subunits and Gβγ dimers bind and activate 
downstream effectors.  GAP proteins accelerate the intrinsic GTP hydrolysis of the Gα 
subunit to convert the enzymes to their GDP-bound state.  When agonist is removed, the 
entire catalytic cycle shuts off, and the Gα subunit remains in its inactive GDP-bound 
state.  We hypothesize that a GAP-deficient PLC-β3 mutant will deactivate at a greatly 
reduced rate when agonist is removed because its activating G protein remains GTP-
bound.  To test this hypothesis, deactivation of Gαq was first measured in a reconstitution 
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assay in collaboration with Gary Waldo.  Purified P2Y1-R, Gαq, and Gβ1γ2 were 
reconstituted into phospholipid vesicles.  As show in Figure 4.11, little GTPase activity 
was observed in the presence of PLC-β3 alone.  In contrast, addition of both 2MeSADP 
and PLC-β3 greatly accelerated steady-state GTP hydrolysis, and this effect was rapidly 
blocked with a saturating concentration of P2Y1-R competitive antagonist MRS2500, 
reducing GTPase activity to basal levels (Fig. 4.11). 
PLC activity of GAP-deficient PLC-β3 was quantified in [3H]PtdIns(4,5)P2-
containing phospholipid vesicles reconstituted with purified P2Y1-R, Gαq, and Gβ1γ2.  
Addition of 2MeSADP activated P2Y1-R to catalyze GTP exchange on Gαq.  PLC-β3 
isozymes were subsequently added to proteoliposomes, and accumulation of [3H]inositol 
phosphates was quantified (Fig. 4.12).  Wildtype PLC-β3 containing vesicles displayed a 
significant increase in steady-state PtdIns(4,5)P2 hydrolysis in the presence of 2MeSADP 
(Fig. 4.12A).  Addition of antagonist rapidly inhibited this effect, reducing agonist-
promoted PLC activity to basal levels.  In phospholipid vesicles containing GAP-
deficient PLC-β3(N260A) mutant, stimulation with 2MeSADP promoted PtdIns(4,5)P2 
hydrolysis similar to wildtype PLC-β3 (Fig. 4.12B).  In contrast, antagonist addition had 
no effect on agonist-stimulated steady-state PLC activity, and the rate of 
[3H]PtdIns(4,5)P2 hydrolysis was virtually unchanged.  These results illustrate that the 
GTPase accelerating activity of PLC-β isozymes is critical for rapid termination of PLC 
activity and maintaining the fidelity of phospholipid signaling. 
 We next examined PLC activity of GAP-deficient PLC-β3 mutants in intact cells.  
We hypothesized that loss of PLC-β3 GAP activity would prevent GTP hydrolysis, and 
therefore, retain Gαq in an active GTP-bound state.  Consequently, GTP-bound Gαq 
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would increase PLC activity compared to wildtype PLC-β3.  To test this hypothesis, 
wildtype PLC-β3 and PLC-β3 δEF were cotransfected into COS-7 cells with Gαq or 
Gβ1γ2, and accumulation of [3H]inositol phosphates was measured after incubating with 
LiCl for 1h (Fig. 4.13).  Expression of Gαq greatly increased activity of wildtype PLC-β3 
at all DNA concentrations tested.  Interestingly, Gαq stimulated activity of PLC-β3 δEF 
to a level similar to that of wildtype despite a loss of PLC-β3 GAP activity as shown in 
Figure 4.10A (Fig. 4.13A).  As expected, expression of Gβ1γ2 resulted in activation of 
both wildtype PLC-β3 and PLC-β3 δEF over a broad range of DNA concentrations (Fig. 
4.13B).  Comparable expression of wildtype PLC-β3 and PLC-β3 δEF was confirmed by 
immunoblot analysis.  Gαq and Gβ1γ2 also stimulated activity of GAP-deficient PLC-
β3(N260G) and PLC-β3(N260S) mutants similar to wildtype PLC-β3 (data not shown).  
These results suggest that loss of PLC-β3 GAP activity has no effect on the overall extent 
of PLC activity under the conditions tested.  Alternatively, it is possible that this 
particular assay is not sensitive enough to measure differences in PLC activity between 
wildtype and GAP-deficient PLC-β3.  Quantification of intracellular calcium is a more 
sensitive technique, and kinetic experiments are in progress to examine how loss of PLC-
β3 GAP activity affects PLC-β3-promoted calcium release at various times. 
The intact cell assays were performed in the absence of receptor stimulation, 
which may be needed to observe any steady-state increases in PLC activity and calcium 
mobilization when GAP activity is absent.  Several attempts were made to develop an 
assay to measure receptor-promoted PLC activity in COS-7, HeLa, and HEK293 cells by 
stimulating various endogenous or recombinant GPCRs.  Unfortunately, robust activation 
of endogenous PLC-β isozymes masked any effects of exogenous expression of wildtype 
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and mutant PLC-β3 in these cell lines (data not shown).  Experiments are currently 
underway to knockdown endogenous PLC-β isozymes in HEK293 cells using short 
hairpin RNAs (shRNAs) and to reintroduce siRNA resistant forms of GAP-deficient 
PLC-β3 mutants.  Using these cell lines, we can better evaluate how loss of PLC-β3 GAP 
activity affects Gαq-stimulated PLC activity and release of intracellular calcium.  We can 
examine the rates of receptor-promoted signal initiation and termination as well as 
quantify signal magnitude and duration. 
PLC-β3 engages both the conserved effector and RGS binding domains of Gαq 
 Three-dimensional crystal structures have been solved for each of the four 
families of heterotrimeric G proteins in complex with their effectors (Posner et al., 1999; 
Slep et al., 2001; Chen et al., 2005; Tesmer et al., 2005; Lutz et al., 2007; Chen et al., 
2008).  Comparison of these structures shows that distinct effector proteins bind to the 
same localized region of Gα subunits.  The α2 (Switch II) and α3 helices of each Gα 
subunit form a hydrophobic cleft, and effector proteins use nonpolar residues to dock 
between these two conserved helices (Fig. 4.14, A and C).  RGS proteins also bind to a 
localized region of Gα subunits (Posner et al., 1999; Slep et al., 2001), making contacts 
with all three switch regions to stabilize the Gα backbone for GTP hydrolysis (Fig. 4.14, 
A and D).  RGS proteins and effectors bind to distinct sites on Gα and can engage Gα 
subunits simultaneously to modulate signaling (McEntaffer et al., 1999; Skiba et al., 
1999; Slep et al., 2001; Tesmer et al., 2005; Shankaranarayanan et al., 2008).  PLC-β 
isozymes are both effectors and GAPs and engage the effector and RGS binding surface 
of Gαq (Fig. 4.14B).  PLC-β3 and other G protein effectors share common Gα contact 
sites and bind to the same hydrophobic cleft of Gα.  The EF hand loop of PLC-β3 
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promotes GTPase accelerating activity and interacts with Gα residues that are required 
for RGS binding (Fig. 4.14, B and D). 
4.5 Discussion 
 In the present study, we have identified three novel contacts between PLC-β3 and 
Gαq based on analysis of a three-dimensional crystal structure of a C-terminally truncated 
form of PLC-β3 in an AlF-4-dependent complex with Gαq.  Previous biochemical and 
mutational analysis suggested that the long C-terminal region of PLC-β isozymes 
engages Gαq and is needed for PLC-β activation (Blank et al., 1993; Park et al., 1993b; 
Wu et al., 1993).  A PLC-β1 fragment lacking the C-terminal region was impaired in 
Gαq-promoted PLC activity but retained activation by Gβγ (Park et al., 1993b).  
Sequential deletion of this C-terminal portion suggested that residues 903-1030 are 
needed for membrane association and residues 1030-1142 contact Gαq for activation of 
PLC-β1 (Wu et al., 1993).  Preliminary studies in the Harden lab, however, found that a 
PLC-β3 fragment truncated at residue 886 and missing the analogous C-terminal region 
still formed a high affinity complex with Gαq, suggesting that this region is dispensable 
in Gαq binding.  Inspection of the PLC-β3 ΔCT⋅Gαq structure revealed that a 20 amino 
acid region following the C2 domain is a major site of Gαq binding (Fig. 4.2).  This 
region adopts a helix-turn-helix domain and docks in the hydrophobic pocket of Gαq 
between the α2 and α3 helices, forming nonpolar interactions with Gαq (Fig. 4.6B).  
Mutation of key residues (Y855, L859, N861, P862, I863) significantly decreased Gαq-
stimulated PLC activity but had no effect on activation by Gβγ subunits.  Furthermore, 
mutation of the highly conserved Leu residue in PLC-β1 also prevented activation by 
Gαq.  Multiple sequence alignment of PLC-β isozymes revealed complete conservation 
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of L859 and P862 and partial conservation for the remaining residues, suggesting that 
PLC-β isozymes use the same mechanism to engage Gαq subunits for PLC activation 
(Fig. 4.4C).  A second region of PLC-β3 preceding the C2 domain was also found to 
interact with Gαq.  Four charged residues (R707, D709, K710, D721) in the C2 domain 
make electrostatic interactions with amino acids in Switch I and the β1 and β3 strands of 
Gαq (Fig. 4.7B).  Mutation of these four amino acids in PLC-β3 inhibits Gαq-promoted 
PLC activity, and these charged residues are completely conserved in PLC-β isozymes 
from worms to mammals, suggesting that the electrostatic interactions between PLC-β 
and Gαq are required for PLC-β activation (Fig. 4.7). 
Representative crystal structures from each heterotrimeric G protein family (Gαs, 
Gαi, Gαq, Gα12) in complex with their effector molecules have provided insight into the 
interaction domains on Gα subunits.  These crystal structures include complexes of 
Gαs⋅adenylyl cyclase, Gαt⋅PDEγ⋅RGS9, Gαq⋅GRK2, Gαq⋅p63RhoGEF, 
Gα13⋅p115RhoGEF, and Gα13⋅PDZRhoGEF (Tesmer et al., 1997b; Slep et al., 2001; 
Chen et al., 2005; Tesmer et al., 2005; Lutz et al., 2007; Chen et al., 2008).  Similar to 
other effector proteins, PLC-β3 binds the same conserved hydrophobic pocket of Gα 
between the α2-helix of Switch II and α3-helix.  These results confirm earlier mutational 
analysis demonstrating that the α3-helix of Gαq interacts with PLC-β1 (Arkinstall et al., 
1995; Venkatakrishnan and Exton, 1996).  Small synthetic peptides corresponding to the 
α3- and α4- helices of Gαq were shown to inhibit PLC-β activation by GTPγS-bound 
Gαq (Arkinstall et al., 1995).  In a separate study, regions of constitutively activated Gαq 
were replaced with analogous regions of Gαs to determine the PLC-β binding domain 
(Venkatakrishnan and Exton, 1996).  The α3 helix and α3/β5 linker of Gαq but not the 
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α4-helix were identified as regions needed for Gαq activation of PLC-β isozymes in 
agreement with the structure of PLC-β3 ΔCT⋅Gαq (Venkatakrishnan and Exton, 1996).  
Structural and biochemical analysis also suggests that interactions occur between 
the α4/β6 loop of Gαs and adenylyl cyclase, Gαt and PDEγ, as well as Gαq and 
p63RhoGEF (Berlot and Bourne, 1992; Rarick et al., 1992; Tesmer et al., 1997b; Liu et 
al., 1999; Tesmer et al., 2005; Lutz et al., 2007).  In addition, the C-terminal region of 
Gαq engages the DH domain of p63RhoGEF (Lutz et al., 2007).  While the structure of 
PLC-β3 ΔCT⋅Gαq does not indicate contacts between PLC-β3 and the α4/β6 loop or the 
C-terminus of Gαq, additional contacts may occur between Gαq and the C-terminal 
region of PLC-β3 deleted in this crystal structure.  However, these potential interactions 
presumably would be less significant based on the high affinity binding of PLC-β3 ΔCT 
and Gαq.  Indeed, surface plasmon resonance studies showed that PLC-β3 ΔCT has 
virtually the same binding affinity for Gαq as full-length PLC-β3, suggesting that the C-
terminal region of PLC-β3 is dispensable in Gαq binding. 
PLC-β isozymes were the first GTPase activating proteins identified for 
heterotrimeric G proteins (Berstein et al., 1992).  PLC-β isozymes are Gαq-specific GAPs 
and accelerate GTP hydrolysis on GTP-bound Gαq by ~1000-fold (Berstein et al., 1992; 
Biddlecome et al., 1996; Mukhopadhyay and Ross, 1999).  C-terminal peptides of PLC-
β1 displayed GAP activity and accelerated GTP hydrolysis approximately 4-fold, 
suggesting that a portion of the C-terminal region was required for PLC-β1 GAP activity 
(Paulssen et al., 1996).  The authors concluded that the difference in GAP activity 
between full-length PLC-β1 and the C-terminal peptides was possibly due to the peptides 
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binding Gαq at a much lower affinity or due to the requirement of other regions of PLC-
β1 in promoting GTP hydrolysis.   
We have identified a highly conserved loop between the third and fourth EF 
hands of PLC-β3 in accelerating PLC-β3 GAP activity.  As shown in Figure 4.9, the EF 
hand loop is located near the nucleotide binding pocket, and N260 interacts with Q209 of 
Gαq, positioning the residue for stabilizing nucleophilic water for GTP hydrolysis.  The 
model shown in Figure 4.9B is analogous to the mechanism used by RGS proteins to 
accelerate GTP hydrolysis of heterotrimeric G proteins (Fig. 4.15).  RGS proteins bind 
Gα subunits in the GTP-bound transition state and stabilize the flexible switch regions to 
accelerate the intrinsic GTP hydrolysis of Gα (Tesmer et al., 1997a; Slep et al., 2001).  
Comparison of Gαi-bound RGS4 to Gαq-bound PLC-β3 illustrates that the Asn residues 
are in the same location and position Q209 for stabilizing nucleophilic water for GTP 
hydrolysis.  Mutation of N260 in PLC-β3 significantly impaired PLC-β3 GAP activity 
(Fig. 4.10).  Furthermore, deletion of the entire EF hand loop and replacing it with the 
analogous region of PLC-δ1 also reduced PLC-β3 GAP activity whereas mutation of 
V262 had no effect (Fig. 4.10).  While mutation of the EF hand loop prevented PLC-β3 
GAP activity, no effect was observed on the apparent affinity for Gαq.  When PLC 
activity was quantified in vitro, GAP-deficient PLC-β3 deactivated much more slowly 
than wildtype PLC-β3 when agonist was removed because activated Gαq was still GTP-
bound.  Consequently, the rate of [3H]PtdIns(4,5)P2 hydrolysis was largely unchanged 
(Fig. 4.12B).  These results illustrate the importance of PLC-β GAP activity in 
accelerating signal termination when agonist is removed to maintain the fidelity of 
intracellular phospholipid signaling. 
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GAP proteins work to sharpen intracellular signaling in the presence of agonist 
(Ross, 2008).  At steady-state, signal amplitude is maintained by a balance of receptor-
catalyzed GTP binding on heterotrimeric G proteins and GAP-accelerated GTP 
hydrolysis.  This balance allows for a fraction of Gα subunits to remain GTP-bound and 
active and provides a mechanism for rapid deactivation when agonist is removed.  Using 
a phospholipid vesicle system, Ross and colleagues demonstrated this point for PLC-β1 
(Biddlecome et al., 1996; Mukhopadhyay and Ross, 1999).  GTP hydrolysis or PLC 
activity was quantified for purified PLC-β1 reconstituted into proteoliposomes containing 
purified M1 mAChR and heterotrimeric Gq.  Despite a rapid rate of GTP hydrolysis in the 
presence of agonist, sufficient GTP-bound Gαq was available for activation of PLC-β1 at 
steady-state.  This was a consequence of an increased rate of receptor-promoted 
GDP/GTP exchange in the presence of PLC-β1 (Mukhopadhyay and Ross, 1999; 
Turcotte et al., 2008).  Similarly, Posner et al. also observed an increased rate in receptor-
catalyzed exchange activity when RGS4 was added to phospholipid vesicles containing 
heterotrimeric Gi and M2 mAChR (Posner et al., 1999). 
Ross and colleagues proposed a model for kinetic scaffolding to explain how 
PLC-β1 activity is maintained despite continuous GAP activity (Biddlecome et al., 1996; 
Mukhopadhyay and Ross, 1999).  In this model, a stable complex of receptor, Gα, and 
GAP is formed at steady-state since GTP hydrolysis occurs much faster than the time 
needed for receptor and Gα to dissociate (Biddlecome et al., 1996; Mukhopadhyay and 
Ross, 1999; Ross, 2008; Turcotte et al., 2008).  Therefore, agonist-occupied receptor 
catalyzes multiple rounds of GDP/GTP exchange and promotes many GTPase cycles.  In 
this way, GAP proteins indirectly increase G protein activation and accelerate 
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deactivation to sharpen signaling without attenuating the magnitude of signaling at 
steady-state (Biddlecome et al., 1996; Mukhopadhyay and Ross, 1999; Ross, 2008). 
Analysis of GAP-deficient PLC-β3 δEF in intact cells revealed that Gαq activated 
PLC-β3 δEF to the same extent as wildtype PLC-β3 despite the loss of deactivating GAP 
activity.  In these experiments, Gαq and either wildtype PLC-β3 or PLC-β3 δEF are 
cotransfected into COS-7 cells, and accumulation of inositol phosphates is quantified 
after 1h LiCl treatment.  Results from these experiments suggest that under these 
conditions loss of PLC-β3 GAP activity has no effect on overall accumulation of inositol 
phosphates.  Future studies are underway to determine the effect of PLC-β3 GAP activity 
on the rate of receptor-promoted signal initiation and termination as well as signal 
amplitude and duration.      
PLC-β isozymes were the first effector GAPs identified for heterotrimeric G 
proteins, and subsequent studies identified p115RhoGEF, a Gα13-specific effector and 
GAP (Berstein et al., 1992; Kozasa et al., 1993).  Structural comparison of PLC-β3 with 
known effector⋅Gα and RGS⋅Gα complexes revealed that PLC-β3 engages both the 
conserved effector and GAP binding domains of Gαq, indicating a similar mechanism of 
binding to Gα subunits for proteins that contain these domains separately or as a single 
molecular unit (Fig. 4.14).  It is not completely understood why an effector protein would 
evolve to terminate its own signaling.  Based on kinetic analysis, an effector GAP may 
provide more efficient temporal control that would be lacking if additional proteins were 
required to bind and deactivate Gα subunits (Mukhopadhyay and Ross, 1999).  In 
addition, as a GAP for heterotrimeric Gq, PLC-β isozymes specifically modulate 
phospholipid signaling pathways whereas RGS proteins regulate signaling for several G 
 124 
protein pathways (Ross and Wilkie, 2000).  Effector GAP proteins also ensure that signal 
transduction occurs before signaling is prematurely terminated (Ross and Wilkie, 2000).  
Effector GAPs require newly activated Gα subunits to bind and activate a signaling 
pathway before deactivation proceeds (Ross and Wilkie, 2000).  Therefore, in the 
absence of agonist, deactivation occurs rapidly upon effector binding to prevent basal 
signaling.  If agonist is present, signaling is sustained by a balance of activation and 
deactivation steps in the GTPase cycle. 
Analysis of the three-dimensional crystal structure of the PLC-β3ΔCT⋅Gαq 
complex enhances our understanding of the molecular mechanisms of Gαq-dependent 
activation and deactivation of PLC-β isozymes.  Identification of regions specifically 
required for Gαq-stimulated PLC activity will now allow us to interrogate the importance 
PLC-β activation by Gαq vs. Gβγ in cells and in in vivo models.  In addition, we can 
determine the importance of GAP activity in regulating the rates of PLC-β activation and 
deactivation as well as the amplitude and duration of PLC-β signaling.  Results from 
these studies will further our knowledge of the molecular mechanisms regulating the 
canonical PLC-β/Gαq signaling axis. 
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Table 4.1. Data collection and current refinement statistics of PLC-β3 ΔCT⋅Gαq 
structure. 
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Figure 4.1. Mutagenesis strategy. (A) Using QuikChange mutagenesis, silent 
mutations were introduced into PLC-β3 cDNA to add HindIII and XbaI restriction 
sites to the 5′ and 3′ ends of a ~550 bp region.  These restriction sites encompass the 
helix-turn-helix (HTH) region of PLC-β3.  A ~550 bp DNA cassette of the HTH 
region containing the appropriate mutations was digested with HindIII and XbaI and 
ligated into the modified PLC-β3 plasmid. The PLC-β3 gene is cloned into pcDNA 
using EcoRI and XhoI restriction sites.  (B) Mutations in the EF hands of PLC-β3 
were made using a similar strategy.  ClaI and BsrGI sites were introduced into PLC-β3 
and enclose a region of ~400 bp.  A DNA cassette consisting of the same region and 
desired mutations was digested with ClaI and BsrGI and ligated into PLC-β3.  (C) To 
generate the DNA cassettes, the HTH region was PCR amplified using a forward 
primer containing tandem 5′ KpnI and HindIII sites and a reverse primer consisting of 
a 3′ XbaI sites.  The PCR fragment was digested with KpnI and XbaI and ligated into 
pBS SK vector.  The HTH cassette was mutated using QuikChange mutagenesis 
according to the manufacturer’s protocol.  (D) The EF hand was PCR amplified using 
a forward primer containing a 5′ ClaI site and a reverse primer consisting of tandem 3′ 
BsrGI and BamHI sites.  The PCR product was digested with ClaI and BamHI, ligated 
into pBS SK, and mutated. 
 
 127 
 
Figure 4.2. Three-dimensional crystal structure of PLC-β3 ΔCT in an AlF-4-
dependent complex with Gαq.  (A) PLC-β isozymes contain an N-terminal PH 
domain (blue), four series of EF hands (yellow), a catalytic TIM barrel (red), a C2 
domain (cyan), and a long C-terminal extension of ~400 amino acids (white).  For 
generating the crystal structure, PLC-β3 was truncated to remove the entire C-terminal 
extension (residue 886-1234) shown in the box.  (B) Gαq interacts with PLC-β3 at 
three distinct interfaces, a 20 amino acid region following the C2 domain, a region 
before the C2 domain, and a short loop within the EF hands.  The colors used in the 
domain diagram are the same as in the structure.  Gαq is shown in green, and the three 
switch regions (SwI, SwII, SwIII) are highlighted in red.  GDP (magenta), 
Mg2+(orange), and the catalytic water (salmon) are depicted as spheres and AlF-4 is 
presented as sticks.  The calcium ion in the active site of PLC-β3 is highlighted in 
yellow. 
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Figure 4.3. Comparison of the binding interfaces of PLC-β3⋅Gαq and 
p63RhoGEF⋅Gαq  (A) Structure of PLC-β3 in an AlF-4-dependent complex with 
Gαq.  C2 domain extension of PLC-β3 is highlighted in cyan and engages the α2 and 
α3 helices of Gαq.  The remaining regions of PLC-β3 are shaded in gray, and the 
calcium ion in the active site of PLC-β3 is depicted as a sphere (yellow).  Gαq is 
shown in green, and the three switch regions are highlighted in red.  GDP (magenta), 
Mg2+ (orange), water (salmon) are depicted has spheres and AlF-4 (cyan) is shown as 
sticks. (B) Crystal structure of p63RhoGEF in a nucleotide-dependent complex with 
Gαq and RhoA (Lutz et al., 2007). The PH domain extension of p63RhoGEF (blue) 
docks between the α2 and α3 helices of Gαq.  The remaining regions of p63RhoGEF 
and RhoA are shaded in gray. (C) Structural overlay of PLC-β3⋅Gαq and 
p63RhoGEF⋅Gαq complexes.  Also shown is a sequence alignment of the Gαq binding 
domain of human p63RhoGEF and human PLC-β3. Residues in p63RhoGEF required 
for Gαq binding, Gαq-stimulated exchange activity, and the corresponding residues in 
PLC-β3 are shown in red.  (D) Multiple sequence alignment of PLC-β isozymes.  
Highlighted in red are key residues in the helix-turn-helix domain of PLC-β3 that are 
required for Gαq-dependent PLC activity and the corresponding residues in other 
PLC-β isozymes.   
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Figure 4.4. Mutation of L859 abolishes Gαq but not Gβγ-dependent activation of 
PLC-β3.  COS-7 cells were cotransfected with (A) Gαq or (B) Gβ1γ2 and varying 
amounts of either wildtype () or mutant () PLC-β3 DNA.  Accumulation of 
[3H]inositol phosphates was measured 36 h after transfection as described in Materials 
and Methods.  Data (mean ± S.E.) are shown as percent of maximum wildtype PLC-
β3 activity and averaged from three individual experiments.  Cell lysates from COS-7 
cells transfected as described above were subjected to SDS-PAGE, transferred to 
nitrocellulose membranes and immunoblotted with rabbit polyclonal anti-PLC-β3 
antibody.  Membranes were also probed with mouse monoclonal anti-actin antibody to 
control for loading. 
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Figure 4.5. The conserved leucine residue in the PLC-β3⋅Gαq binding interface 
serves the same function in PLC-β1.  COS-7 cells were cotransfected with Gαq and 
varying amounts of either wildtype () or mutant () PLC-β1 DNA.  [3H]inositol 
phosphates were quantified 36 h after transfection as described in Materials and 
Methods.  Data (mean ± S.E.) are shown as percent of maximum wildtype PLC-β1 
activity and averaged from three separate experiments.  Cell lysates from COS-7 cells 
transfected as described above were resolved by SDS-PAGE, transferred to 
nitrocellulose membranes and probed with rabbit polyclonal anti-PLC-β1 antibody 
and mouse monoclonal anti-actin antibody as a loading control. 
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Figure 4.6. PLC-β3 helix-turn-helix mutants are defective in Gαq but not Gβγ-
stimulated PLC activity. (A) COS-7 cells were cotransfected with either Gαq (red) or 
Gβ1γ2 (blue) and 50 ng wildtype or mutant PLC-β3 DNA.  Total [3H]inositol 
phosphates were measured as described in Materials and Methods.  Data (mean ± 
S.E.) shown is averaged from four individual experiments and presented as percent of 
wildtype PLC-β3 activity.  Immunoblot analysis shows equal expression of wildtype 
PLC-β3 and each PLC-β3 mutant.  Membranes were also probed for actin to control 
for loading of cell lysates. (B) Close-up view of the PLC-β3 (cyan) and Gαq (green; 
switch regions in red) binding interface shows that the helix-turn-helix region of PLC-
β3 docks between switch II (SwII) and the α3 helix of Gαq, forming nonpolar 
interactions with the hydrophobic cleft of Gαq.   
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 Figure 4.7. Mutation of charged residues preceding the C2 domain of PLC-β3 
attenuates Gαq but not Gβγ-promoted PLC activity. (A) COS-7 cells were 
cotransfected with either Gαq (red) or Gβ1γ2 (blue) and 50 ng wildtype or mutant 
PLC-β3 DNA.  Accumulation of [3H]inositol phosphates was measured as described 
in Materials and Methods.  Immunoblots show expression levels of wildtype or mutant 
PLC-β3 and actin as a loading control. (B) Structural detail of contacts between PLC-
β3 (cyan) and Gαq (green).  The switch regions of Gαq are shown in red.  (C) Multiple 
sequence alignment of PLC-β isozymes.  Highlighted in red are charged residues 
mutated in PLC-β3 and the corresponding residues in other PLC-β isozymes. 
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Figure 4.8. PLC-β3 EF hand insert is conserved in other PLC-β  isoforms. A 
multiple sequence alignment of PLC-β isozymes and human PLC-δ1 reveals that the 
EF hand domain contains an eight amino acid insert that is not present in PLC-δ1.  
The EF hand insert is located between the third and fourth EF hands of PLC-β 
isozymes shown in the box.  Also shown is the secondary structure of portions of the 
third and fourth EF hands.  Unstructured regions are depicted as black lines.  
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Figure 4.9. Structural details of the nucleotide binding site of Gαq in the PLC-β3 
ΔCT⋅Gαq complex.  (A) Residue Asn260 (yellow) of PLC-β3 positions conserved 
Gln209 (red) of Gαq, which stabilizes nucleophilic water for GTP hydrolysis.  Residue 
Arg183 of Gαq stabilizes the γ-phosphate leaving group of GTP and also interacts with 
the α and β phosphates of GTP.  GDP (magenta) and AlF4 (cyan) are shown as sticks, 
and Mg2+ (orange) and catalytic water (salmon) are depicted as spheres.  (B) The side 
chain nitrogen of Asn260 forms hydrogen bonds (dashed lines) with the carbonyl 
oxygen of Gln209, stabilizing the GTP transition state for GTP hydrolysis. 
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Figure 4.10. Mutation of the PLC-β3 EF hand loop abrogates PLC-β3-promoted 
GTP hydrolysis on Gαq. (A) Purified P2Y1-R, Gαq, and Gβ1γ2 were reconstituted 
into phospholipid vesicles, and steady-state hydrolysis of [γ-32P]GTP was measured in 
the presence of 0.3 µM 2MeSADP and increasing concentrations of wildtype PLC-β3 
() or the following PLC-β3 mutants: PLC-β3 δEF (; red), N260A (; blue), 
N260G (; blue), N260S (; blue), and V262A (; green).  The data (mean ± S.E.) 
shown are averaged from three individual experiments and presented as percent of 
maximal PLC-β3 wildtype response. (B) Table presented shows the calculated EC50 
values (mean ± S.E.) for GTP hydrolysis in the presence of wildtype and mutant PLC-
β3.  
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Figure 4.11. Competitive antagonist of P2Y1-R rapidly terminates P2Y1-R and 
PLC-β3-stimulated GTP hydrolysis of Gαq. Purified P2Y1-R, Gαq, and Gβ1γ2 were 
reconstituted into phospholipid vesicles.  Steady-state hydrolysis of γ-[32P]GTP was 
quantified at 30oC at the times indicated in the presence of 100 nM PLC-β3 alone () 
or both 0.3 µM 2MeSADP and 100 nM PLC-β3().  P2Y1-R competitive antagonist, 
MRS2500, (; red) was added at 10 µM saturating concentration at the times 
indicated before quantifying GTP hydrolysis. 
 139 
 
Figure 4.12. GAP-deficient PLC-β3(N260A) mutant displays a much slower rate 
of deactivation in the presence of P2Y1-R competitive antagonist. Purified P2Y1-R, 
Gαq, and Gβ1γ2 were reconstituted into phospholipid vesicles containing 
[3H]PtdIns(4,5)P2.  2MeSADP (0.3 µM) was added to activate P2Y1-R and catalyze 
GTP exchange on Gαq at 25oC.  Proteoliposomes were incubated with 30 nM PLC-β3 
wildtype (A) or PLC-β3(N260A) (B), and steady-state PtdIns(4,5)P2 hydrolysis was 
measured at the indicated times.  P2Y1-R competitive antagonist, MRS2500, (red) was 
added to proteoliposomes at 10 µM, and total [3H]inositol phosphates were quantified 
at the times shown.   
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Figure 4.13.  Activation of GAP-deficient PLC-β3 by Gαq in intact cells. COS-7 
cells were cotransfected with either Gαq (A) or Gβ1γ2 (B) and a broad range of PLC-
β3 wildtype () or δEF () DNA concentrations.  Accumulation of [3H]inositol 
phosphates was measured as described in Materials and Methods.  Data (mean ± S.E.) 
are shown as percent of maximum wildtype PLC-β3 activity and averaged from three 
individual experiments.  Cell lysates were subjected to SDS-PAGE, transferred to 
nitrocellulose membranes, and probed with rabbit polyclonal anti-PLC-β3 antibody 
and mouse monoclonal anti-actin antibody.   
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Figure 4.14. PLC-β3 engages both the conserved effector and RGS binding 
domains of Gαq.  (A) Switch I (Sw1), switch II (Sw2), and switch III (Sw3) are 
highlighted on the surface of Gαq.  The white asterisk indicates the position of highly 
conserved Gln209.  (B) PLC-β3 (blue) and heterotrimeric G protein effectors (green) 
share common Gα contact sites.  The EF hand loop of PLC-β3 (yellow) engages 
residues on the surface of Gαq that are also observed between RGS proteins (purple) 
and their interacting Gα subunit.  The EF hand loop and other regions of PLC-β3 have 
some overlapping contact residues shown in dark blue.  (C) The sites of interaction 
between effectors and their heterotrimeric G proteins were mapped onto the surface of 
Gαq.  These effector⋅Gα complexes included Gαs⋅adenylyl cyclase, Gαt⋅PDEγ,  
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Gαq⋅GRK2, and Gαq⋅p63RhoGEF (Tesmer et al., 1997b; Slep et al., 2001; Tesmer et 
al., 2005; Lutz et al., 2007).  Structures of seven RGS⋅Gα complexes were used to 
highlight RGS contacts sites and include RGS1⋅Gαi1, RGS4⋅Gαi1, RGS8⋅Gαi3, 
RGS9⋅Gαt, RGS10⋅Gαi3, RGS16⋅Gαi1, and RGS16⋅Gαo (Tesmer et al., 1997a; Slep et 
al., 2001; Slep et al., 2008; Soundararajan et al., 2008).   Colors in (C) and (D) were 
varied to depict low (light green or purple) to high (dark green or purple) conservation 
of effector and RGS contact sites. 
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Figure 4.15. Structural comparison of the nucleotide binding site of Gα  in the 
PLC-β3 ΔCT⋅Gαq and RGS4⋅Gα i complexes.  (A) Residue Asn260 (yellow) of 
PLC-β3 interacts with highly conserved Gln209 (red) of Gαq to stabilize the GTP 
transition state for GTP hydrolysis. (B) Residue Asn128 (blue) of RGS4 serves the 
same function in stabilizing conserved Gln204 of Gαi for GTP hydrolysis.  GDP 
(magenta) and AlF-4 (cyan) are presented as sticks, and Mg2+ (orange) and catalytic 
water (salmon) are shown as spheres.  Hydrogen bonds between atoms are depicted 
has dashed lines.      
 
  
 
 
CHAPTER 5 
CONCLUSIONS AND FUTURE DIRECTIONS 
 Cells respond to changes in their surrounding environment by using cell surface 
receptors to detect extracellular cues and relay information to intracellular compartments.  
Heterotrimeric G protein-coupled receptors (GPCRs) are the largest and most diverse 
family of cell surface receptors encoded in the mammalian genome and respond to 
various extracellular stimuli, including hormones, neurotransmitters, peptides, and 
proteases.  In Chapter 2 of this thesis, we examined signal regulation of G protein-
coupled protease-activated receptor 2 (PAR2), a cell surface receptor for extracellular 
proteases.  Unlike classic GPCRs, PAR2 is irreversibly activated by proteolytic cleavage, 
and the mechanisms of signal regulation are likely unique from reversibly activated 
GPCRs.  Most activated GPCRs are rapidly desensitized and internalized following 
receptor phosphorylation and β-arrestin binding.  For PAR2, however, the role of 
phosphorylation in regulating signaling and trafficking is not clearly understood and is 
the focus of Chapter 2 in this thesis. 
 Activated PARs and other GPCRs catalyze GDP/GTP exchange on the α subunit 
of heterotrimeric G proteins.  GTP-bound Gα dissociates from Gβγ, and both Gα and 
Gβγ dimers bind and activate downstream effectors including adenylyl cyclases, ion 
channels, RhoGEFs, and PLC-β isozymes.  In Chapter 4 of this dissertation, we 
examined the mechanisms of Gαq-dependent activation and deactivation of PLC-β 
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isozymes.  The Harden lab has recently generated a three-dimensional crystal structure of 
PLC-β3 in an AlF-4-dependent complex with Gαq.  We have identified three novel 
contacts within the PLC-β3⋅Gαq interface and used structure/function analysis to 
determine the importance of these interactions in PLC-β3 activation and deactivation 
(Chapter 4).   
5.1 Signal Regulation of Protease-activated Receptor 2 
 In the present study, we found that phosphorylation of PAR2 differentially 
regulates desensitization and trafficking.  Upon agonist addition, wildtype PAR2 was 
rapidly and robustly phosphorylated on serine and threonine residues within the 
cytoplasmic tail (C-tail).  A phosphorylation-deficient mutant (PAR2 0P) failed to recruit 
β-arrestins to the cell surface and was markedly impaired in receptor desensitization.  We 
also showed that PAR2 0P internalizes independent of G protein activation and 
phosphorylation, suggesting that phosphorylation or a distinct conformation of the 
receptor C-tail are required for cell surface retention.  In addition, we demonstrated that 
the phosphorylation-deficient PAR2 0P mutant constitutively internalizes and sorts 
through the endocytic pathway to lysosomes through a dynamin-dependent but clathrin- 
and β-arrestin-independent pathway.  These results suggest that phosphorylation is 
dispensable for PAR2 endocytic trafficking but essential for controlling receptor 
desensitization and β-arrestin binding. 
 Ligand-bound GPCRs are rapidly phosphorylated by G protein-coupled receptor 
kinases (GRKs) or second messenger kinases.  For PAR2, however, the protein kinases 
responsible for receptor phosphorylation are not currently known.  Previous studies found 
that pharmacological inhibitors of protein kinase C (PKC) enhanced PAR2-stimulated 
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calcium signaling in KNRK and hBrie 380 cells, suggesting that PKC may be important 
for PAR2 desensitization (Bohm et al 1996).  PAR2 contains several potential PKC sites 
within its C-tail region that could serve as potential sites of phosphorylation.  Currently, 
there is no direct evidence for PAR2 phosphorylation by PKC. 
PKC and other second messenger kinases are known to indiscriminately 
phosphorylate agonist-occupied receptors as well as unoccupied GPCRs.  GRKs, 
however, strictly recognize ligand-bound receptors.  There are seven GRKs (GRK1-7) 
encoded in the mammalian genome and all share a core domain architecture.  GRKs 
contain a catalytic domain flanked by an N-terminal RGS homology domain and a C-
terminal region that functions in membrane association.  GRK1 and GRK7 are expressed 
exclusively in the retina, and GRK4 is primarily found in the testis.  The remaining 
GRKs (GRK2, GRK3, GRK4, GRK5) are ubiquitously expressed in a variety of tissues.  
GRKs do not appear to recognize particular consensus sequences in GPCRs but 
specifically bind to the activated form of receptors and phosphorylate serine and 
threonine residues near negatively charged amino acids.  Thus, GRK2, GRK3, GRK5, 
and/or GRK6 are potential candidates for mediating PAR2 phosphorylation.  Future 
studies are needed to identify the specific GRK(s) and/or second messenger kinases that 
regulate PAR2 phosphorylation and signaling. 
 Most GPCRs require phosphorylation by GRKs for β-arrestin binding.  Recent 
studies suggest that phosphorylation of GPCRs at distinct sites by specific GRKs may 
also regulate β-arrestin function.  In studies of V2 vasopressin and AT1A angiotensin 
receptors, siRNA depletion of GRK2 and GRK3 prevented agonist-induced receptor 
phosphorylation and internalization but had no effect on arrestin-mediated ERK1/2 
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activation (Kim et al., 2005; Ren et al., 2005).  Alternatively, loss of GRK5 and GRK6 
had little effect on receptor phosphorylation and internalization but reduced arrestin-
dependent ERK1/2 activation.  Similar findings were also shown for the β2AR and 
follicle-stimulating hormone (FSH) receptor (Kara et al., 2006; Shenoy et al., 2006).  The 
authors proposed that GRK5 and GRK6 phosphorylate distinct sites on GPCRs that 
allows β-arrestins to bind and adopt a conformation for mediating ERK1/2 activation 
whereas phosphorylation by GRK2 and GRK3 fails elicit the same response.  Similar to 
V2 vasopressin and AT1A receptors, PAR2 also stimulates β-arrestin-mediated ERK1/2 
signaling that is reported to be independent of heterotrimeric G protein activation (DeFea 
et al., 2000; Stalheim et al., 2005).  The distinct determinants within PAR2 that are 
critical for the diverse functions of β-arrestins are not clearly understood.  Differential 
phosphorylation by specific GRK subtypes may be a mechanism to confer distinct 
signaling events of PAR2 and is an important future pursuit to better understand 
regulation of PAR2 signaling. 
 PAR2 appears to internalize in a dynamin-dependent but clathrin- and β-arrestin-
independent pathway in the absence of receptor phosphorylation.  Most activated GPCRs 
associate with β-arrestins, which couple receptors to clathrin and adaptor protein 
complex-2, components of the endocytic machinery.  β-arrestin binding promotes GPCR 
internalization through clathrin-coated pits.  Some GPCRs, however, use a dynamin-
dependent but clathrin-independent pathway for receptor internalization.  Clathrin-
independent internalization occurs through lipid raft microdomains enriched in 
glycosphingolipids and cholesterol (Mayor and Pagano, 2007).  A subset of lipid rafts, 
known as caveolae, have a similar lipid composition as other lipid microdomains but also 
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contain additional protein components including the structural protein, caveolin.  
Caveolin proteins oligomerize, generating a cytoplasmic coat around lipid microdomains 
and facilitate formation of flask-shaped pits at the plasma membrane. 
Caveolin proteins are thought to sequester GPCRs and other membrane proteins 
into caveolae through protein interactions with caveolin binding motifs.  Analysis of the 
PAR2 protein sequence revealed that the receptor contains a putative caveolin binding 
motif (YYFVSHDF, φXφXXXXφ) within the C-terminal end of its seven transmembrane 
domain.  Caveolin may interact with the binding motif to promote movement of PAR2 
into caveolar membranes and clathrin-independent endocytosis.  In MDA-MB-231 cells, 
PAR2 was found to co-fractionate with caveolin-1 in detergent insoluble microdomains 
and also shown to co-localize with caveolin-1 in immunofluorescence microscopy studies 
(Awasthi et al., 2007).  Further analysis is needed to determine if PAR2 directly interacts 
with ubiquitously expressed caveolin-1 or caveolin-2 and whether phosphorylation-
deficient PAR2 0P resides in caveolar membranes and internalizes using lipid rafts.  We 
have previously shown successful depletion of caveolin-1 from EA.hy926 endothelial 
cells using shRNAs (Russo et al., 2009a).  In addition, there are several pharmacological 
methods to alter cholesterol-rich lipid rafts and inhibit clathrin-independent endocytosis 
(Ivanov, 2008).  For example, methyl-β-cyclodextrin has a high affinity for cholesterol 
and forms soluble lipid complexes, effectively depleting cholesterol from lipid 
microdomains and altering their structure.  Reintroducing cholesterol to cells can reverse 
these effects.  Filipin and nystatin are polyene antibiotics that remove cholesterol from 
lipid raft microdomains by forming large cholesterol-rich aggregates.  Using these 
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methods, we can determine the role of caveolae and/or lipid rafts in internalization of 
phosphorylation-deficient PAR2 0P. 
Localization of GPCRs in caveolar membranes and lipid rafts is also thought to 
compartmentalize GPCR signaling (Chini and Parenti, 2004; Patel et al., 2008).  
Compartmentalization may be particularly important for PAR2 since this receptor is not 
only activated by soluble extracellular proteases like trypsin but also by proteases that 
require membrane bound cofactors.  The transmembrane protein tissue factor (TF) is 
required for the activity of coagulant protease factor (F)VIIa and proteolytic cleavage of 
PAR2.  In MDA-MB-231 cells, cholesterol depletion and siRNA knockdown of caveolin-
1 severely impaired TF-FVIIa-dependent PAR2 signaling whereas disruption of lipid 
rafts and caveolae had no effect on signaling induced by the PAR2-specific agonist 
peptide (Awasthi et al., 2007).  A similar result was also observed for PAR1 signaling in 
endothelial cells (Russo et al., 2009b).  When activated by thrombin, PAR1 stimulates 
Rho activation, endothelial barrier permeability, and proinflammatory responses 
(Coughlin, 2005).  Alternatively, activation of PAR1 by activated protein C (APC) 
promotes Rac1 activation, endothelial barrier protection, and anti-inflammatory effects 
(Feistritzer and Riewald, 2005; Russo et al., 2009b).  APC requires the transmembrane 
cofactor, endothelial protein C receptor (EPCR) and compartmentalization into caveolar 
membranes for activating PAR1 signaling pathways (Riewald et al., 2002; Bae et al., 
2007a; Bae et al., 2007b; Russo et al., 2009b).  Collectively, these results suggest that 
localization of PARs in caveolar membranes may be a general mechanism for protease-
selective signaling.  Future studies are needed to investigate whether 
compartmentalization of the membrane bound TF-FVIIa complex and PAR2 activates 
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PAR2 signaling pathways that are distinct from cellular responses stimulated by trypsin 
or agonist peptide. 
Our studies further suggest that PAR2 is sorted from endosomes to lysosomes and 
degraded in the absence of receptor activation and phosphorylation.  Studies of the β2AR 
and CXCR4 indicate that ubiquitination is essential for lysosomal sorting and degradation 
of these receptors (Marchese and Benovic, 2001; Shenoy et al., 2001; Marchese et al., 
2003).  Ubiquitin-deficient β2AR and CXCR4 mutants fail to degrade in the presence of 
agonists.  Ubiquitinated cargo interacts with the ubiquitin binding motif of hepatocyte 
growth factor-regulated tyrosine kinase substrate (HRS) (Marchese et al., 2003).  HRS 
also associates with tumor suppressor gene product 101 (Tsg101) of the ESCRT 
complex, which is needed for multivesicular body formation, lysosomal fusion, and 
degradation of proteins and lipids.  Post-endocytic sorting of PAR2 requires receptor 
ubiquitination and binding of HRS, but the role of Tsg101 and other members of the 
ESCRT machinery is unknown (Jacob et al., 2005b; Hasdemir et al., 2007).    In contrast 
to wildtype PAR2, δ-opioid receptor and PAR1 are degraded independent of receptor 
ubiquitination (Whistler et al., 2002; Wolfe et al., 2007).  Degradation of δ-opioid 
receptors is regulated by GPCR-associated sorting proteins (GASP), which target some 
GPCRs to lysosomal pathways (Whistler et al., 2002).  Proper sorting of PAR1 to 
lysosomes requires association with SNX1, a protein that functions in vesicular 
trafficking (Gullapalli et al., 2006).  Whether phosphorylation-deficient PAR2 0P mutant 
is ubiquitinated and sorts to lysosomes through an ESCRT-dependent or independent 
pathway remains to be determined.   
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5.2 Mechanisms of Gαq-dependent Activation and Deactivation of Phospholipase C-
β  
 In the present study, we examined the mechanisms of PLC-β activation by Gαq.  
Inspection of the PLC-β3⋅Gαq crystal structure revealed three novel interactions within 
the PLC-β3⋅Gαq binding interface.  The primary region of contact occurs between the 
hydrophobic effector binding pocket of Gαq and a 20 amino acid extension following the 
C2 domain of PLC-β3.  The C2 domain extension adopts a helix-turn-helix topology and 
docks between the α2 (Switch II) and α3 helices of Gαq.  Mutation of key residues 
(Y855, L859, N861, P862, I863) within the helix-turn-helix of PLC-β3 severely impaired 
Gαq-stimulated PLC activity whereas activation by Gβγ remained intact.  PLC-β3 also 
makes electrostatic interactions with Gαq using several charged residues (R707, D709, 
K710, D721) in a region preceding the C2 domain.  Alanine substitution at each of these 
amino acids inhibited PLC-β3 activation by Gαq but not Gβγ.  The third region of contact 
occurs between the nucleotide binding site of Gαq and a small loop connecting the third 
and fourth EF hands of PLC-β3.  The location of the EF hand loop suggested that this 
region might be important for the GTPase accelerating activity of PLC-β3.  An 
asparagine residue (N260) within the EF hand loop stabilizes Q209 in Gαq.  Q209 is a 
highly conserved amino acid in the nucleotide binding pocket of Gαq and is essential for 
positioning the nucleophilic water molecule for GTP hydrolysis.  Deletion of the entire 
EF hand loop or single point mutations at N260 abrogated PLC-β3-stimulated GTP 
hydrolysis on Gαq.  Furthermore, a GAP-deficient PLC-β3 mutant displayed a strikingly 
slower rate of deactivation since Gαq remained GTP-bound.  Consequently, GAP-
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deficient PLC-β3 activity was largely unchanged when agonist was removed compared to 
the rapid shutoff of wildtype PLC-β3. 
 PLC-β isozymes are unique from other PLC family members in that they have a 
long C-terminal extension following the C2 domain.  Previous studies of PLC-β 
isozymes suggested that the C-terminal region was required for Gαq binding and 
stimulation of PLC-β.  The Harden lab, however, found that a truncated mutant of PLC-
β3 (PLC-β3 ΔCT), lacking ~350 amino acids of the C-terminal region, still forms a high 
affinity complex with Gαq.  In fact, both full-length PLC-β3 and PLC-β3 ΔCT have 
virtually the same affinity for Gαq by surface plasmon resonance analysis, suggesting that 
the C-terminal region is actually dispensable for PLC-β binding to Gαq.  Instead, the 
primary region of Gαq binding is a small helix-turn-helix region directly after the C2 
domain.  Based on these observations, the role of the long C-terminal extension of PLC-β 
isozymes in regulating enzyme activity is not clearly understood. 
 Mutational analysis of the PLC-β1 C-terminal region suggested that this domain 
is also important for membrane association.  PLC-β1 isozymes lacking residues 903-1030 
of the C-terminal region were found in soluble fractions of COS-7 cell lysates whereas 
full-length PLC-β1 was present in particulate fractions (Wu et al., 1993).  Consequently, 
loss of membrane association completely abrogated Gαq-stimulated PLC activity.  
Similarly, expression of Gαq in COS-7 cells failed to activate PLC-β3 ΔCT whereas Gαq 
robustly stimulated full-length PLC-β3 (data not shown).  It remains to be determined if 
PLC-β3 ΔCT is sufficiently targeted to membranes for activation by Gαq.  A future 
direction of this work is to determine the importance of the C-terminal extension in 
membrane association versus Gαq binding.  Membrane localization sequences are often 
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used to target cytosolic proteins to the cell surface.  A common membrane localization 
sequence used for prenylation of target proteins is the C-terminal CaaX box (where C is 
cysteine, a is usually an aliphatic residue, and X is the last residue of the protein) of N-, 
H-, and K-Ras GTPases (Stickney et al., 2001).  A polybasic region or palmitoylation 
signal is also added to the N-terminal end of the CaaX box motif to enhance membrane 
association.  Addition of a membrane localization sequence to PLC-β3 ΔCT would 
determine if simply anchoring PLC-β isozymes to the plasma membrane is sufficient for 
activation by Gαq proteins and would show that the C-terminal region primarily functions 
in attaching PLC-β isozymes to lipid bilayers rather than in binding to Gαq.          
 PLC-β isozymes are both effectors and GAPs of the Gαq family of heterotrimeric 
G proteins.  As a result, Gαq proteins directly stimulate PLC activity, and PLC-β 
isozymes accelerate the intrinsic GTP hydrolysis of Gαq to deactivate phospholipid 
signaling.  As effector GAP proteins, PLC-β isozymes must maintain phospholipid 
signaling at steady-state and also rapidly terminate signaling when agonist is removed.  
The mechanism by which PLC-β isozymes act as both activators and deactivators of 
phospholipid signaling is not clearly understood.  We have identified a small loop 
between the third and fourth EF hands of PLC-β3 that mediates the GTPase accelerating 
activity of PLC-β3.  We have demonstrated that removing the entire loop or introducing 
single point mutations in PLC-β3 inhibits PLC GAP activity without affecting the 
apparent affinity of PLC-β3 for Gαq. 
Identifying the GAP domain of PLC-β isozymes and generating GAP-deficient 
mutants have provided the tools to examine the effects of PLC-β GAP activity on 
phospholipid signaling.  We found that a GAP-deficient PLC-β3 mutant has a much 
 154 
slower rate of deactivation when agonist is removed.  Consequently, the rate of 
PtdIns(4,5)P2 hydrolysis was largely unchanged.  Interestingly, analysis of GAP-deficient 
PLC-β3 in intact cell assays showed that Gαq stimulated the GAP-deficient mutant to the 
same extent as wildtype PLC-β3 despite the loss of deactivating GAP activity.  In these 
experiments, COS-7 cells are co-transfected with wildtype or mutant PLC-β3 and Gαq, 
and hydrolysis of [3H]PtdIns(4,5)P2 is quantified after incubation with LiCl for 1 h.  
Under these experimental conditions, only the accumulation of inositol phosphates is 
measured, suggesting that GAP activity of PLC-β isozymes has no effect on the overall 
extent of phospholipid signaling.  It is also possible that a more sensitive technique, like 
measuring intracellular calcium levels, will better demonstrate differences in wildtype 
and GAP-deficient PLC-β3 activity.  In future studies, we will examine how loss of GAP 
activity affects the rate of PLC-β3-promoted release of intracellular calcium. 
The intact cell assays are performed in the absence of receptor stimulation, which 
may be needed to observe any differences in wildtype and GAP-deficient PLC-β3 
activity.  We have stimulated several recombinant and endogenous Gαq-coupled 
receptors and measured accumulation of [3H]inositol phosphates in COS-7, HEK293, and 
HeLa cells.  Unfortunately, robust activation of endogenously expressed PLC-β isozymes 
masked any effects of over-expressed wildtype or GAP-deficient PLC-β3.  Thus, our new 
strategy is to deplete cells of endogenous PLC-β isozymes using shRNAs and reintroduce 
siRNA-resistant forms of either wildtype or GAP-deficient PLC-β3 in HEK293 cells.  
Using these cell lines, we will examine the effects of GAP activity on receptor-promoted 
PtdIns(4,5) hydrolysis and calcium mobilization and measure the rates of signal initiation 
and termination as well as quantify changes in signal magnitude and duration. 
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PLC-β isozymes are activated by all members of the Gαq family of heterotrimeric 
G proteins as well as Gβγ dimers released from abundantly expressed Gαi subtypes.  
PLC-β2 and PLC-β3 are the most responsive to Gβγ dimers whereas PLC-β1 shows little 
to no activation (Park et al., 1993a; Smrcka and Sternweis, 1993).  Currently, the 
differential effects of PLC-β activation by Gαq proteins versus Gβγ dimers is not clearly 
understood.  The crystal structure of the PLC-β3 ΔCT⋅Gαq complex has revealed specific 
contacts between Gαq and PLC-β isozymes that are distinct from the proposed regions of 
Gβγ binding (Kuang et al., 1996; Sankaran et al., 1998; Wang et al., 1999b; Wang et al., 
2000).  In fact, single point mutations in the helix-turn-helix domain of PLC-β3 
completely ablate Gαq-stimulated PLC activity with no effect on activation by Gβγ 
dimers.  It is possible that the cellular consequences of Gβγ activation of PLC-β isozymes 
are unique from that of Gαq proteins.  Activation and deactivation of Gαq proteins are 
regulated by PLC-β isozymes due to the GTPase accelerating activity of PLC-β (Berstein 
et al., 1992; Biddlecome et al., 1996; Mukhopadhyay and Ross, 1999).  In contrast, signal 
termination of Gβγ signaling would require Gαi-specific RGS proteins and reassociation 
of Gβγ and GDP-bound Gαi.  Consequently, the rates of signal initiation and termination 
as well as signal magnitude and duration may be significantly different from Gαq-
promoted PLC activity.  Using PLC-β2 or PLC-β3 mutants that disrupt Gαq binding, we 
can specifically examine the effects of Gβγ-promoted PLC-β activity in cells and in vivo 
in the absence of Gαq signaling. 
The mechanism of Gβγ-promoted activation of PLC-β isozymes is currently 
unknown and an important future pursuit to fully understand heterotrimeric G protein 
activation of PLCs.  A future direction of these studies is to generate a high-resolution 
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crystal structure of a PLC-β isozyme in complex with Gβγ.  Gβγ has a higher affinity for 
PLC-β2 than PLC-β3, suggesting that PLC-β2 may be a better crystallography target for 
this complex (Park et al., 1993a; Smrcka and Sternweis, 1993).  A fragment of PLC-β2 
containing the N-terminal PH domain, four EF hands, catalytic TIM barrel, and C2 
domain was used to generate two crystal structures and a similar fragment of PLC-β3 was 
used to generate the PLC-β3⋅Gαq structure (Jezyk et al., 2006; Hicks et al., 2008).  Based 
on these observations and previous studies suggesting that Gβγ binds to the PH domain 
and Y box of PLC-β2, this fragment of PLC-β2 is a good initial target for crystallizing 
the PLC-β2⋅Gβγ complex (Kuang et al., 1996; Sankaran et al., 1998; Wang et al., 1999b; 
Wang et al., 2000). 
Structural information from PLC-β2 in complex with Rac1 and the PLC-β2 
holoenzyme provide a possible mechanism for Gβγ-stimulated activation of PLC-β 
isozymes.  Comparison of these two crystal structures revealed that PLC-β2 does not 
undergo a conformational change upon Rac1 binding.  In addition, an ordered portion of 
the X/Y linker blocks the active site, forming hydrogen bonds with several residues on 
the catalytic TIM barrel (Jezyk et al., 2006; Hicks et al., 2008).  Removing this ordered 
portion or the entire X/Y linker of PLC-β2 increased basal PLC activity by 5-20-fold in 
intact cell assays.  These results were confirmed with purified proteins in reconstitution 
experiments (Hicks et al., 2008).  Removing the X/Y linker of PLC-β1 or divergent PLC 
isozymes PLC-δ1 and PLC-ε also caused a robust increase in basal PLC activity.  The 
X/Y linkers of PLC isozymes vary in length and amino acid sequence, but they all 
contain a large number of negatively charged residues.  Hicks et al. proposed that Rac1 
recruits PLC-β isozymes to lipid bilayers and negatively charged membranes repel the 
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negatively charged X/Y linker, releasing autoinhibition of PLC-β (Hicks et al., 2008).  
The authors also proposed that this is a possible mechanism for Gβγ-dependent activation 
of PLC-β isozymes.  Comparison of the PLC-β2 holoenzyme to a structure of Gβγ in 
complex with PLC-β2 will provide evidence for either Gβγ-dependent recruitment of 
PLC-β2 to the membrane or a conformational change to confer activation. 
G protein-coupled signaling transmits information from extracellular stimuli to 
intracellular compartments and controls a host of physiological responses including 
cardiac function, vision, olfaction, and neurotransmission.  Cell surface receptors, like 
PAR2 and other GPCRs, are essential for transmitting these signals across the plasma 
membrane by coupling to heterotrimeric G proteins and promoting activation of 
intracellular protein effectors like PLC-β.  Each of these components of the G protein-
linked signaling pathway is tightly regulated to maintain the fidelity and temporal control 
of transmembrane signaling.  The work presented here and the proposed future directions 
will further our knowledge of PAR2 signal regulation at the cell surface and PLC-β 
activation and deactivation within intracellular compartments. 
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